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Humoral immunity provides protection against subsequent infections. Antigen-
specific, high-affinity, class-switched antibodies are produced by B cells through 
rounds of proliferation, B cell receptor rearrangement and selection in the germinal 
centres (GC). T cells play an essential and indispensable role in this process and in 
the recent years the term T follicular helper cells (TFH) was coined to describe this 
cell subset. The aim of my thesis is to investigate whether there is more than one 
type of T cells within the TFH population and whether it has important functional 
consequences. 
Firstly, I use sheep red blood cell immunisation (SRBC) and Salmonella enterica 
infection to show phenotypical differences between TFH expressing high and low 
level of surface molecule PD-1. In order to investigate the relationship between 
different TFH populations gene profiling was carried out on the microarray platform. 
Detailed transcriptome analysis revealed the discrete nature of isolated TFH cell 
subsets and provided an overview of their genetic landscape. 
Secondly, I have investigated the dependence of TFH subsets on cognate 
interactions with B cell in SRBC model by generating BM chimeras. I have 
demonstrated that generation of PD-1HI TFH, but not of PD-1LO TFH, depends on 
antigen presentation by B cells. Furthermore, I have shown that provision of wild-
type but not MHC II knock-out B cells rescues PD-1HI formation in BM chimeras 
after SRBC immunisation. Finally, I have explored plasticity within TFH subsets and 
showed that none of the populations is in a terminally differentiated state, as they can 
convert into one another. 
Thirdly, experiments with S. enterica model revealed that the absence of PD-
1HI TFH is independent of the splenic architecture disruption present within the first 
week of the response. Surprisingly, co-immunisation studies showed that PD-1HI 
population is not only present but even enhanced in the group which received both 
SRBC and S. enterica when compared to single immunisations.  
The work presented in the thesis documents that there is a significant and 
previously unappreciated heterogeneity within TFH subset. This knowledge is 
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important for designing optimal vaccine strategies and treating autoimmune diseases, 
as in both processes the antibody production plays a crucial role and its manipulation 
(either enhancing or blocking antibody production, respectively) can significantly 
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CHAPTER 1- INTRODUCTION 
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1 Introduction 
1.1 Overview of the immune system 
The mammalian immune system has evolved to defend the organism from 
invading pathogens. Its main purpose is to provide a rapid response to infection, 
clear the pathogen, repair the damage and establish long-lasting protection. 
Therefore, the cells of the immune system are able to recognise and be activated by 
foreign entities while they at the same time remain non-responsive to one’s own cells 
and tissues. The ability to distinguish between self and foreign antigen is one of the 
crucial aspects of the immune system.  
The immune response consists of an innate and an adaptive phase. While the 
innate response acts early and is not specific to the pathogen, the adaptive response 
requires time to develop and is highly specific for the infectious agent. The activation 
of the innate immune cells (macrophages, dendritic cells (DCs), neutrophils, 
eosinophils and others) initiates the adaptive immune responses (T and B 
lymphocytes). Following the capture of the pathogen in the tissue, antigen presenting 
cells (APCs) migrate to the secondary lymphoid organs (SLO) where they process 
and display the antigen on their surface. The recognition of antigen by T cells 
(mediated by T cell receptor, TCR) as well as the influence of cytokines secreted by 
APC leads to T cell activation and differentiation (discussed in detail later).  
Activated T cells migrate back to the site of the infection to facilitate pathogen 
clearance and control the magnitude of the immune response at the same time. 
Additionally, in the SLO specialised T cells support B cell differentiation into either 
plasma cells, which secrete large amounts of antibodies, or memory B cells, which 
are the source of a long-lasting immunity to the invading pathogen.  
The interplay between the innate and adaptive immune response is incredibly 
complex, as it involves multiple cell types in various locations of the body over a 
period of time. The biggest challenges for immunologists is to understand this 
complicated process in the first place and then to take advantage of it by designing 
protective vaccines and treatments involving the cells of the immune system. 
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1.2 Structure of the spleen 
The spleen is the largest SLO. It is a major site of haematopoiesis in the mice until 
the 5th month of gestation at which stage the BM takes over the role. The spleen 
develops at embryonic day 12 by the formation of the splanchnic mesodermal plate 
(1). Two and a half days later, after the arrival of the progenitors of the erythroid and 
myeloid cell lineages, the first haematopoietic stem cell settles in the spleen. 
Additionally, at this stage inductive signals for the development of other SLO are 
derived from lymphoid-tissue-inducer cells (LTi), also located in the spleen (1). The 
anatomically and functionally mature spleen is divided into the red and the white 
pulp (Fig. 1.1). 
1.2.1 Red	pulp	
The red pulp is a specialised area of the spleen committed to extensive blood 
filtering. One of the functions of the red pulp is to remove old erythrocytes and 
recycle iron contained within them. Aged erythrocytes display a stiffening membrane 
and get stuck to the cords made of fibroblasts and reticular fibres (1). They are later 
phagocytosed by splenic macrophages located in the same cords. Iron recovered 
from the old red blood cells is either secreted to the blood stream or is stored inside 
macrophages in form of insoluble complexes (1). At the same time, macrophages 
capture the haemoglobin found in the blood stream from the erythrocytes, which 
were damaged intravascularly in different sites of the body (1). The second important 
function of the red pulp of the spleen is to capture and limit the spread of systemic 
pathogens. This function is performed by red pulp macrophages (1). Finally, it is in 
the red pulp of the spleen where plasmablasts and plasma cells reside and secrete 
large amount of antibodies, which then enter the bloodstream directly. This 
localization of plasma cells is mediated by the high concentration of the CXCL12 
chemokine in the red pulp and the expression of its receptor, CXCR4, on the plasma 
cells (2). Therefore, blood entering the spleen (via collective vein) is cleared of old 
erythrocytes, haemoglobin and pathogen born particles and is supplied with iron and 
antibodies.  
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1.2.2 White	pulp	
The white pulp of the spleen is composed of spatially segregated T and B cell 
zones. The separation of lymphocytes into discreet compartments is possible due to 
differences in chemokines produced by non-lymphoid stromal cells and their 
receptors expressed by lymphocytes. B cells express the CXCR5 chemokine 
receptor, which binds CXCL13 produced by stromal cells and follicular DCs (FDC) 
within the B cell follicle (Fig. 1.1, (3-5)). T cells, on the other hand, express in the 
steady state the CCR7 receptor responding to CCL19 and CCL21 chemokines, 
produced by fibroblast reticular cells within the T cell zones (6). Additionally, high 
endothelial venules (HEV) express CCL19 and CCL21 in order to attract and recruit 
naïve T cells from the circulation (7). The highly organised structure of the white 
pulp allows for the efficient interactions between naïve T cells and antigen 
presenting DCs as well as the interaction between activated T and B cells, increasing 
the probability of interaction between rare antigen-specific cells. As a consequence 
of this interaction, lymphocytes alter their chemokine receptor expression, which 
enables migration within the white pulp according to the activation status of the cell 
(Fig.1.1). 
1.2.3 Marginal	zone	
The marginal zone (MZ) is the interface between the circulation and the lymphoid 
compartments, flanked by the red and the white pulp of the spleen (Fig. 1.1). The 
MZ is an entry point for the blood via the marginal sinus (8,9). It is composed of 
distinct subsets of resident cells, namely MZ macrophages, metallophilic 
macrophages and MZ B cells.  
Two resident MZ macrophage populations can be distinguished by their location 
and the unique expression of their surface receptors. MZ macrophages expressing 
SIGN-R1 (C-type lectin receptor, mouse homologue of human DC-SIGN) and 
MARCO (macrophage receptor with collagenous structure, type I scavenger 
receptor) receptors form the outer ring of macrophages (1,10). MZ metallophilic 
macrophages are defined by the expression of Siglec-1 (Sialic acid binding IG-like 
lectin) and MOMA-1 (Monocyte-Macrophage receptor 1) (1,10,11). Macrophages of 
the MZ play two important roles, namely pathogen phagocytosis and clearance from 
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the circulation as well as further activation of the immune system. The first task is 
possible due to the expression of various pattern recognition receptors (PRRs), such 
as Toll-like receptors (TLRs), C-type lectin receptors and scavenger receptors (10). 
PRRs sense pathogen-associated molecular patterns (PAMPs) characteristic for 
bacteria, viruses and yeast, such as lipopolisaccharide (LPS) or zymosan. 
Additionally, the bacterial or viral uptake by MZ macrophages limits the spread of 
pathogens to peripheral organs (12). The second function of MZ macrophages 
(activation of the immune system) is mediated by the secretion of the cytokines 
tailored to the invading pathogen (e.g. IFN-α and IFN-β in response to viral antigens, 
(1)). CD8+ T cell activation can also be initiated through direct interaction between 
MZ metallophilic macrophages and DCs (10). Additionally, MZ metallophilic 
macrophages can activate invariant natural killer cells (iNKTs) by the expression of 
CD1-d, a lipid-binding non-classical MHC molecule (9). Interestingly, the 
clodronate-mediated depletion of both MZ macrophage populations showed that 
these cells are dispensable in T cell dependent (TD) responses (10). This is also 
supported by the observation that neither of the macrophage populations expresses 
MHC class II, which refutes their role as APCs (1) .  
Another resident cell subset of the MZ is MZ B cells. These MZ B cells can be 
distinguished from follicular B cells by their anatomical location, surface phenotype 
and function. Unlike follicular B cells, MZ B cells do not enter the circulation (8). 
High surface expression of IgM, CD1d, CD9, CD21, CD22, CD25 and CD38 and 
low surface levels of IgD, CD23 and B220 defines MZ B cells phenotypically (8,9). 
Although MZ B cells are best known for their role in T-cell independent responses 
(described below), they also take part in TD responses. In fact, MZ B cells express 
higher surface levels of CD80/86 and MHC class II molecules and are therefore 
considered to be more potent T cell activators than follicular B cells (8,13,14).  
Additionally, the regulatory role of MZ B cells is illustrated by the fact that these 
cells secrete more IL-10 in response to apoptotic cells than follicular  
B cells (15). 
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1.3 T cell independent responses 
T-cell independent (TI) responses describe B cell activation in the absence of  
T cell help. This phenomenon is observed most prominently in MZ B cells and B-1b 
cells subsets. 
MZ B cells can readily detect and respond to blood-born pathogens due to their 
privileged positioning adjacent to the marginal sinus (9,14). The recognition of the 
infectious agent can be mediated by extensive cross-linking of the B cell receptor 
(BCR) due to repetitive motifs present on the pathogen surface as well as activation 
of TLRs (9). In fact, the BCR repertoire of MZ B cells is slightly skewed to 
recognise such conservative motifs (9,16). Additionally, MZ B cells have a lower 
activation threshold than follicular B cells, partly due to their strong expression of 
the complement receptor 2 (CD21) and an enhanced ability to bind immune 
complexes (14,17). The MZ B cell activation results in cytokine secretion, enhanced 
antigen presentation and extensive production of class-switched, non-mutated low-
affinity antibodies (9,17). The rapid antibody production by MZ B cells can be 
partially attributed to high levels of transcription factor (TF) Blimp-1 (B-
lymphocyte-induced maturation protein 1), essential for the plasma cell formation 
(9).  Impressively, MZ B cells can secrete antigen-specific antibodies as early as day 
1 to 3 upon administration of blood–derived antigen, whereas it takes between 5 and 
7 days for the GC B cells to start secreting high-affinity antibodies (9,13,17). 
Therefore, antibodies secreted by MZ B cells are crucial to control the systemic 
infection in the early phases of the response prior to the generation of high-affinity 
antibodies in the GC after somatic hypermutation (SHM, (9,13,17,18)).  
Another subset displaying TI responses are ‘innate-like’ B cells – B-1b cells1. 
These cells reside in the peritoneal and the pleural cavity, they also display an 
enrichment in BCR sequences mediating recognition of repetitive antigens (16). 
Similarly to MZ B cells, B-1b cells readily produce large amounts of antigen-specific 
IgM antibodies in response to TLR activation or BCR engagement (14,16,19). 
																																																								
1	B-1a	cells,	also	found	in	the	pleural	and	the	peritoneal	cavity,	produce	constant	
low-levels	of	polyreactive	antibodies (against e.g. influenza virus).	These	are	IgM	
of	low	or	high	affinity	antibodies	directed	against	conservative	motives	found	
on	many	pathogens. 
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1.4 TD responses and GC 
1.4.1 TD	responses	
In contrast to TI responses directed mainly towards polysaccharides, protein 
antigens are TD immune responses. Follicular B cells (termed also B-2b cells) 
predominate in these responses. Apart from BCR engagement (signal 1), B cells 
additionally need to receive help from T cells to be fully activated (signal 2). The 
need for two signals has evolved in order to avoid strong and damaging immune 
responses to self-antigens by auto-reactive B cells.  
Naïve T cells are contained within T cell zones, where the constant probing of 
DCs loaded with antigen occurs (20). When a naïve T cell encounters a DC 
presenting the cognate antigen and co-stimulatory molecules such as CD40 and 
OX40L, it up regulates the CXCR5 chemokine receptor and migrates towards the  
B cell zone (Fig. 1.1 (21)). Another requirement for the positioning of T cells on the 
border of the B cell follicle and for the successful entry of T cells into the follicle is 
the down-regulation of CCR7, as the expression of the CXCR5 receptor per se is not 
sufficient to drive these processes (22).  
1.4.2 	B	cell	activation	
Antigen-specific CD4+ T helper cells interact with B cells displaying the peptide-
MHC class II (p:MHC) complex on their surface. Alongside cognate interaction, a 
set of activation receptors on the cell surface of both T and B cells needs to be 
engaged, including ICOS-ICOSL and CD28-CD80/86, respectively. The outcomes 
of this cell-cell interaction for the B cell are either to become a plasma cell 
(terminally differentiated cells secreting large amount of antibodies in the 
extrafollicular zone) or to return to the follicle and seed the GC (Fig. 1.1). The choice 
between those two fates is thought to be at least partially determined by BCR signal 
strength, as low affinity B cells will form GC and high will turn into plasma cells 
(23). Other factors involved in the process might involve the amount of co-
stimulatory signals derived by T cells and the level of antigen-receptor engagement 
(24). On the molecular level, plasma cells and GC B cells can be defined by the 
expression of two antagonistic TFs: Blimp-1 and B cell lymphoma-6 (Bcl-6), 
respectively (25,26). 
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1.4.3 	Follicular	DCs	(FDC)	
The GC is a specialized B cell area within the B cell follicle, where SHM, 
antibody class switch and affinity maturation take place (26,27). The scaffold of the 
GC is formed by cells of stromal origin called follicular dendritic cells (FDCs, 
(24,27,28)). FDCs produce the chemokine CXCL13 (also known as B-cell 
chemoattractant, BLC) and are therefore crucial in maintaining the structure of SLO 
(Fig. 1.2 (28)). Additionally, FDCs are a potential source of other cytokines 
supporting GC B cells, namely IL-6 and BAFF (B cell-activating factor belonging to 
TNF family (29)), although their role in this process is still controversial (30). Most 
importantly, FDCs capture and retain antigen in the form of spatially organised 
immune complexes called iccosomes, which are displayed on their surface to naïve B 
cells in the primary follicle or activated B cells within the GC (27,30,31). The 
requirement for FDCs in GC response is illustrated by a study showing that selective 
FDC ablation leads to GC disappearance within 48 h (31).   
1.4.4 Dark	zone	of	GC	
Some of the activated B cells initiate the GC reaction. They start to proliferate 
rapidly and are called centroblasts (Fig. 1.2). Centroblasts form the dark zone of the 
GC and by their expansion naïve B cells (IgM+ or IgD+) are pushed to the outer part 
of the GC, and form a so called follicular mantle (Fig. 1.2 (32)). Centroblasts are 
undergoing SHM, where mutations are introduced to the variable (V) regions 
encoding the BCR in order to increase the affinity of the BCR to the foreign antigen 
(24,32,33). These mutations are targeted to complimentary-binding regions (CDRs), 
which form an antigen binding site and, therefore, define the specificity and affinity 
of BCR towards particular antigens (24,32,33). Both somatic hypermutation and 
class-switch (occurring in the centrocytes, discussed below) are genomic mutations 
processes mediated by the enzyme called activation-induced cytidine-deaminase 
(AID) (33). AID mediates the deamination of deoxycytidine residues of the DNA, 
which can transform a C:G base pair into a U:G base pair and subsequent repair 
mechanisms fill the abasic site with potentially any nucleotide  (32). Additionally, 
deamination can cause double strand DNA breaks and ultimately lead to the deletion 
of large DNA regions important in isotype switch recombination (32). During these 
extensive DNA rearrangements centroblasts do not express BCR on their surface.  
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1.4.5 	Light	zone	of	GC	
Once the BCR rearrangement is complete, centroblasts stop dividing and the new 
receptor is expressed on the surface of B cells termed centrocytes (Fig. 1.2 (32,33)). 
Thereafter, class-switching takes place. This is a process in which the constant part 
of the BCR, made of the µ or δ heavy chain in naïve B cells, is exchanged to either 
the α, γ or ε heavy chain to form (secreted) BCR of different isotype (IgA, IgG or 
IgE, respectively).  The (improved) affinity of the new BCR for foreign antigen is 
tested in the light zone of the GC by binding to immune complexes on the FDC 
surface (24,32,33). BCR-mediated signals are essential for the B cell survival. 
Additional survival signals, delivered by FDC and T follicular helper cells, are also 
essential for escaping apoptosis but their precise role is still unknown (33). 
Centrocytes can re-enter the dark zone and undergo secondary rearrangements; there 
is direct evidence for the bi-directional exchange of B cells between the dark and 
light zone within the GC (24). Movement between these compartments is mediated 
by chemokine receptors and their ligands: CXCR4-CXCL12 in the light zone and 
CXCR5-CXCL13 in the dark zone (32,33). 
1.4.6 Termination	of	GC	
Centrocytes, which have undergone a successful BCR rearrangement become 
either long-lived plasma cells or memory cells (Fig. 1.2). The post-GC differentiation 
into plasma cells depends on down-regulation of TF Bcl6 and PAX5 (Paired box 5), 
which is initiated by combined signals from BCR and CD40-ligation (32). As a 
consequence, Blimp-1 (B Lymphocyte-Induced Maturation Protein 1) is expressed, 
alongside other important proteins involved in terminal plasma cell differentiation, 
such as IRF4 (Interferon Regulatory Factor 4) and XBP1 (X-box-binding protein 1) 
(23,32). The signals initiating the development into memory cells are less well 
understood. It seems that centrocytes which continue to express PAX5 become 
memory cells (32).  CD40-CD40L interactions are another required signal for the 
acquisition of memory phenotype (32). The decision whether a cell becomes a 
plasma cell or a memory cell might also be determined by the affinity of the newly-
formed BCR. It was suggested that cells which express a high-affinity BCR 
preferentially become plasma cells, while memory cells express a low-affinity 
receptor (32). Long-lived plasma cells migrate to the red pulp of the spleen as well as 
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the BM, where they can survive in the specialised niches, secreting low-levels of 
antibodies even for a life time (34). Memory B cells locate to various anatomical 
sides, including spleen, lymph nodes, or mucosal-associated anatomical tissue; they 
are also found circulating in the blood (34). 
The presence of GC producing high-affinity antigen-specific antibodies is a pre-
requisite for the provision of protection from subsequent infections. Therefore, long 
lasting immunity is a feature absolutely dependent on the successful interaction 
between T and B lymphocytes. The requirement for sustained contacts between  
B and T cells is illustrated by the fact that in SAP (SLAM-associated Protein) knock 
out (KO) mice, where these interactions are disturbed, no GC formation or humoral 
responses take place (25,35). It is now clear that help to B cells is provided by a 
specialised subset of T cells and the term ‘follicular B helper T cells’ (TFH) was 
coined to refer to this population. The name describes the characteristic localisation 
in the SLO and the predominant function of this cell subset. TFH cells are the main 
focus of this thesis and they are therefore discussed in great detail later. 
1.5 T cell subsets and differentiation 
1.5.1 	T	cell	activation	
As discussed earlier, naïve T cells are held in the white pulp of the spleen due to 
the expression of the CCR7 receptor responding to the CCL19 and CCL21 
chemokines produced by fibroblast reticular cells within the T cell zones (6). Here 
they become activated by the interaction with mature DCs, which have sensed, 
engulfed and processed the pathogen (36,37). 
Immature DCs leave the BM (their site of generation) and migrate to the 
epithelium, a potential entry site for the pathogens2. DCs are highly endocytic cells, 
dedicated to sampling the environment in order to detect pathogens or host cells 
damage. Upon encountering PAMPs or danger signals released by injured cells DCs 
become activated and unresponsive to the environment. They start expressing CCR7, 
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T cells by displaying processed antigen on their cell surface on MHC class I or class 
II molecules. In addition to an antigen specific TCR, co-stimulatory molecules, 
which are also up-regulated upon DC maturation, are an essential component of 
efficient activation of a naïve T cell. Furthermore, DCs secrete cytokines essential 
for differentiation of T cell subsets appropriate to the invading pathogen. Thus, three 
signals (cognate MHC:TCR interaction, engagement of co-activating receptors and 
presence of secreted cytokines) are required for the DC-induced T cell differentiation 
into effector subsets (discussed below) (36,37).  
Although DCs play a crucial role in activating T cells in the SLO, other innate 
cells are important for the activation and support of adaptive responses at the 
infection site. For example, natural killer cells (NK cells) are an important source of 
early IFN-γ, supporting Th1 differentiation, basophils influence Th2 responses by 
secreting IL-4, and γδ T cells enhance Th17 responses by secreting IL-17 (38).  
1.5.2 CD4+	T	cell	differentiation	
Different effector CD4+ T helper (Th) cell subsets are generated in order to 
provide an optimal immune response tailored to the invading pathogen. T cell 
subsets are usually defined by the expression of a master TF responsible for the 
acquisition of the stable phenotype and the secretion of the ‘signature’ cytokine, 
resulting in their specialised function (Fig. 1.3).  
Th1	and	Th2	subsets	
For a long time Th1 and Th2 cells were recognised as the main Th subsets (39). 
They are defined by the expression of specific TFs:  T-bet (encoded by the gene 
Tbx21) and the selective production of IFN-γ or TF GATA-3 (GATA-binding 
protein 3) and IL-4, respectively (Fig. 1.3, (39,40,41)). Th1 cells are involved in the 
response to intracellular pathogens (including bacteria and viruses). This subset is 
induced by IL-12, secreted by innate immune cells (mainly DCs and macrophages) 
and IFN-γ, produced by NK cells as well as T cells (41). IL-12 and IFN-γ signalling 
activates STAT1 and STAT4 (Signal Transducer and Activator of Transcription 1 
and 4) pathways as well as T-bet, which starts the Th1 cell differentiation 
programme (41).  
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 Th2 cells play a role in helminth and worm infections (41). The master TF for 
this subset is GATA3 and the major signalling pathways involved in the 
differentiation are signalling via the IL-4 receptor and STAT6 (Fig. 1.3, (41)).  
Regulatory	T	cells	(Tregs)	
Another T cell subset recognised as a separate lineage are regulatory T cells 
(Tregs), which express Forkhead Box P3 (Foxp3) TF (Fig. 1.3) (42). Tregs can be 
generated either in the thymus (and are termed ‘natural’ nTregs) or induced in the 
periphery (‘inducible’ iTregs) under the influence of TGF-β (Transforming Growth 
Factor- β) (41,43). They play an important role in the suppression of immune 
responses, which is crucial in preventing and controlling autoimmunity (43). 
Multiple mechanisms are employed by Tregs to perform their function, such as direct 
killing of the target cell by the cell-to-cell contact, inhibition of cytokine secretion by 
other cells (especially IL-2 by cytotoxic T cells) and secretion of the 
immunosuppressive cytokines such as IL-10 and TGF-β (44). 
	Th17	cells	
Th17 cells are one of the most recently described Th subsets. They are defined by 
the secretion of IL-17A, IL-17F, IL-21 and IL-22 (39) and the expression of RORγ-T 
(Retinoic Acid Binding Orphan Receptor γ, Fig. 1.3) (40). Th17 cells play an 
important role in clearing fungi and extracellular bacteria at the mucosal sites and are 
also involved in inflammatory diseases (41). This subset seems to display a ‘flexible’ 
phenotype, as their conversion to Th1 cells and Tregs cells has been documented 
(41). Moreover, it seems that the protective or pathogenic role of Th17 cells depends 
strongly on the environmental cues to which cells are exposed. For example, in the 
absence of IL-23, Th17 cells can secrete anti-inflammatory IL-10, whereas the 
presence of IL-23 results in the acquisition of a pathogenic potential and the 
secretion of inflammatory cytokines (41). 
Th9	and	Th	22	subsets	
Th9 cells have been only recently documented and are quite controversial. Their 
development requires IL-4 (similarly to Th2 cells) and TGF-β (Fig. 1.3) (38). Other 
cytokines, such as IL-2, IL-1, IL-33 and IL-25 may also support Th9 differentiation 
(45). Several TFs are important in the Th9 differentiation, namely Gata3, IRF-4, 
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STAT6 and PU.1, which would also suggest relationship with Th2 cells. Th9 cells 
secrete IL-9 alongside other cytokines such as IL-10 and IL-21 (45). The role of Th9 
cells is not well defined and is controversial: Th9 cells were shown to play a 
pathogenic role in allergic lung inflammation and cancer, and a protective or 
pathogenic role in experimental autoimmune encephalitis (EAE) (45). IL-9 seems to 
be a difficult cytokine to study, since it shows a pleiotropic character, it can be 
derived from more than one cell source and its production is transient (45).  Clearly 
much more work needs to be done before Th9 cells become fully recognised as a 
separate T cell lineage or remain considered a transient developmental phase of other 
T cell subsets (especially Th2 cells).  
The last Th cell subset discussed in current literature (but not yet recognised as a 
separate lineage) are Th22 cells (Fig.1.3). These cells are found only in humans and 
are implicated in skin inflammatory conditions, such as psoriasis (38). Th22 cells 
secrete IL-22 but not IL-17 and seem to be induced by plasmacytoid DC (pDCs) 
(1,38). 
1.5.3 T	cell	plasticity	
Although T cell lineages are considered to display a stable phenotype once 
differentiation is complete, there is growing evidence of substantial plasticity within 
T cell subsets (Fig. 1.3). This plasticity can be illustrated by the fact that although 
each of the subsets produces its ‘signature’ cytokine, very often it is not an exclusive 
source of this cytokine. For example, IFN-γ, hallmark of the Th1 programme, can 
also be made by Th17 cells (40). IL-10, originally thought to be derived from Th2 
cells, is produced by many cell types, including Tregs, Th1 cells and cells of the 
innate system (40). IL-21, the signature cytokine of TFH cells, is also produced by 
Th17 cells (40). Additionally, in Peyer’s patches, Th17 cells can acquire a TFH 
phenotype and support IgA production from mucosal sites (46). Moreover, the 
inflammatory environment can push the differentiation of iTreg (generated by TGF-
β) into Th17 cells through the presence of IL-6 (38). An extreme example of T cell 
plasticity is the complete re-programming of Th2 cells into Th1 cells. IFN-α and β, 
secreted during viral infections, was shown to induce T-bet and IFN-γ expression in 
Th2 cells, leading to their differentiation into the Th1 subset subset (38,40). 
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1.6 Phenotype and development of T follicular helper cells (TFH) 
1.6.1 Inducible	Co-Stimulatory	Molecule	(ICOS)	
ICOS is a member of the CD28 family of co-stimulatory and co-inhibitory 
molecules (47). ICOS is absent from the surface of naïve T cells. Its expression is 
induced upon activation and, therefore, ICOS is found on activated and memory  
T cells (48). It binds to the ICOS-ligand (ICOSL) protein receptor, which is 
constitutively expressed on the surface of B cells (49). ICOS binds 
phosphatidylinositol 3-kinase (PI3K) and activates protein kinase B (PKB) and 
phosphoinositide-dependent kinase 1 (PDK1) (48). The kinases PDK-1 and PKB 
together with glycogen synthase kinase 3 (GSK) regulate numerous events, such as 
the prevention of cell death, protein translation and up-regulation of cellular 
metabolism (48). 
The indispensible role of ICOS in humoral responses is illustrated by the 
phenotype of ICOS-/- mice, which exhibit severe impairment in IgG isotype class 
switching and GC formation in response to TD antigens (50-53). Similar results are 
obtained when mice are treated with the anti-ICOSL antibody (53). ICOS was found 
to enhance CD40/CD40L interaction, since CD40 stimulation could restore the 
isotype class switch in ICOS-/- mice (50). ICOS signalling was also implicated in 
driving IL-4, but not IFN-γ, secretion (51,52). 
Alongside a defect in GC formation, ICOS-/- mice and mice treated with the anti-
ICOSL antibody were found to have reduced numbers of CXCR5+ CD4+ T cells (53) 
and therefore ICOS-ICOSL interactions were implicated in the TFH development. 
Furthermore, adoptive T and B cell transfers into SCID mice (Severe Combined 
Immune Deficiency mice, that is, animals severely deficient in B and T cells, (54)) 
showed that the frequency of CXCR5+ CD4+ ICOS+ cells is increased in the presence 
of B cells and depends on the engagement of ICOS on T cells and the ICOSL on  
B cells (53). In keeping with this finding, studies with B cells exclusively deficient in 
the ICOS-L (using mice expressing floxed ICOS-L allele and CRE-recombinase 
driven by the CD19 promoter) confirmed that the impaired generation of the TFH 
population and GC responses is directly related to the absence of the ICOS-L on B 
cells (55).  
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A very recent study by Xu et al. provided an important insight into the role of 
ICOS in the TFH cell development beyond the co-stimulation process (56). The 
ICOS-ICOSL interactions were found to be essential for the migration of T cells to 
the T/B cell zone border and the entry into B cell follicles (56). Interestingly, this 
phenomenon was independent of the expression of CXCR5, CCR7 or Bcl6 (56). DC 
and cognate B cells were found to be dispensable for the recruitment of T cells to the 
B cell follicle. Fascinatingly, non-cognate ‘bystander’ follicular B cells were 
identified as essential source of the ICOSL (56). This study is in keeping with other 
published reports that describe normal T cell localisation to B cell follicles in the 
absence of cognate B cells (57). Therefore, ICOSL deficiency in non-cognate  
B cells has profound effects on the T cell positioning and results in the inhibition of 
the TFH development as well as in suboptimal GC responses (56). Additionally, 
continuous ICOS-ICOSL signalling is essential for retaining T cells in the B cell 
follicle, as the administration of the anti-ICOSL antibody results in the relocation of 
fully differentiated TFH from the GC to the T cell zone (58). On molecular levels, 
ICOS signalling was found to regulate expression of several homing molecules, 
including Cxcr5, Ccr7 and Selplg (Selectin P ligand, also known as P-selectin 
glycoprotein ligand 1, PSGL1) (58). Interestingly, TF Krüppel-like factor 2 (Klf2) 
was shown to act downstream of ICOS signalling and to bind directly to targeted 
genes, whereas Bcl-6 and Achaete-scute homologue 2 (Ascl-2) TFs were shown to 
be dispensable in this pathway (58).  
Summing up, ICOS-ICOSL interactions are one of the most important cues for 
TFH differentiation and they mediate almost every step of the process, for instance by 
engagement during the priming stage, by sustaining the TFH phenotype and by 
controlling T cell motility within SLO. The exact intracellular events following  
ICOS-ICOSL engagement still need to be clarified, as this would provide an 
important insight into the molecular processes governing TFH differentiation. 
1.6.2 	Programmed	Cell	Death	1	(PD-1)	
Another important member of the CD28 family expressed by TFH is PD-1 
(Programmed cell death 1, CD279). Similarly to ICOS, PD-1 is not expressed on 
resting lymphocytes but is induced upon cell activation in CD4+ T cells, CD8+  
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T cells, B cells (expressed upon engagement of TCR or BCR), monocytes and 
natural killer T cells (NK T cells) (49,59,60). It co-localises physically with TCR and 
CD28 to perform its function (49). The intracellular domain of PD-1 contains the 
immunoreceptor tyrosine-based inhibitory motif  (ITIM) and the immunoreceptor 
tyrosine-based switch motif (ITSM) (59,61). The inhibitory effect of PD-1 signalling 
is mediated via the SHP phosphatase (SRC homology 2 (SH2)-domain-containing 
protein tyrosine phosphatase 2), which upon recruitment dephosphorylates and 
deactivates molecules involved in the membrane-proximal TCR signalling, including 
Syk kinase and phosphatydyloinosytol-3-OH-kinase (60). Downstream effects of  
PD-1 signalling include glucose metabolism limitation, Akt activation (by CD28-
mediated activation of PI3K), the limitation of the expression of pro-survival gene 
Bcl-xL and inhibition of cytokine mRNA production (49,60,61).  
PD-1 binds to PD-L1 (B7-H1, CD274) and PD-L2 (B7-DC, CD273) (49,59,60). 
PD-L1 and PD-L2 differ in their distribution, with PD-L1 showing a much broader 
expression than PD-L2. PD-L1 is expressed constitutively and is further up regulated 
upon activation by T cells, B cells, DCs and macrophages (49,60). It is also 
expressed in many non-lymphoid tissues, such as the heart, lungs, pancreas, 
epithelium, liver, brain and muscles as well as immunoprivileged sites such as the 
eye and placenta (49,60). PD-L2 shows a much more restricted expression pattern, 
which is limited to DCs, macrophages and cultured BM-derived mast cells (49,61).  
The inhibitory character of PD-1 receptor in autoimmunity is illustrated by the 
phenotype developed by PD-1 deficient mice (Pd1-/-). On C57BL/6 background,  
PD-1 deficiency leads to the development of a late-onset lupus-like proliferative 
arthritis and glomerulonephirtis with IgG3 deposition (59,61). On BALB/c 
background, the lack of PD-1 results in autoimmune dilated cardiomyopathy and 
high levels of IgG directed against cardiac troponin I protein, leading to early and 
sudden death by congestic heart failure (59,61). Furthermore, the co-inhibitory role 
of PD-1 in response to foreign antigens is shown by studies using an antagonistic 
antibody specific for PD-1, in which blockade of PD-1 resulted in enhanced graft vs 
host disease (GVHD) and hapten-induced contact hypersensitivity in mice (59). 
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A recent study by Hams et al. has identified PD-1:PD-L1 interaction as crucial in 
limiting humoral responses by controlling the expansion of TFH (62). In this study 
mice deficient in PD-L1 (B7-H1-/-), infected with helminth Schistosoma mansoni 
showed higher titres of total and antigen-specific IgE, IgG1 and IgG2a as well as 
expanded GC B cells and plasma cell populations, when compared to WT mice (62). 
B7-H1-/- mice also showed enhanced TFH expansion in response to helminth infection 
or immunisation with model antigen keyhole limpet hemocyanin (KLH) (62). 
Additionally, this phenotype (TFH expansion and increased antibody titres) was 
recapitulated by treatment with anti-PD-L1 or anti-PD-1 (but not anti-PD-L2) 
antibody (62), which suggests that PD-L1 is a primary receptor for PD-1 expressed 
by TFH cells. This finding might be surprising considering studies with fusion 
proteins, which indicated that PD-L2 has a two- to six-fold higher affinity for PD-1 
than PD-L1 (49). In vivo co-transfer studies have indicated that B cells are a source 
of PD-L1 involved in limiting TFH expansion and humoral responses, although 
possible contributions of other subsets expressing PD-L1 have not been fully 
eliminated (62).  
1.7 Cytokine production by TFH cells 
1.7.1 IL-21	
IL-21 is produced by CD4+ T cells (TFH and TH17) as well as NK T cells (63). It 
has pleiotropic effects and impacts cells of both lymphoid and non-lymphoid lineage 
(63).  
The IL-21 receptor (IL-21R) belongs to the common γ-chain family of 
cytokine receptors, alongside IL-2, -4, -7, -9, -13 and -15 (64, 65). It signals via Jak-
1 and Jak-3, as well as STAT1, STAT3 and STAT5 (66), including STAT5a and 
STAT5b (63). Of these, STAT3 seems to have the most potent effect in IL-21 
signalling (63). The MAPK and PI3K pathways have also been implicated in IL-21-
mediated proliferation (67). IL-21R is expressed by many cells of the innate and 
adaptive immune system, including CD4+ T cells, CD8+ T cells, B cells, DC, MF as 
well as NK cells and non-immune cells such as keratinocytes, fibroblasts and 
endothelial cells (64). IL-21R-/- mice show an unaltered lymphoid development (64). 
The expression of IL-21R on CD4 and CD8 T cells, although low in naïve cells, is 
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increased in response to TCR stimulation or IL-21, revealing the autocrine 
amplification loop in IL-21 signalling. Similarly, B cells also up regulate IL-21R in 
response to BCR or IL-21 stimulation (63). B cells show the highest surface levels of 
IL-21R (even in the resting state) and follicular B cells express more IL-21R than 
MZ B cells (63). Plasma cells do not express IL-21R (which is in agreement with the 
non-proliferative state of the terminal differentiation observed in these cells) (63).  
IL-21 has an important role in driving Th17 differentiation and expansion. The 
Th17 cell subset is generated under the influence of TGF-β and IL-6. One of the 
genes and proteins most potently induced by IL-6 signalling is IL-21 (63,65,68). 
 IL-21 expression creates an autocrine loop, since it further enhances IL-21 
production and IL-21R expression in Th17 cells (68). Furthermore, IL-21 signalling 
induced the expression of IL-23R, which can also facilitate the expansion of already 
differentiated Th17 cells (but not naïve CD4+ T cells) (63,65). 
The NK T cell subset was also found to be a potent source of IL-21, which 
implicates its role in B cell responses (discussed later in section ‘NK TFH’, p. 35, 
(63)).  
Even though IL-21 is considered a hallmark cytokine of the TFH cell subset, only a 
portion of TFH cells (CXCR5+ PD-1+ Bcl6+ CD4+ T cells) expresses IL-21 (30-40% 
of TFH cells) and this population seems to be stable in IL-21 expression (69). It has 
not been determined whether IL-21 is restricted to the TFH residing in the GC, which 
actively support B cell selection, although that seems to be a plausible explanation 
for the selective IL-21 expression. However, there is no difference of the GC-
associated marker GL-7 between IL-21+ and IL-21- TFH cells (69). Interestingly, IL-
21+ and IL-21- TFH showed equally high levels of the TFs Bcl-6 and Interferon 
Response Factor 4 (IRF4), and low levels of Blimp-1 (69). The optimal IL-21 
secretion requires ICOS expression on CD4+ T cells (70), since ICOSL-/- mice show 
an impaired production of IL-21 (when compared to WT mice) due to the disrupted 
ICOS/ICOSL interaction between T cells and B cells (55). Similarly to Th17 cells, 
IL-21 signalling in TFH was shown to have an autocrine character, since this 
population expresses also IL-21R which is further up-regulated upon IL-21 
signalling (70). 
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IL-21 impacts B cells in various ways. Firstly, it leads to caspase-dependent (and 
Bcl-2 independent) apoptosis of naïve B cells in the absence of BCR or CD-40 
signalling and in the presence of TLR signals (63). IL-21 increases levels of pro-
apoptotic Bim and decreases levels of pro-survival gene Bcl-xL (63). The reason for 
this might be to inhibit the non-specific, polyclonal responses when cognate antigen-
specific interaction is taking place at the same time, since IL-21 can be produced by 
TFH cells and NK TFH cells engaged with antigen-specific B cells. Secondly, IL-21 
induces the differentiation of activated B cells and human memory cells into plasma 
cells via induction of TFs Blimp-1 and c-Maf (63,65,66,71,72). Thirdly, IL-21 plays 
a crucial role in the immunoglobulin production. IL-21R-/- animals show a severe 
impairment in the total and antigen-specific IgG1 production as well as elevated 
levels of IgE antibodies after immunisation with OVA, KLH or NP-KLH (64). This 
was shown to be a B-cell intrinsic effect (64). Finally, IL-21 was found to induce 
AID and consequently support CSR (but not SHM) (71). Therefore, via broad 
expression of IL-21R, IL-21 impacts various cell types and displays both an 
activatory and inhibitory character. Crucial role of IL-21 in GC formation is further 
discussed in details in the section on TFH function (p. 29) and the role of IL-21 in 
extra follicular responses in the section on TFH heterogeneity (p. 34). 
1.7.2 IL-4	and	IFN-γ	
Alongside IL-21, TFH cells secrete other cytokines to ensure that B cells undergo 
the class-switch appropriate for the invading pathogen. Tracking IL-4 mRNA and 
protein expression in CD4+ T cells after immunisation with S. mansoni revealed that 
the majority of IL-4 is derived from T cells expressing TFH markers, such as CXCR5, 
ICOS and PD-1 (73). These IL-4-producing cells expressed the TFH-specific TF  
Bcl-6, alongside the Th2-specific GATA 3 TF (73). Similarly, the IL-4 production 
was identified in cells with TFH hallmark markers (expressing CXCR5, ICOS, PD-1,  
IL-21 and Bcl-6) after Heligmosomoides polygyrus infection (74). Finally, 
experiments with IL-21 reporter mice revealed that IL-21+ CD4+ T cells (exhibiting 
other TFH markers, such as CXCR5, PD-1 and Bcl-6) also expressed significant 
amounts of mRNA for T-bet, Gata3, IL-4 and IFN-γ, as well as mRNA for IL-10 
(69). Additionally, the non-antigen specific stimulation with PMA and ionomycin 
showed that these IL-21+ TFH can also secrete IL-2 (69), although no other in vivo 
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studies have reported a biologically significant IL-2 production by TFH. In contrast to 
that, TFH cells were shown to have a low expression of CD25 (IL-2Rα, (75)). Role of 
IL-4 and IFN-γ in shaping humoral responses is described in section ‘TFH function’, 
p. 29. 
1.8 Development of TFH cells 
1.8.1 The	role	of	APCs	(APCs)	
The induction of the TFH programme occurs, similarly to other CD4+ effector  
T cell populations, during the interaction with activated DC, which present cognate 
peptide in the context of the MHC class II molecules. The interaction between the 
co-stimulatory molecule CD28 (constitutively expressed on the surface of naïve  
T cells) and CD80/86 (expressed on DC) is essential for the TFH formation, since 
CD28-/- mice fail to generate TFH (76). CD28 signalling was found to be important 
for the initial up regulation of Bcl-6 (58,76). Moreover, CD28 plays also an 
important role in the later stages of TFH cell differentiation and survival by 
maintaining the expression of CXCR5 and Bcl6 (76). These effects are attributed to 
molecules acting down stream of CD28 signalling, such as pro-survival protein  
Bcl-XL and ICOS signalling (76).  
Early studies, with B cell-deficient and BCR transgenic animals showed that the 
TFH population is absent or vastly impaired in the absence of cognate B cells after 
protein immunisation (22), viral infection (77) or parasite infection (73). 
Additionally, physical contact in the form of stable T-B cell conjugates was also 
found indispensible for TFH survival (25,75). Therefore, B cells were found to be 
essential for the development of functional TFH cells. However, soon it became clear 
that despite the absence of TFH at the peak of the immune response, T cell priming by 
DCs is sufficient to induce TFH population at earlier stages. Firstly, the entry of  
T cells to the B cell follicles was found to be dependent on the T cell activation by 
DC and not antigen presentation by B cells (21). Secondly, CD4+ CXCR5+ Bcl6+ T 
cells were found abundantly at day 3 after protein immunisation or infection, and 
thus prior to the activation of cognate B cells (57,75,78). Moreover, in the absence of 
antigen-specific B cells, CD4+ CXCR5+ PD-1+ Bcl6+ T cells are still found in the  
B cell follicle (57,78-80). Finally, the TFH genesis might be accelerated by 
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immunisation with Ag-pulsed DCs (75,80,81). However, it is very important to bear 
in mind that even though the presence of DC seems to be sufficient for the TFH cell 
genesis, these cells have a phenotype that differs from fully developed TFH found in 
the GC and their functional capacity for helping B cells is also questionable.  
Upon contact with activated DC, cognate T cells can further differentiate into 
effector T cells or TFH. The exact signals influencing this choice remain elusive. 
Asymmetrical cell division of the activated T cell (after interaction with DC) has 
been described as one of the possible models explaining commitment to the effector 
T cell pool of TFH population (75). That bi-modal choice depends on the quantity of 
IL-2 signalling (75). IL-2RαHI T cells show the preferential commitment to the 
effector T cell pool (via induction of Blimp-1), while IL-2RαLOW T cells favour TFH 
cell differentiation (mediated by Bcl6) (75). The described process of asymmetrical 
division was completed within 72h and depended strictly on the priming mediated by 
DC (75). B cells were shown to be dispensable for TFH priming but to be playing an 
essential role in TFH maintenance at later stages (75). The role of B cells in TFH 
biology is described in details in the introduction to Chapter 4, on p. 111. 
The commitment to the TFH lineage is a matter of discussion and no clear 
developmental pathway has yet been established. Fascinatingly, the TFH subset 
displays a unique characteristic by depending on two different APCs for its 
differentiation: DCs at the priming stage for induction of TFH precursor cells and  
B cells at later stages for their survival and full development. Possible models of TFH 
differentiation are discussed in detail in the synoptic discussion of this thesis 
(Chapter 6, p. 176).  
1.8.2 TCR	signalling	in	TFH	development	
The strength of T cell receptor (TCR) signaling has a profound influence on the 
differentiation of effector T cell subsets. However, the role of TCR signaling in the 
TFH development has not been fully investigated. So far only a handful of studies 
have directly addressed the impact of TCR signaling on the TFH cell population 
(82,83). T cells that display more restricted TCR and TCR with high affinity for the 
antigen were shown to be preferentially recruited to the TFH pool (82). On the other 
hand, another group reported that Ag avidity does not play any role in the 
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commitment to the TFH pool (83). Details of these studies and TCR specificity within 
the TFH population are discussed in detail in Chapter 5 (see p. 174).  
1.9 TFs 
1.9.1 B-cell	lymphoma	6	(Bcl6)		
The B-cell lymphoma 6 (Bcl6) protein was identified as a master TF involved in 
TFH differentiation independently by three research groups nearly a decade after the 
first recognition of TFH cells (77,84,85). Early in vivo and in vitro studies provided 
clear evidence that Bcl-6 over expression leads to an increased expression of many 
TFH markers, such as CXCR5, PD-1, CD200, CXCR4 and B and T lymphocyte 
attenuator (BTLA), and results in the down regulation of CCR7, Blimp-1 and SLAM 
(signalling lymphocytic activation molecule, Fig. 1.5, (77,84,85)). Additionally, Bcl6 
was shown to inhibit directly the differentiation into Th1 or Th17 cells by controlling 
T-bet and ROR-γt, which results in the downstream inhibition of the IFN-γ and IL-17 
cytokines production (Fig. 1.5, (84,85)), although TFH cells were still found to 
express low levels of IFN-γ as well as IL-4 (77,84). On the other hand, Blimp-1 was 
identified as an antagonistic TF inhibiting the commitment to the TFH lineage and 
promoting the differentiation into other effector T cell subsets (77). Furthermore, 
Bcl-6-expressing TFH cells were functionally competent to drive GC reactions and 
enhance humoral responses (77). Adoptive cell transfers into RAG-1-/- mice 
(Recombination Activating Gene 1 deficient mice, which lack mature T and B 
lymphocytes, (86)) and experiments utilising BM chimeras showed clearly that the 
expression of Bcl-6 in B cells as well as T cells is essential for GC formation and 
Ag-specific antibody responses (77,84). 
1.9.2 c-Maf	
Interestingly, none of the initial reports (77,84,85) nor further in vivo studies (87) 
linked Bcl-6 expression to IL-21 production. Although the lack of a coordinated 
expression of two proteins that play a pivotal role in the TFH function might seem to 
be surprising, there is a very reasonable explanation for this phenomenon. As 
discussed earlier, IL-21 is produced by other cell types (alongside TFH the most 
important source of IL-21 are Th17 cells). Therefore, linking the IL-21 expression to 
the expression of the Bcl6 TF, which governs the differentiation into a certain cell 
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subset (by inducing global gene expression changes), might be highly 
disadvantageous for other cell populations. Importantly, two other TFs have been 
found to regulate the IL-21 production. 
c-Maf was shown to drive the IL-21 production in CD4+ T cells both in vitro 
(88,89) and in vivo (Fig. 1.5, (90)). c-Maf expression was shown to be dependent on 
ICOS signalling (90) and the presence of the cytokines IL-6 (88) or IL-21 and IL-27 
(91). Additionally, c-Maf was also found to regulate positively the expression of  
IL-4, but not IL-5 or IL-13 (92), which is also relevant since IL-4 is one of the 
important cytokines secreted by TFH. c-Maf was also found to be important for the 
CXCR5 expression and, together with Bcl6, c-Maf was shown to play a role in the 
induction of optimal levels of CXCR4, PD-1 and ICOS (89). 
1.9.3 Interferon	response	factor	4	(IRF4)	
The interferon response factor 4 (IRF4) was found to be crucial for the TFH 
development after protein immunisation or infection with L. major (93). Irf4-/- mice 
lack GC and do not form TFH cells (the CXCR5+ ICOS+ BCL-6+ population is 
missing) (93). Importantly, the IL-21 production is also abolished in Irf4-/- mice 
(93,94). Moreover, IRF4 plays an important role in the IL-21 induction in Th17 cells 
(95). IRF4 was found to cooperate with the STAT3 TF in the regulation of IL-21-
controlled genes in CD4+ T cells, including Prdm1 (encoding the Blimp-1 protein, 
Fig. 1.5, (94)). 
1.9.4 Basic	leucine	zipper	TF,	ATF-like	(Batf)	
Batf (Basic leucine zipper TF, ATF-like) was found to be essential for TFH 
development by two lab groups (96,97). Batf was shown to control expression of 
Bcl-6 and c-Maf, therefore providing an important signal upstream of Bcl6 in the TFH 
generation (Fig. 1.5, (97)). Restoring the TFH activity in Batf-/- T cells could only be 
achieved in the presence of both c-Maf and Bcl-6 (c-Maf alone was not sufficient) 
(96,97). The signals influencing the Batf expression and other Batf target genes still 
remain to be identified, although Batf was shown to bind directly to the Il21 locus 
(98). Other CD4+ T cells subsets that were reduced in the absence of the Batf protein 
included the Th2 and, most prominently, Th17 cells (97).  
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Furthermore, Batf-deficient mice do not generate GC and show a severe 
impairment in class-switch recombination (CSR) (96). Impaired humoral responses 
to T cell-dependent Ag were manifested by almost a complete absence of IgG1, 
IgG2c, IgA and IgE antibodies after SRBC administration, while they showed a mild 
reduction in IgM antibody titres (96). Although this can be viewed as a secondary 
effect of the absent TFH population, the B cell-intrinsic requirement for Batf was 
demonstrated by in vitro re-stimulation assays and immunisation with a T-cell 
independent antigen (96). Additionally, Batf was found to regulate the expression of 
AID and germline transcripts, encoding the intervening heavy-chain locus and 
constant heavy-chain locus in B cells (97).  
1.9.5 Achaete-scute	homologue	2	(Ascl2)	
Early observations of the TFH phenotype reported a correlation of the Bcl-6 and 
CXCR5 expression (77,84,85). The analysis of Bcl-6-deficient T cells showed that 
Bcl6-/- T cells did not differentiate into CXCR5+ T cells (77,84,85). Furthermore,  
Bcl-6 expression tracked by flow cytometry staining in activated CD4+ T cells was 
shown to precede the expression of CXCR5 (80). These observations lead to the 
hypothesis that Bcl-6 might directly drive the CXCR5 expression. Additional 
supporting evidence came from the analysis of the microRNA cluster 17-92, which 
showed that 3 microRNAs (miR-17, miR-18a, mi-20a) were repressed by Bcl-6, 
leading to the up regulation of CXCR5 (85). Importantly, in the experiments 
described above the expression of CXCR5 was assessed at later stages of the 
response, such as day 6 or 7. However, the analysis of the Bcl-6 expression with red 
fluorescent protein (RFP) reporter mice showed that CXCR5 expression precedes the 
Bcl-6 expression by around 3 days (87), which questions the role of Bcl-6 in the 
induction of the CXCR5 expression. Indeed, a recent study by Liu et al. has 
identified another TF, namely Achaete-scute homologue 2 (Ascl2), as acting early in 
the TFH differentiation and as driving the CXCR5 expression (99). Ascl2 was shown 
to be selectively expressed in mouse and human TFH cells and not in other T helper 
cell lineages (99). In fact, Ascl2 was found to repress the Th1, Th2 and Th17 
differentiation (99). A very elegant experiment with transferred WT OT.II cells, 
Ascl2fl/fl OT.II cells and Bcl6-/- OT.II cells transduced with the CRE-expressing GFP 
vector showed that the early generation of CXCR5+ CD4+ T cells (day 3 after protein 
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immunisation) is fully dependent on the expression of Ascl2 (99). Bcl6 was shown to 
be dispensable in the induction of CXCR5 on CD4+ T cells but to be required at later 
stages of the response (99).  
Moreover, Ascl2 seems to act independently of the Bcl6, Blimp1 and Batf TFs, 
since Ascl2 over expression did not influence the levels of Bcl6, Prdm1 and Batf 
mRNA (99). Intriguingly, other genes unaffected by the manipulation of Ascl2 
include Icos, Sh2d1a (SAP), Pd1, Btla, Cd40lg and Il21(99). Targeted transcripts of 
Ascl2 include the genes involved in T cell migration (Cxcr5, Ccr7 and Selplg 
(Psgl1), Fig. 1.5) as well as the IL-2 signaling pathway (Cd25 and Cd22- encoding 
proteins IL2-Rα and IL2-Rβ, respectively, (99)).  
Summing up, this study has established the crucial role of Ascl2 in the TFH 
induction and of Bcl6 in the maintenance of the TFH phenotype. The important 
question remaining to be answered concerns the nature of the signal leading to the 
induction of the Ascl2 expression. ‘Classic’ T cell and TFH cell stimulation protocols, 
including the combination of anti-CD3, anti-CD28, anti-ICOS and IL-6 and/or IL-21, 
did not lead to the Ascl2 up regulation (99). Agonists of the Wnt pathway, including 
TWS119, have been shown to induce the Ascl2 expression in CD4+ T cells (99) but 
so far the role of the Wnt signaling pathway in the TFH differentiation has not been 
fully investigated.   
 T-bet is expressed in low amounts by TFH and even though it plays an 
important role in the CD4+ T cell activation, it was show to be dispensable for the 
TFH development as Tbx-/- mice developed a TFH population equivalent to WT mice, 
in terms of frequency and functional capacity, after protein immunisation (69).  
1.10 The roles of cytokines in the TFH development 
1.10.1 IL-21	and	IL-6	
Th1, Th2 or Th17 cells can be generated in vitro from purified naïve CD4+ T cells 
by stimulation with IL-12, IL-4 or IL-6/TGF-b, respectively. The situation is more 
complicated in the case of the TFH cell subset. Although numerous in vitro studies 
showed that the exposure of naïve CD4+ T cells to IL-6 or IL-21 induces the 
expression of IL-21 and some characteristics of TFH cells (the expression of mRNA 
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encoding CXCR5, PD-1 and Bcl-6 (55,84,100-103)) other experiments failed to 
show up regulation of these genes after culturing naïve T cells with IL-6 and IL-21, 
despite showing high IL-21 production (104,105). This raised concerns about the 
insufficient replication of the in vivo environment by in vitro studies and the 
subsequent lack of reliable results. Therefore, it became crucial to assess the impact 
of cytokines on the TFH development in completely physiological conditions by using 
the in vivo system.  
Numerous in vivo studies addressed the requirement of IL-6 and IL-21 for TFH 
generation, providing important evidence about the roles of these cytokines in T cell 
biology. The analysis of IL-6-/- mice showed a normal (79,102) or only mild decrease 
(55,70) in the TFH development when compared to WT mice after viral infection 
(79,102) and protein immunisation (79). Similarly, the dispensable role of IL-21 in 
TFH formation was illustrated by the normal TFH development in IL-21-/- or Il-21R-/- 
mice after protein immunisation (72,79,106) or viral infection (102,107). Although 
neither IL-6 nor IL-21 alone seems to have a great impact on the TFH differentiation, 
the absence of both IL-6 and IL-21 blunts the TFH genesis significantly (by around 
25%) (102). This can be explained by the fact that both IL-21 and IL-6 signal via 
STAT3 (63,108) and therefore can compensate for each other’s absence. Indeed, 
STAT3 deficiency in CD4+ T cells results in an impaired (although not fully 
abrogated) TFH development (55,103). Even though CD4+ T cells with intrinsic 
STAT3 deficiency (STAT3flox/flox CD4-CRE mice) can become CXCR5+ T cells, 
these cells were not competent to deliver help to B cells, neither in vitro nor in vivo 
(104). The lack of B cell help was tied to impaired IL-21 production (104). 
1.10.2 IL-27	
Interestingly, one study has also implicated another STAT3 signalling cytokine, 
IL-27, in the TFH development (101). IL-27 was shown to induce the IL-21 
expression (101).  IL-27Rα-/- mice had significantly reduced TFH numbers, impaired 
GC formation, and humoral responses after protein immunisation (101). This 
explains the presence of a significant TFH population (although lower than in WT 
mice) in IL-21-/- mice treated with anit-IL6 antibodies after protein immunisation 
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(102), since IL-27  could provide STAT3 signalling and rescue the TFH development 
in the absence of IL-6 and IL-21.  
Summing up, in vitro studies with purified naïve T cells failed to provide a 
reliable answer to the question of the cytokines essential to TFH differentiation. Even 
though IL-21-producing cells can be generated in vitro, they show overall much 
lower expression of many TFH-attributed molecules than TFH found in vivo, and these 
IL-21 producers might represent a precursor stage in the TFH development. The 
inability to generate TFH in vitro suggests that multiple environmental cues, such as  
T cell positioning and interactions with numerous APC, are especially important in 
the TFH development. Consequently, the TFH differentiation is not a one-step process 
with a single signal received at the stage of priming (which seems to be the case for 
other effector cell populations). Thanks to the effort of many groups, a clearer 
picture has emerged from numerous in vivo studies, which overall provided evidence 
for the compensating roles of IL-6, IL-21 and IL-27, and for the requirement of the 
STAT3 signalling pathway in the TFH development (101,102).  
1.10.3 IL-2	and	STAT5	signalling	
The IL-2 and STAT5 signalling axis has been implicated as negative regulator of 
the TFH development (Fig. 1.5, (75,109,110)). This effect is mediated by the 
induction of the Blimp-1 TF (111), which acts reciprocally to Bcl-6 (77,84).  
Choi et al. showed that antigen-specific cells undergo asymmetric cell division 
within the first 48 h of priming, resulting in the generation of IL-2Rα (CD25)HIGH 
and IL-2RαLOW CD4+ T cell populations (75). Furthermore, IL-2RαHIGH cells activate 
STAT5 signalling and Blimp-1 expression, which leads to the suppression of Bcl-6 
and to the preferential commitment to the effector T cell pool (75). The reciprocal 
situation was observed in IL-25RαLOW CD4+ T cells, which started expressing Bcl-6 
TF, repressed the Blimp-1 expression and, as a consequence, differentiated further 
into TFH cells (75). This bi-furcation process was completed within the first 72 h of 
the immune response (75). 
Further evidence for the role played by IL-2 and STAT5 in the TFH genesis came 
from studies carried out by Johnston et al. and Nurieva et al. Both groups have 
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shown that the targeted deletion of STAT5 in CD4+ T cells (STAT5flox/flox CD4+ T 
cells transduced with the CRE vector (109) and STAT5flox/flox CD4-CRE mice (110)) 
or IL-2 inhibition facilitates the TFH formation in vivo by inducing the expression of 
Bcl-6.  Additionally, the over expression of the constitutively active form of STAT5 
limits the TFH formation (109,110). Finally, the STAT5-mediated inhibition of the 
TFH population depends on Blimp-1, since the effect of STAT5 is lost in the absence 
of Blimp-1 (109) and, conversely, the over expression of Blimp-1 in STAT5 
deficient cells inhibits the TFH formation (110). 
Collectively, there is clear evidence that IL-2 signalling via STAT5 induces 
Blimp-1 expression and consequently inhibits Bcl-6 expression and TFH 
development. Therefore, IL-2 has been identified as a negative regulator of the TFH 
differentiation program.  
1.11 Function of TFH cells 
The main function of TFH subset is GC support. TFH cells fulfil their role by 
employing various cell surface receptors as well as by secreting soluble mediators.  
1.11.1 Surface	molecules	
ICOS 
ICOS signalling has profound effect on the development of TFH cells (Introduction 
p. 13). Surprisingly little is known about the effects of ICOSL signalling in GC B 
cells (Fig. 1.5). The absence of GC and humoral responses in ICOS-/- mice is viewed 
as a secondary consequence of the missing TFH population (53). The extent and 
function of a cell intrinsic ICOSL signalling in B cells and GC reactions remains 
unknown (Fig. 1.4). 
PD-1 
The effect of PD-1 signalling on GC B cells was revealed by work of Good-
Jacobson et al. (112). In this study interactions between PD-1 expressed by TFH and 
PD-L2 on B cells were shown to be crucial for rescuing GC B cells from apoptosis 
(Fig. 1.4). Furthermore, PD-1 signalling was found to be essential for IL-21 
expression by TFH cells, which enhances the formation of long-lived plasma cells 
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(113). Alternatively, it was suggested that a high expression of PD-1 on TFH cells 
localised within GC might reflect an ongoing cell activation by continuous TCR 
stimulation due to repeated interactions with cognate B cells (114).  
B and T lymphocyte attenuator (BTLA) 
BTLA is a co-inhibitory receptor and a member of the CD28 superfamily of 
surface receptors expressed by B and T cells (49,59,115). The co-inhibitory character 
of this receptor is illustrated by the fact that BTLA-/- mice have enhanced antibody 
titres and expanded GC B cell population after protein immunisation (116). 
Interestingly, BTLA deficiency has no impact on numbers of TFH (116). Instead, 
BTLA regulates TFH function by limiting IL-21 production (116). Additionally, 
BTLA might directly regulate numbers of GC B cells by engaging its ligands, 
HVEM (herpesvirus-entry mediator) or LIGHT (tumor necrosis factor superfamily 
member 14, Tnfsf14, (59,115). Any molecular mechanisms involved in BTLA 
signalling in TFH cells are unknown. Summing up, BTLA acts as a co-inhibitory 
receptor to hinder TFH function in order to regulate the magnitude of a humoral 
response. 
CD40L 
CD40L is the only binding partner of CD40 (114). Lack of either CD40 or CD40L 
completely abrogates GC formation (117,118) as well as plasma cell response (119-
121). CD40 signalling in GC B cell provides crucial survival signals by rescuing B 
cells from apoptosis (122), possibly by induction of Bcl6 (123), (Fig. 1.4). Together 
with IL-21 or IL-4, CD40-CD40L interaction is an important proliferation factor for 
GC B cells (124). CD40 signalling is also involved in the memory B cell 
differentiation (125), although the molecular mechanisms governing CD40 signalling 
and fate decisions of B cells need further investigation. The exact nature of CD40-
CD40L signalling and its effects on TFH cells are also not fully understood.  
SLAM family proteins 
SLAM family includes several surface proteins involved in T-B cell interactions, 
such as CD84, SLAM (Slamf1, CD150), Ly108 (Slamf6) and Ly9 (Slamf3, CD229) 
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(126,127). There is a significant functional redundancy in the SLAM family of 
proteins, illustrated by the fact that mice deficient in only one of the SLAM proteins 
exhibit mild or no decrease in GC formation and TFH differentiation (as discussed in 
(114). SLAM-associated protein (SAP) is an intracellular adaptor of SLAM (CD150, 
(126,127)). Indispensible role of SAP in GC formation is illustrated by the fact that 
SAP-deficient mice do not form GC and have completely abrogated humoral 
responses (25,128). This defect is attributed to lack of stable conjugates between T 
and B cells. Importantly, SAP-deficient mice have unaltered interactions with DC 
(25,128), which illustrates the significance of prolonged physical contact between 
TFH and B cells. Additionally, signalling via SAP is required for IL-4 production by 
TFH cells within GC (Fig. 1.4, (129)).  
1.11.2 	 Cytokines	
TFH secrete cytokines, which are essential for shaping humoral responses. IL-21 
has a profound impact on GC, as well as extra-follicular responses. IL-4 and IFN-γ 
play indispensible role in driving appropriate class-switch tailored to the ongoing 
immune response. 
IL-21 
The crucial role of IL-21 in TD responses and GC formation was demonstrated by 
the complete ablation of GC in IL-21-/- mice (72) and IL-21R-/- (64,72). This was 
accompanied by a vast reduction of the IgG1 antibody levels. The reason for this 
phenotype could be B- or T- cell intrinsic, since both B cells as well as TFH cells 
express IL-21R (70,130). The transfer of IL-21-sufficient CD4+ T cells into IL-21-/- 
mice showed that, after antigen challenge, donor cells could differentiate into TFH 
cells, and GC responses as well as antibody responses were restored (70). The GC 
could not be rescued by transferring WT (IL-21 sufficient) B cells.  However, IL-21 
deficiency in B cells has also a profound impact on GC responses, since the lack of 
IL-21 secretion or IL-21R expression by B cells led to the cessation of GC and to the 
premature formation of memory B cells, which additionally showed impaired SHM 
(72). Importantly, IL-21R signalling in B cells was required for the optimal induction 
of Bcl-6 in B cells, as well as SHM in response to TD antigens (SRBC, Fig. 1.4, 
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(106)). Therefore, IL-21 signalling is essential in T cells as well as B cells in order to 
generate optimal GC responses.  
Additionally, IL-21 became implicated in the extra-follicular response, although 
its exact role remains elusive. IL-21 seems to be dispensable for the extra follicular 
responses (such as early response to Salmonella enterica, (106)). On the other hand, 
another study showed that IL-21 is essential in supporting extra follicular B cells 
(131). These studies are discussed in details in section ‘Heterogeneity within TFH 
cells on p. 34. 
IL-4 and IFN-γ  
The question of the local cytokine secretion by TFH within GC was very elegantly 
addressed in a study with IL-4/IFN-γ double-reporter mice that were infected with 
Leishmania major (L. major) (132). The analysis of the isolated conjugates of T and 
B cells showed that IFN-γ-secreting T cells were paired with B cells that were 
undergoing a switch to IgG2a, whereas IL-4-secreting T cells were paired with B 
cells switching to IgG1 (132). These conjugates were found within the same GC, 
which demonstrates that the cytokine production by TFH cells acts locally rather than 
globally, and therefore even modest amounts of cytokine are sufficient to drive the 
appropriate class switch. This can also explain why microarray analysis results 
indicate a lack of IFN-γ or IL-4 production in TFH cells (55), which may express only 
low amount of transcripts for these cytokines. Production of IL-4 and IFN-γ by TFH 
was discussed in section ‘cytokines secreted by TFH’ on p. 18.  
1.12 Regulation of TFH responses 
The TFH population supports GC formation and production of high-affinity, class-
switched antibodies. These processes need to be tightly regulated in order to 
maintain self-tolerance and avoid the generation of auto-antibodies. So far, two 
populations of T cells have been identified as controlling the TFH population: a subset 
of CD8+ T cells and CD4+ T follicular regulatory cells (TFR).  
1.12.1 TFH	regulation	by	CD8+	T	cells	
CD8+ T cells expressing the non-classical MHC I molecule Qa1 were shown to 
inhibit autoimmunity by controlling TFH numbers in the steady state as well as during 
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viral infection (133). Qa1 mutant mice (with D227K mutation disrupting Qa-1 
binding to the TCR/CD8 co-receptor) were found to develop spontaneous 
autoimmunity, characterised by elevated levels of the IgG antibody in the blood, 
increased deposition of IgG in renal glomeruli and autoantibodies directed against 
nuclear antigens (133). This phenotype was associated with TFH expansion and 
enhanced GC formation (133). The suppressive capacity of regulatory CD8+ T cells 
required the expression of perforin and the presence of IL-15 (133). 
1.12.2 TFH	regulation	by	CD4+	T	follicular	regulatory	cells	(TFR)	
In 2011, a special population of CD4+ dedicated to control humoral responses was 
identified and termed T follicular regulatory cells (TFR) (134). The TFR population 
shares phenotypical traits with both the TFH and Treg subset. TFR express a set of 
genes linked to the effector and suppressive function associated with the Treg 
phenotype, namely glucocorticoid-induced tumor necrosis factor receptor (GITR), 
Cytotoxic T-lymphocyte protein 4 (CTLA4), BTLA, killer cell lectin like receptor 
G1 (KLRG1), CD25, ICOS, Blimp-1, Granzyme A (Gzma) and IL-10, as well as 
features characteristic of TFH cells, such as CXCR5, Bcl6, CXCL13 and ICOS 
(134,135). Interestingly, the TFR formation is dependent on CD28 and SAP-mediated 
interactions with B cells, which is also the case for the TFH but not the Treg subset 
(134).  Importantly, TFR did not express CD40L or transcripts for IL-21 or IL-4, 
which indicates that their capacity to provide help to B cells is limited and suggests a 
functional divergence from the TFH population (134). 
Microarray analysis revealed that in terms of global changes in the gene 
expression TFR more closely resemble Tregs than TFH cells (134). Moreover, 
adoptive transfer experiments showed that TFR cells are generated from thymus-
derived natural T regs (nTregs) and not from TFH cells that have switched on Foxp3 
expression (134,135).  
TFR were found to express Blimp-1 as well as Bcl-6 (134,135), which is 
fascinating as these TFs are known to be mutual repressors in B cells (136,137). 
mRNA analysis showed that the levels of Blimp-1 found in TFR are higher than in 
any other effector cell subset, whereas Bcl-6 is expressed in lower amounts than in 
TFH cells (134). The Bcl-6 expression enables TFR to acquire a migratory profile 
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similar to TFH cells, which enables TFR to locate to GC, where they perform their 
function. Indeed, Tregs were found to express TFs specific to other suppressed T cell 
lineages: T-bet for the Th1, IRF-4 for the Th2 and Ror-γt for the Th17 populations 
(ref. (138-140), respectively).  
TFR function includes limiting the expansion of TFH cells, controlling non-antigen 
specific B cells within the GC (134), as well as class switch and plasma cell 
differentiation (135). In vitro assays revealed that TFR cells showed a suppressive 
potential equivalent to classic Tregs (134,135). Interestingly, the CXCR5+ Bcl6+ 
Treg population was also identified in human tonsils (135). The exact mechanism by 
which TFR perform their functions has not been identified and clearly more work is 
needed to understand fully the role of this subset in humoral responses. Importantly, 
the suppressive potential of TFR makes this subset an attractive target for designing 
treatments for autoimmune diseases.. 
1.12.3 Plasma	cells	
A study by Pelletier et al. described the previously unknown phenomenon of TFH 
regulation by plasma cells (141). Antigen-specific plasma cells were shown to 
express the co-stimulatory molecules CD80/86 and MHC II as well as to present 
antigen in vivo (141). In vitro co-culture experiments showed a diminished IL-21 and 
Bcl6 mRNA expression when in-vitro- or in-vivo-derived TFH were cultured with 
plasma cells (141). Additionally, plasma-cell-deficient mice had increased TFH 
numbers (141).  
However, these results should be treated with some caution, as many aspects 
involving spatial and temporal interactions between TFH and plasma cells were not 
addressed. Furthermore, multiple in vitro studies failed to replace the complexity of 
the follicular environment essential for studying TFH development and function. 
Finally, so far, there are no other reports supporting the hypothesis that plasma cells 
negatively regulate the TFH differentiation. Whether this phenomenon plays a 
significant biological role remains to be established. 
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1.13 Heterogeneity within the TFH population  
The heterogeneity within CD4+ TFH cells is increasingly appreciated since the 
phenotypically similar CXCR5+ PD-1+ Bcl6+ T cells were shown to have a distinct 
localisation within the SLO and different capacity to provide help to B cells 
(114,142). 
1.13.1 Pre-TFH	(TFH)	
Several studies have described the presence of CXCR5+ PD-1+ Bcl6+ T cells in 
the interfollicular zone shortly after immunisation (within 2-3 days p.i.) (57,78,143). 
Pre-TFH (also called ‘TFH’ in some nomenclatures) show lower expression of 
CXCR5, ICOS, PD-1 and Bcl-6 than TFH found at the peak of the GC response 
(57,78,143). These cells are considered to be precursors of GC TFH, although the 
exact cues guiding the transition from pre-TFH to GC TFH have not been elucidated. 
Additionally, these pre-TFH cells were found to play a role in supporting extra 
follicular responses (described below).  
1.13.2 GC	TFH	
Initially all TFH cells were thought to localise within the GC in order to support 
GC B cells. However, it soon became clear that there are also TFH populations 
performing a function outside the GC, and hence the term “GC TFH” has been coined 
to describe GC-resident TFH.  
GC TFH were found to express the highest amount of PD-1, CXCR5 and Bcl6 
among CD4+ T cells,(22,131). BTLA, CD200 and SAP have also been described to 
be expressed on higher levels in GC TFH than in the TFH localised in the apposition to 
the follicles (22,79,114,129). Moreover, GL7 was identified as a marker exclusively 
expressed by GC TFH (129), although another study reported the expression of GL7 
in extra-follicular TFH cells at day 2 p.i. (and prior to the establishment of GC (57)). 
On the other hand, GC TFH were found to express low levels of CCR7 and PSGL1, 
which facilitate the deep penetration of B cell follicles and the location to the GC 
(114).  Interestingly, a low expression of IL-7R (CD127) was also reported for GC 
TFH in mice (78) and  GC TFH in human tonsillar tissue (144), although the 
physiological role of IL-7 signalling in the TFH differentiation remains unexplained. 
Finally, GC TFH were found to express exclusively IL-4 (22,129), and so far there 
CHAPTER 1- INTRODUCTION 
 34	
has been no description of IL-4 expression in TFH populations residing outside the 
GC. The IL-4 expression in GC TFH is mediated by SLAM (Slamf1, CD150) and its 
adaptor SAP (129).  
1.13.3 Extra-follicular	TFH	
The role TFH play in supporting extra-follicular responses became clear after 
published studies that showed that the presence of Bcl6+ CXCR5LO PD-1LO TFH is 
essential for B cell help, prior to the establishment of GC in response to TD antigen 
(SRBC, (131)), and in early extra follicular response to S. enterica (106,131). The 
subset of TFH supporting extra follicular responses was found to be dependent on 
Bcl6 expression, and was localised in the inter-follicular zone (131).  
The role of IL-21 in the extra-follicular zone remains unclear. Initially, IL-21 was 
shown to be dispensable for extra-follicular responses to S. enterica (106). In this 
study, IL-21-/- mice infected with S. enterica showed a humoral response equivalent 
to WT mice (106). However, a study by Lee et al. was performed by transferring IL-
21R-/- and IL21R+/+ SWHEL B cells (B cells specific for HEL antigen capable of 
switching to all isotypes) to congenic hosts followed by immunising with SRBC 
coupled to HEL (131), thus directly addressing the requirement of IL-21 signalling in 
B cells. The results showed impaired (although not completely absent) extra-
follicular plasmablast formation as well as a reduced GC B cell population (131). 
This suggests that IL-21 plays an important, although not absolutely necessary role, 
in extra follicular B cell responses.  
The unimpaired extra-follicular responses in IL-21-/- mice (106) can be explained 
with redundancy in STAT3 signalling and the compensatory roles of other cytokines 
in the process (such as IL-6 and IL-27, as discussed in section ‘The role of cytokines 
in TFH development’ on p. 25). Supporting observations of IL-21 expression in both 
extra follicular TFH and GC TFH come from IL-21 reporter mice, which showed an 
equal expression of PD-1, GATA3, IL-4 and Bcl6 between IL-21+ and IL-21- TFH 
cells (69). This suggests that IL-21 production is not limited to Bcl-6HI TFH, which 
are thought to reside within the GC.  
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 Additionally, the population of TFH residing outside the B cell follicles in the 
human tonsils was found to secrete IL-21 and IL-10 in even higher amounts than GC 
TFH, thus showing a higher capacity for helping naïve and memory B cells than GC 
TFH (145). However, these extra-follicular TFH were unable to help GC B cells due to 
the FAS/FASL-mediated apoptosis triggered in GC B cells upon contact with extra-
follicular TFH (145). Interestingly, this suggests that the distinct function of TFH 
subsets is at least partially explained by cell-intrinsic differences and not only by the 
distinct location of each subset. In keeping with mice studies, human extra-follicular 
TFH were found to express higher levels of IL-7R and lower levels of the Bcl6 
protein than GC TFH (145).  
1.13.4 NK	TFH		
Natural killer (NK) T cells are a heterogeneous population of cells, consisting of 
Type I and Type II NK T cells. Type I NK T cells express invariant TCRα V and J 
segments (Vα14 Jα18 in mice and Vα24 Jα18 in humans) and highly restricted, but 
not invariant, TCRβ (most common chains are Vβ8.2, Vβ7 and Vβ2 in mice and Vβ11 
in humans) (146). This combination of V and J chains generates TCR which 
recognises glycolipids in the context of the non-classical MHC molecule CD1d 
(146). The most characterised antigen recognised by Type I NK T cells is α-
galactosylceramide (α-GalCer) found on the surface of many bacterial species, 
including Borrelia burgdorferi and Sphingomonas (147). A synthetic mimic of α-
GalCer is often used to investigate NK T cell functions in vitro and in vivo. Type II 
NK T cells also express invariant TCR and recognise hydrophobic antigens, such as 
sulfatide or lysophosphatidylcholine, as well as small aromatic (non-lipid) molecules 
(146).  
Type I NK T cells (described below as simply ‘NK T cells’) interact with B cells, 
which have internalized lipid particles via BCR and displayed the lipid antigen via 
CD1d MHC molecule. This cognate engagement results in enhanced extra-follicular 
antibody production (148).  Thus, NK T cells became implicated in supporting B cell 
responses.  
A recent study describes a population of follicular helper NK T cells (NK TFH 
cells) (147). It is a small subset of NK T cells (~3% of NK T cells generated after 
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lipid administration) expressing CXCR5 and PD-1, which are surface receptors also 
expressed by the TFH population. NK TFH cells were found to form stable and motile 
conjugates with antigen-specific B cells, which resulted in an enhanced B cell 
proliferation (147). Immunisation with lipids forming low-, intermediate- or high-
affinity complexes with MHC CD1d molecules revealed that the NK TFH cell 
formation is greater when high-affinity p:MHC interactions are present (147). Other 
factors required for the NK TFH formation and survival (shared with TFH population) 
are the presence of TF Bcl6 and of co-stimulatory receptor CD28 (147). B cells 
expressing the CD1d molecule and SAP-mediated interactions are also indispensable 
for NK TFH generation (147). NK TFH cells were found within the GC and shown to 
be important for the early induction of the GC in response to lipid antigens (147). 
Successful B cell help from NK TFH cells requires IL-21 signalling in a B cell-
intrinsic manner (147).  
Therefore, NK TFH cells provide help to B cells in response to glycolipid antigens, 
which are unable to generate protein-dependent  ‘classic’ B cell helper populations 
(TFH). Simultaneous help from both NK TFH cells as well as from the TFH population 
is also possible in the situation when a B cell internalised lipid-containing antigen via 
BCR and (after antigen processing) displays a protein part of this antigen on the 
MHC class II molecule (147). 
1.14 Concluding remarks on heterogeneity 
One of the main issues in investigating TFH heterogeneity is the lack of specific 
cell surface markers that distinguish various TFH subsets. In many cases differences 
between TFH subsets are reflected in the amount of the proteins expressed rather than 
their presence or absence. The prevalent view in the field describes the presence of 
pre-TFH (or early TFH) cells with low to intermediate levels of Bcl6 in T cell follicles, 
which move to the T-B cell border and stabilises Bcl6 to show maximum Bcl6 levels 
in GC (114,142). This supports the model of continuous TFH differentiation, in which 
precursors of TFH cells reinforce Bcl6 expression upon multiple encounters with 
cognate APCs. This is further discussed in final synoptic discussion on p. 176.  
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1.15 TFH memory  
One of the important questions in the TFH field concerns the ultimate fate of TFH 
cells and their ability to persist in the system as memory TFH cells without exposure 
to the antigen. Interestingly, there are striking parallels in the survival requirements 
of memory CD4+ T cells and TFH cells. Neither of the populations can exist in the 
absence of B cells ((119,149,150) for memory T cells and (75) for TFH cells) and 
both populations require the expression of Bcl6 ((151) for memory T cells and 
(77,84,85) for TFH cells). Therefore TFH cells are likely to contribute to memory  
T cell responses.  
Several studies have addressed the issue of TFH persistence and their phenotype 
after recall response. The transfer of IL-21-producing, transgenic TFH cells (from IL-
21 reporter mice) generated after protein immunisation revealed that after recall 
response most of CXCR5+ IL-21+ TFH cells have retained the original phenotype 
(69). Interestingly, a significant proportion of IL-21- TFH cells became IL-21+ cells. 
Finally, CXCR5- effector cells could also give rise to CXCR5+ T cells (69). IL-21+ 
TFH cells were also shown to persist for 32 days after protein immunisation or viral 
challenge in the absence of antigen and they showed the ability to expand upon re-
challenge (69). The magnitude of recall response was similar between CXCR5+ and 
CXCR5- cells, showing that the TFH population is equally efficient to form memory-
like cells as effector T cells (69). In keeping with these findings, Pepper et al. have 
reported that CXCR5+ memory T cells specific for Listeria monocytogenes can give 
rise to both CXCR5+ and CXCR5- T cells after rechallenge (151). Importantly, the 
plasticity of memory CXCR5+ T cells in studies described above can be partially 
explained by the use of a polyclonal CD4+ T cell population, heterogenic in terms of 
their TCR expression. 
In slight contrast to results described above, studies with monoclonal CD4+ 
CXCR5+ T cell populations reported a preferential retaining of the TFH-like 
phenotype by CXCR5+ T cells and a low conversion to CXCR- T cells. Weber et al. 
reported that antigen-experienced CD4+ CXCR5- T cells transferred to congenic 
hosts and rested for several weeks in the absence of antigen, during recall response 
have an enhanced capacity for B cell follicle homing and B cell help due to a higher 
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expression of CXCR5 and IL-21 than effector cell populations or primary T cells 
(152). Interestingly, resting TFH cells down regulated CXCR5, PD-1, Bcl6 and ICOS 
and rapidly re-acquired their high expression after rechallenge (152). Furthermore, 
studies with Bcl6 reporter mice showed that transgenic Bcl6+ CXCR5+ TFH cells 
persisted in the absence of antigen after protein immunisation for nearly 3 weeks and 
preferentially acquired the TFH-phenotype after the transfer (87). Experiments with 
LCMV-specific CD4+ T cells rested for even longer periods of time (60-150 days) 
without the antigen stimulation also reported preferential acquisition of TFH–like 
profile by CXCR5+ transgenic CD4+ T cells after re-challenge with the antigen (153). 
Authors compare the recall response of TFH cells and Th1 cells, concluding that each 
lineage shows considerable stability during the resting period, which is illustrated by 
the acquisition of the original phenotype after the recall response (153). 
Summing up, TFH cells can persist in the absence of antigen, become re-activated 
during a recall response and give rise to functional TFH cells. However, it seems that 
memory-like TFH do not convert to other subsets of memory cells, such as T central 
memory cells (Tcm), Th1 or Th2 memory cells. This is in contrast to Tcm, which 
exhibit a significant level of plasticity and can differentiate into Th1 or Th2 subsets 
upon re-activation. 
Even though the definition of memory T cells describes T cells which have 
undergone Ag-specific proliferation, have persisted in the organism after Ag 
clearance for a long time and can respond to the same Ag upon subsequent 
encounter, whether the organism really becomes Ag-free after terminating the GC 
response is a matter of debate. Depots of antigens can be held on the surface of the 
FDCs for extended periods of time; some pathogens (especially viruses) also show 
low level of persistence after an acute infection has been resolved (114,154). The 
presence of the antigen could therefore be an important signal for the sustenance of 
TFH and TFH-like cells and a continuous support of this memory pool. Nevertheless, 
several adoptive transfer studies have clearly showed that Ag exposure is dispensable 
for the survival of functional TFH memory-like cells, which provides an important 
insight into the maintenance of the population that plays a pivotal role in the 
generation of efficient humoral response. 
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1.16 TFH cells in autoimmunity in mice and humans 
TFH cells need to be tightly controlled in order to avoid a harmful humoral 
response. The expansion of the TFH population was linked to several models of 
autoimmune conditions characterised by the presence of anti-dsDNA antiobodies. 
Increased TFH numbers were found in mice over expressing OX40L or the TLR7 
ligand (33), as well as in mice carrying a mutation in the Roquin gene3 (sanroque 
mice, (155)), all of which develop a Systemic Lupus Erythromatosus (SLE)-like 
disease. The autoimmunity and aberrant GC reactions in sanroque mice were further 
linked to the expansion of TFH (156). Increased frequencies of circulating CXCR5+ 
TFH-like cells were found in human patients with autoantibody-mediated 
autoimmune diseases, such as SLE, Sjörgen’s syndrome and juvenile 
dermatomyositis (142). Moreover, CXCR5+ CD45RO ICOS+ PD-1+ cells were found 
in the blood of some SLE patients (114). 
An excessive production of IL-21 was also found to contribute significantly to 
autoimmune conditions. Single nucleotide polymporphism (SNP) within the IL-21 
locus was found to be associated with SLE disease in human patients (65). SLE 
patients also showed higher plasma levels of IL-21 than healthy controls and 
increased IL-21 mRNA was found in biopsies of SLE patients (65). Although many 
cell types can secrete IL-21, the fact that autoimmune disorders are tied to a 
dysregulated GC formation and antibody production implicates TFH as most likely 
source of this cytokine. Indeed, in sanroque mice developing severe autoimmunity, 
the uncontrolled TFH population also produces an excess of IL-21 (155). 
In contrast to the excessive TFH formation and function in autoimmune diseases, a 
reduction in the TFH population has been reported for several models of 
immundeficiencies. Reduced TFH numbers have been described in human patients 
with mutations in STAT3, CD40Lg and ICOSL and in their corresponding mice 
models (53,114,142,157). In these cases a severe impairment in humoral diseases is 
observed to various bacterial, viral and fungal pathogens (114,142). Therefore, an 
																																																								
3	Roquin is a RING-type ubiquitin ligase involved in repressing mRNA of ICOS and 
possibly mRNA of IL-21 and SAP (155). Sanroque mice with dysfunctional roquin 
protein have elevated levels of ICOS, great increase in TFH and GC B cells as well as 
severe autoimmune phenotype (155). 
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excessive TFH genesis as well as impairment in the TFH generation may have 
detrimental effects on humoral responses. 
1.17 Models used for in vivo studies 
Early observations from our lab indicated that the phenotype of TFH cells 
(measured by the expression of the surface marker PD-1) found after infection with 
Salmonella enterica was different from the phenotype of TFH found after 
immunisation with ovine erythrocytes (SRBC, acting as a simple antigen). This 
sparked our interest and led to the hypothesis that observed heterogeneity within TFH 
population might have functional consequences. I have therefore used two models of 
infection and immunisation to further investigate the phenotype, function and the 
development of these phenotypically distinct TFH populations. 
1.17.1 Immunology	of	Salmonella	infection	
In this project infection with the attenuated aro-A- strain of Salmonella enterica 
serovar Typhimurium (SL3261, termed hereafter S. enterica, (158)) was used to 
study the heterogeneity within the TFH subsets. This strain is commonly used as a 
live-attenuated vaccine since it provides protection against a more virulent strain 
(158). S. enterica is a gram-negative intracellular bacterium which infects humans 
via oral route. It enters Peyer’s Patches via M cells and epithelial cells in the gut 
(159,160). S. enterica spreads via the mesenteric lymph nodes and lymphatic vessels 
to blood, spleen and liver (160,161). The systemic phase of the infection is 
characterised by splenomegaly caused by increased cell numbers of leukocytes 
(CD11b+, NK1.1+ and GR1+ cells) and, more prominently, red blood cells (162). 
S. enterica resides mainly within macrophages (163,164) and employs several 
mechanisms of evasion of the immune system. The bacterium can impede its uptake 
by DCs, evades lysosomal degradation and interferes with antigen presentation on 
MHC class I and class II molecules (165). The bacterial spread is controlled by 
activated macrophages and inflammatory cytokines, such as IL-12, IFN-γ and TNF-α 
(166,167). IL-12, IFN-γ, TNF-α, IL-15 and IL-18 are essential for initiating the 
adaptive responses to S. enterica (167-170). The final clearance of the bacteria 
depends on CD4+ T cells (166). 
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The humoral response to S. enterica consists of an early wave of IgM (directed 
against LPS and flagellin) and the IgG2c antibody (directed against outer membrane 
proteins, OMP) (171). It is produced by extra-follicular plasma cells and its main 
role is to impede the spread of the bacteria (171). Additionally, T cell independent B-
1b cells are the source of IgG2c antibodies generated against OMP C, D and F (18). 
Protection against subsequent infection is provided by antibodies derived from GC in 
much later stages of the infection (around 5-7 weeks p.i) (171,172). The appearance 
of GCs is related to a lower bacterial burden observed in the late stages of the 
infection, since the GC formation can be accelerated by treatment with antibiotics 
(171). B cell-intrinsic TLR signalling is absolutely essential for the switch to IgG2c, 
as the response to S. enterica in MyD88 KO mice is dominated by IgG1 (172).  
The role of B cells in the response to S. enterica infection extends beyond 
antibody production. Although B cells are not necessary for the primary responses to 
S. enterica (149,173,174), they are required in the early phases of the infection to 
mount optimal Th1 responses by enhancing the IFN-γ production in T cells (172). 
This process is dependent on TLR signalling in B cells and is mediated by the 
cytokine secretion from B cells (IL-6 and IFN-γ, (149)). More importantly, T cell 
memory formation4 is dependent on antigen presentation by B cells (149). Therefore, 
the significant role of B cells in the response to S. enterica involves early, non-
cognate interactions with T cells required for an optimal effector response and late, 
cognate signals, providing T cell memory and protection against future infections.  
In all of the experiments presented in this thesis S. enterica was administered intra 
venously (i.v.) and not orally. There were several reasons for not using the natural 
entry route of the pathogen. Firstly, the aim of the project was not to develop a 
vaccine or treatment for typhoid fever but rather to use S. enterica as an example of a 
bacterial infection eliciting a strong Th1 immune response. Secondly, the i.v. route 
allows for a better control of the infectious dose (which shows wider spread in oral 
delivery). Finally, the natural infection quickly becomes systemic (160), therefore we 
																																																								
4	CD4+ memory T cells in mice and humans recognise mainly epitopes derived from 
flagellar filament protein (228). 	
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would hope that any effects observed after i.v. administration would also recapitulate 
events elicited after the oral infection. 
In S. enterica infection model TFH expressing low levels of PD-1 are found within 
the first week of infection. GCs are not found until much later stages of the infection.  
1.17.2 Sheep	red	blood	cells	(SRBC)	
SRBC immunisation is used as a model for studying TD responses, as it generates 
a strong early extrafollicular response (175,176). Additionally, GC induction is 
observed within the first week after immunisation ((177), observations from our lab). 
The character of the immune response to SRBC is dose dependent, as it was shown 
that injection of 4x106 SRBC elicits mostly a Th1 response (measured by the 
quantity of IFN-γ producing cells) while administration of 4x108 SRBC generates 
predominantly IL-4 producing cells (alongside IFN-γ producing cells, (178)). 
Consistent with this and other published studies (70) as well as unpublished 
observations from our lab (T. Slocombe, personal communication), standard SRBC 
dose used in our lab (2x109 SRBC) generates mostly IgG1 antibodies. 
 In SRBC immunisation TFH expressing high and low levels of PD-1 are 
present and GC are found abundantly during the first week of the response. 
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1.18 Aims of this PhD thesis 
The aim of this PhD work was to investigate the heterogeneity of TFH populations 
in two different immunisation/infection models (SRBC immunisation and S. enterica 
infection), which give rise to phenotypically distinct TFH populations, and to test 
whether there are functional consequences of this heterogeneity. In Chapter 3  
I performed an extensive profiling of the TFH populations with the markers known 
from literature to be connected to TFH, showing that there is indeed a considerable 
level of heterogeneity within the TFH populations. I also took a more global approach 
to characterising TFH by subjecting different TFH subsets to microarray analysis. 
Differential gene expression of general cellular pathways and immune pathways 
(including TFH related genes) confirmed that isolated populations are indeed discreet 
cell subsets. In the following chapter (Chapter 4) I investigated the interactions of 
different TFH populations with cognate B cells, which ultimately led to important 
conclusions about the TFH development pathway. In the final chapter (Chapter 5) I 
studied the potential for interaction between these TFH subsets by performing co-
immunisation experiments with S. enterica and SRBC and, following an unexpected 
result of TFH expansion, I try to broadly address the question regarding specificity of 
those TFH cells.  
 
The broad aims of the thesis were: 
1. To investigate and characterise heterogeneity within TFH populations 
2. To improve our understanding of TFH differentiation and role of cognate B 
cells in this process 
3. To investigate the relationship and potential for interaction between different 
TFH populations.  
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(1)	Unknown	receptor	 induces	 expression	of	Batf	TF,	which	positively	 regulates	TFs	Bcl6	and	c-Maf	as	well	as	 IL-21.	 (2)	 Strong	 IL-2	signaling	via	STAT5	
induces	 expression	 of	 Blimp1	 (from	 Prdm1	 locus),	 which	 represses	 transcription	 of	 Bcl6.	 (3)	 Weak	 IL-2	 signaling	 induces	 expression	 of	 Bcl-6,	 which	
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2 Materials and Methods 
2.1 Medium and FACS buffer 
Medium used in all experiments was Iscove's Modified Dulbecco's Media 
(IMDM, Gibco, UK) supplemented with 1% penicillin/streptomycin (Gibco, UK), 
0.1% β-mercapthothanol (Gibco, UK) and 2% heat inactivated foetal calf serum 
(FCS, Biosera, UK).  
FACS buffer (FB) was prepared by supplementing PBS (Sigma-Aldrich, UK) 
with 3% FCS. For cell sorting FB with 1.5% FCS was used.  
2.2 Animals 
C57BL/6 female mice used for all experiments were bred and kept in specific 
pathogen-free conditions in School of Biological Sciences animal facilities at the 
University of Edinburgh. Animals were 6 to 10 weeks old unless stated otherwise.  
Genetically modified (GM) strains were used: MyD88-/-mice (179), B cell 
deficient mice (µMT, (180)) and MHC II deficient mice (I-Ab-/-, (181)). These GM 
animals have C57Bl/6 background and all were females over 8 weeks old. 
All experiments were carried out in agreement with Animal (Scientific 
Procedures) Act 1986 under the project licence and personal licence granted by 
Home Office and approved by the University of Edinburgh Ethical Review 
Committee. 
2.3 BM chimeras generation 
Chimeric mice with deficient MHC II expression in the B cell compartment 
(termed BMHCII-/- chimeras) were used in experiments presented in Chapter 4. BMHCII-
/- chimeras were generated by sub-lethal irradiation (8 Gy of γ-irradiation) of B cell 
deficient (µMT) recipient animals, which were reconstituted with 2 to 4 million BM 
cells on the same day. The injected BM cell mix was depleted of CD90+ mature T 
cells (by labelling with CD90.2 microbeads and passing over LD column, Miltenyi 
Biotech, according to manufacturers instructions). Injected BM cell mix in 
experimental chimeric group consisted of µMT-derived cells (B cell-deficient) and  
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I-Ab-/- cells (MHC II-deficient) cells in a 4:1 ratio. As a result B cells were derived 
exclusively from MHC II deficient cells whereas other haematopoietic cells were 
derived from both compartments (hence showing overall 20% MHC II deficiency). 
Control chimeras received 80% of µMT-derived BM and 20% of WT BM, therefore 
displaying 100% MHC II expression in all cells of hematopoietic origin. Injection 
mix was delivered in 200 µL intra venously (i.v.). Mice were left to reconstitute for 
at least 6 weeks before the start of the experiment and during this time were housed 
in filter cages with baytril- supplemented water. 
2.4 Immunisations 
2.4.1 Sheep	red	blood	cells	(SRBC)			
Sheep red blood cells (SRBC) were purchased from the Mordun Research 
Institute (University of Edinburgh). SRBC were stored in heparin and thoroughly 
washed with Dulbeccos PBS (Sigma-Aldrich, UK) prior to injection. Mice received 
2 x 109 SRBC in 200 µL PBS via intra peritoneal (i.p.) route in all experiments.  
2.4.2 Salmonella	typhimurium	
The attenuated Salmonella enterica serovar typhimurium (SL3261, (158)) was 
grown in Luria-Bertani (LB) broth (DIFCO laboratories, UK) at 37 °C for 16 h 
without shaking. Approximately 1 x 106 colony forming units (CFU), unless 
otherwise stated, from the stationary phase were delivered in 200 µL sterile 
Dulbeccos PBS (Sigma) i.v. Exact infectious dose per experiment was determined by 
growing bacterial colonies on LB agar plates overnight at 37 °C, counting number of 
CFU and then calculating number of viable bacteria per mouse by taking into 
account dilution factor and injected volume. 
Splenic bacterial load was determined by making a single cell suspension in PBS 
from a piece of the organ of a known weight and plating various dilutions on agar 
plates. The number of CFU was determined by counting colonies formed per spleen 
or per gram of spleen after an overnight culture at 37 °C. 
 In some experiment heat killed (HK) S. enterica was used. HK bacteria were 
prepared by incubating a stationary culture of S. enterica at 80 °C for 10 min. The 
remaining suspension was plated on the agar plates and incubated over night at 37 
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°C. No growth was observed, which confirmed that no viable bacteria were present 
in the injection mix.  
2.5 Cell isolation 
Single cell suspensions of splenocytes were obtained by manually disrupting the 
spleen through gauze squares in complete medium. BM was isolated by flushing the 
bones with complete medium using 25G needle (BD Pharmingen). 
Red blood cell (RBC) lysis was done by adding 2 to 3 mL of RBC lysis buffer 
(Sigma Aldrich, UK) for 2 min at room temperature (RT). Viable cell count was 
determined after staining with trypan blue dye (0.1%, Sigma Aldrich, UK).   
2.6 Flow cytometry 
2.6.1 Surface	staining	
Single cell suspensions, containing 4 to 5 million cells, were washed with PBS. 
Cell viability was evaluated in some experiments by staining with amine-reactive 
fluorescent viability dye (1:700, LIVE/DEAD® fixable dead cell stain, Invitrogen). 
After 15 min incubation at 4 ˚C, cells were washed with FACS Buffer (FB) and 
primary antibodies applied for 25 min at 4 ˚C. Cells were then washed and secondary 
antibodies applied if needed (incubation for 15 min at 4 ˚C). Samples were washed 
prior to acquisition. All centrifugations were done at 4 °C for 2 min at 400 G.  
2.6.2 Intracellular	staining	
For intracellular staining eBioscience Foxp3 intracellular staining kit was used 
according to manufacturer’s instructions. Following surface staining, samples were 
fixed in Fix/Perm solution. After 15 min incubation at RT cells were washed with 
Perm Buffer. Blocking solution (2% rat serum and 1% anti-CD132) was applied for 
5 min at RT and then intracellular antibodies were added for further incubation of 60 
min at RT. A final wash step with Perm Buffer was performed prior to re-suspension 
in FB.  
Samples were acquired using the LSR II flow cytometer (BD, UK) and data were 
analysed using FlowJo software (TreeStar). Antibodies used for flow cytometry are 
presented in Table 2.1. 
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2.7 T cell sorts and adoptive transfers 
For isolation of individual TFH populations flow cytometry associated sorting was 
used. TFH populations were isolated at D6 post SRBC immunisation from WT 
C57Bl/6 mice, MHC II deficient mice (MHCII-/-) or mixed BM chimeras.  
CD4 T cell fraction was enriched by depletion of other cell populations prior to 
sorting. The depletion based on magnetic separation was done using Dynabeads 
(Invitrogen). Briefly, splenocytes (1x108 / mL) were labeled with anti-MHCII (clone 
M5114, home grown) and anti-CD8 antibodies (clone 53.6.72, home grown) for 
25min at 4 ˚C in complete medium. After washing step, cells were incubated with 
anti-rat IgG Dynabeads (bead:cell ratio 1:2) for 30 min at 4 ˚C with the rotation. 
MHC II+ and CD8+ cells were bound to the beads and separated from the unlabelled 
cell fraction (containing CD4+ T cell) by using a Dynabead magnet. The frequency 
of CD4 T cells after enrichment process was around 65%. TFH cell staining for flow 
cytometry was done as described in section 2.6. Cells were sorted into PBS 
containing 1.5 - 2% FCS with FACS ARIA (BD) and quality control confirmed high 
sorting purity. The sorting strategy and purity is presented on Figure 2.1. 
In adoptive transfer experiments, sorted T cell populations were washed with 
sterile PBS (Sigma), counted and 0.4 million cells in 200 µL of sterile PBS (Sigma) 
per mouse were injected i.v.  
TFH cells sorted for RNA isolation were stored as cell pellets or in TRIzol reagent 
(Invitrogen) at -80 ˚C until extraction process.  
2.8 RNA extractions and quality control 
RNA was extracted from TFH population stored either in TRIzol (Invitrogen) or as 
cell pellets. RNeasy kit (Qiagen) was used in both cases.  
When extracting RNA from cells stored in TRIzol, the RNA cleanup procedure 
was followed (p.56 of Qiagen handbook). After 5 min incubation at RT, 200 µL 
chloroform per 1 mL of Trizol were added, the sample was vigorously shaken and 
further incubated for 3 min at RT. After spinning step (15 min at 12000 G at 4 °C) 
the upper aqueous phase was transferred to a new collection tube, 350 µL of cold 
RLT buffer were added followed by 250 µL of cold 100% ethanol (both volumes per 
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100 µL of the aqueous phase). Tube was vortexed and liquid loaded on the RNeasy 
Mini column in 730 µL fractions. From then standard manufacturers’ instructions 
were followed. 
In RNA extraction performed from the cell pellets, 750 µL of RLT buffer were 
added to the pellet which was passed via a syringe (21G, BD Pharmingen).  750 µL 
of cold 75% ethanol was then added, the sample was vortexed and liquid loaded on 
the RNeasy Mini column. Standard manufacturers’ instructions were followed as 
above. RNAse inhibitor (Roche) was added at the end of the extraction process and 
clean RNA was stored in DEPC-treated RNAse-free water (Ambion). RNA quantity 
was determined by Nanodrop (Thermoscientific) and RNA integrity was assessed by 
Bioanalyzer (Agilent Technologies). In the latter case RNA-Nano chips (Agilent 
Technologies) were used strictly as per manufacturers’ instructions. RNA integrity 
number (RIN) confirmed that isolated RNA was of very high quality and no 
significant degradation was detected (RIN values were between 8-10, out of 10 
possible, Table 2.2).  
2.9 cDNA synthesis and quantitive real-time PCR 
RNA was converted into cDNA using Superscript First Strand Synthesis System 
(Invitrogen) according to manufacturers’ instructions with 50-200 ng of RNA input 
used per 10 µL reaction volume.   
Real time qPCR was performed using probe-based assays enabling sequence-
specific detection of target genes. TaqMan Gene expression master mix (Applied 
Biosystems, 10 µL per reaction), 55 ng of cDNA of interest, 1 µL of probe-labeled 
primers and water was mixed to give a total volume of 20 µL per reaction. Primer 
sequences or assay numbers (IDT technologies) are shown in Table 2.3 and Table 
2.4. mRNA levels were normalized to reference genes UBC and 18s from GeNorm 
kit (Primer Design). Differences in the samples were calculated using delta delta 
method. 
2.10 Microarray analysis of T cell populations 
RNA extracts from sorted T cell populations were subjected to quality control by 
Nanodrop and Bioanalyzer, as described above. Extracted mRNA was stored at -70 
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°C until analysis. Hybridisation of mRNA to the microarray chips was performed in 
ARK Genomic Technologies (The Roslin Institute, University of Edinburgh). Files 
were fully analysed by Dr. Al Ivens (Centre for Immunity, Infection and Evolution, 
Edinburgh). Data were subjected to quality control (Appendix Fig. 7.1-7.4), 
normalisation and correction for multiple testing. As a result, tables containing lists 
of differentially expressed genes alongside P values and fold changes in expression 
were generated.  
2.11 mRNA isolation, cDNA synthesis and library preparation for TCR 
sequencing 
Sample preparation for TCR sequencing was carried out by Dr. Graeme Cowan, 
who kindly provided the protocols described below. 
2.11.1 mRNA	isolation	
Dynabeads mRNA DIRECT Kit (ThermoFisher Scientific) was used for mRNA 
isolation. The cell pellet (containing up to 1 x 106 cells) was resuspended in 300 µL 
of lysis buffer in order to release the genomic DNA. The lysate was passed through a 
21G needle (BD Pharmingen) to shear the genomic DNA. 100 µL of Dynabeads 
were prepared for the reaction by washing in 50 µL of lysis/binding buffer. The 
sample lysate was added to the dynabeads and the sample was thoroughly mixed by 
repeated pipetting and incubation with continuous mixing for 3 to 5 min at RT. 
Microcentrifuge tube was then placed on a magnet for 2 min and supernatant was 
removed. Beads were washed twice with 600 µL of wash buffer A and twice with 
300 µL of wash buffer B. These washing steps were performed at RT and the magnet 
was used to separate beads from the solution. Samples with mRNA bound to the 
beads was stored in -80 °C until cDNA synthesis was performed.  
2.11.2 First	strand	cDNA	synthesis	
First strand cDNA synthesis was carried out with the SmartScribe polymerase kit 
(Clontech). Washed magnetic beads (9 µL) with bound mRNA were incubated with 
First Strand Buffer (4 µL), DTT (0.5 µL), mix of dNTPs (2 µL of 10mM solution), 
SMARTer IIA PTO oligo (2 µL of 12 µM solution), SMARTScribe RTase (2 µL) 
and RNase inhibitor (0.5 µL, Clontech). The solution was incubated for 50 min at 42 
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°C with repeated mixing to resuspend the beads. Reactions were terminated by 10 
min incubation at 70 °C. Samples were stored again at -80 °C until further 
processing.  
2.11.3 Library	preparation	–	amplification	of	variable	regions	
PCR reactions were carried out on a LightcCycler® 480 System qPCR machine 
(Roche) with suitable qPCR multiwell plates (Roche).  
 
Primers used (also showed in Fig. 5.2): 
Reverse primer fused to P5 Illumina adapter: 
AATGATACGGCGACCACCGAGATCTACACCTTGGGTGGAGTCACATTTCT  
 
Forward primer fused to P7 Illumina adapter with SMART indexed sequence: 
CAAGCAGAAGACGGCATACGAGATTCTCGAAAGCAGTGGTATCAACGCAGAGT 
 
PCR mix (total volume of 20 µL) contained Phusion flash (10 µL, PCR master mix, 
Thermo Fisher Scientific), forward and reverse primers (2 µL of 12 mM solution 
each), cDNA (2 µL) and dH20 containing diluted SYBR green (4 µL, 1:2000 
dilution, Invitrogen). PCR cycles were set up as follows: 
98°C 2min   (cDNA denaturation) 
 
98°C 10s } 
60°C 15s } x 5 cycles (elongation) 
72°C 25s } 
 
98°C 10s } 
65°C 15s } x 25 cycles (elongation) 
72°C 25s } 
 
72°C 2min   (termination of the reaction) 
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PCR products, containing amplicons of variable TCR regions, were then run on a 
2% agarose gel to remove residual primers and truncated products. Bands of 
appropriate size were excised and purified using the Gel Extraction Kit (Qiagen) 
according to manufacturers’ instructions. 
2.12 Statistical analysis 
Statistical analyses were carried out with Prism 6 software (GraphPad Software 
Inc., USA). Student’s t-test or one-way ANOVA analyses were used to determine 
significance between the groups. For two-way ANOVA Tukey’s correction for 
multiple testing was used. Significance was depicted in the graphs as follows: * for 
P= 0.01 to 0.05, ** for P = 0.001 to 0.01, *** for P < 0.001. P> 0.05 was considered 
as not significant (ns).  
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(A)	 Sorting	 strategy	 for	 naive	 T	 cells.	 Lymphocytes	were	 selected	 on	 the	 basis	 on	 site	
scatter	 (SSC-A)	 and	 forward	 scatter	 (FSC-A).	 Single	 cells	 were	 then	 positively	 selected	
based	on	 the	width	of	 the	cell	 (FSC-A	vs	FSC-W).	B	 cells	 and	CD8+	 T	 cells	were	 further	
excluded	(CD19	vs	CD8).	CD4+	T	cells	were	selected	(FSC-A	vs	CD4)	and	naïve	T	cells	were	
sorted	 based	 on	 the	 expression	 of	 CD44	 and	 CD62L.	 (B)	 Sorting	 strategy	 for	 TFH	
populations	 from	WT	mice	6	days	after	S.	enterica	 infection	or	 (C)	SRBC	 immunisation.	
(B)	 and	 (C):	 lymphocytes	 and	 singles	 cells	 were	 gated	 as	 in	 (A).	 CD19+	 B	 cells	 were	
excluded	and	CD4+	T	cells	were	selected	(CD19	vs	CD4).	T	cell	subsets	were	sorted	based	
on	the	expression	of	CXCR5	and	PD-1	into	PD-1HI	TFH,	PD-1LO	TFH	and	CXCR5-	T	cells.	
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Table 2.1. Antibodies used for flow cytometry staining.  
 
Antibody/	reagent	 Conjugate	 Clone	 Dilution	 Provider	
Anti-CD3ε	 PE	 145-2C11	 1:200	 eBiosciences 
Anti-CD4 FITC	 GK1.5	 1:200	 Southern	Biotech	
Anti-CD4 APC—eFluor780	 RM4-5	 1:200	 eBiosciences	
Anti-CD8α	 PE	 53-6.7	 1:200	 BD	Pharmingen	
Anti-CD8α	 BV	650	 53-6.7	 1:200	 Biolegend	
Anti-CD11b	 APC-Cy7	 M1/70 1:200	 Biolegend	
Anti-CD11c	 FITC	 N418	 1:100	 home	grown	
Abti-CD16/CD32	 unlabelled	 2.4G2	 1:100	 home	grown	
Anti-CD19	 PE	 1D3	 1:200	 BD	Pharmingen	
Anti-CD19	 PercP	 6D5	 1:200	 Biolegend	
Anti-CD19	 BV	421	 6D5	 1:200	 Biolegend	
Anti-CD25	 Pe-Cy7	 PC61.5	 1:200	 eBioscience	
Anti-CD44	 FITC	 polyclonal	 1:200	 home	grown	
Anti-CD45.1	 FITC	 A20	 1:200	 Biolegend	
Anti-CD45.1	 PE	 A20	 1:200	 BD	Pharmingen	
Anti-CD45.1	 BV650	 A20	 1:100	 Biolegend	
Anti-CD45.2	 FITC	 104	 1:200	 BD	Pharmingen	
Anti-CD45.2	 PE	 104	 1:200	 Biolegend	
Anti-B220	(CD45R)	 PerCP	 RA3-6B2	 1:200	 BD	Pharmigen	
Anti-CD62L	 PerCP/Cy5.5	 MEL-14	 1:200	 Biolegend	
Anti-CD62L	 BV	605	 MEL-14	 1:200	 Biolegend	
Anti-CD127	 BV421	 A7R34	 1:200	 Biolegend	
Anti-CD162	 PE	 2PH1	 1:100	 BD	Pharmingen	
Anti-ICOS	(CD278)	 PE	 7E.17G9	 1:100	 eBiosciences	
Anti-PD-1	(CD279)	 PE	 RMP1-30	 1:100	 Biolegend	
Anti-PD-1	(CD279)	 Pe-Cy7	 RMP1-30	 1:100	 Biolegend	
Anti-Bcl6		 PE	 K112-91	 1:100	 BD	Pharmingen	
Anti-CXCR5	 Biotin	 2G8	 1:100	 BD	Pharmingen	
Anti-F4/80	 APC	 BM8	 1:100	 eBiosciences	
Anti-IgD	 Pacific	Blue	 11-26c.2a	 1:200	 Biolegend	
Anti-Foxp3	 FITC	 FJK-16s	 1:100	 eBioscience	
Anti-Ki67	 PE	 B56	 1:100	 BD	Pharmingen	
Anti-KLRG1	 Pe-Cy7	 2F1	 1:200	 eBioscience	
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Anti-MHC	II	 FITC	 M5114	 1:200	 home	grown	
Anti-MHC	II	 Pacific	Blue	 M5114.5.2	 1:200	 Biolegend	
PNA	 FITC	 N/A	 1:1600	 Vector	Laboratories	
















1 Naïve CD44LOCD62LHI Naive T cells 9.3 
2 Naïve CD44LOCD62LHI Naive T cells 9.1 
3 Naïve CD44LOCD62LHI Naive T cells 8.5 
4 S. enterica CXCR5+PD-1+ TFH (PD-1LO) 8.5 
5 S. enterica CXCR5+PD-1+ TFH (PD-1LO) 8.1 
6 S. enterica CXCR5+PD-1+ TFH (PD-1LO) 8.5 
7 S. enterica CXCR5-PD-1+ CXCR5 neg. T cells 9.9 
8 S. enterica CXCR5-PD-1+ CXCR5 neg. T cells 9.8 
9 S. enterica CXCR5-PD-1+ CXCR5 neg. T cells 10.0 
10 SRBC CXCR5+PD-1HI TFH (PD-1HI) 9.4 
11 SRBC CXCR5+PD-1HI TFH (PD-1HI) 8.6 
12 SRBC CXCR5+PD-1HI TFH (PD-1HI) 9.2 
13 SRBC CXCR5+PD-1LO TFH (PD-1LO) 9.8 
14 SRBC CXCR5+PD-1LO TFH (PD-1LO) 9.0 
15 SRBC CXCR5+PD-1LO TFH (PD-1LO) 9.1 
16 SRBC CXCR5- PD-1+ CXCR5 neg. T cells 9.5 
17 SRBC CXCR5- PD-1+ CXCR5 neg. T cells 9.3 
     18 SRBC CXCR5- PD-1+ CXCR5 neg. T cells 9.6 
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Table 2.3. qPCR primer sequences (Integrated DNA Technologies, Iowa, USA). 
Gene 
symbol 
Gene name Forward primer 5’-3’ Reverse primer 5’-3’ 
Bcl6 B cell lymphoma-6 AGTCACATTCGTTGCAGAAGA CAGAGATGTGCCTCCATACTG 
Tox2 TOX High Mobility Group 




Table 2.4. PrimeTime® qPCR assay  numbers (Integrated DNA Technologies, Iowa, USA) 
Gene symbol Gene name PrimeTime qPCR assay number 
Ascl2 Achaete-scute complex homolog 2, Drosophila Mm.PT.58.11676006.gs 
Ccr7 Chemokine (C-C motif) receptor 7 Mm.PT.58.31257202 
Il7r IL-7 Receptor Mm.PT.56a.14297778 
Il21 IL-21 Mm.PT.56a.7853071 
Klrg1 Killer cell lectin like receptor G1 Mm.PT.56a.30803964 










Chapter	3	–	Characterisation of TFH populations 
 61	
3 Characterisation of TFH cell populations in SRBC 
immunisation and S. enterica infection  
3.1 Introduction 
In the current literature the existence of more than one type of TFH population is a 
matter of debate. Clearly, there is some heterogeneity among CXCR5+ CD4+ T cells 
revealed by the existence of TFR (134) and NK TFH ((147), discussed in main 
introduction on p. 33), but whether other CXCR5+ PD-1+ Bcl6+ cells contain 
specialized subsets that perform different functions is unknown.  
In the early days after the discovery of TFH, all CD4+ cells expressing CXCR5 and 
ICOS were termed TFH. Since many cell types up-regulate ICOS after the cell 
activation, it became clear that there is the need for another marker for TFH 
population. PD-1 protein was shown to be highly expressed by CXCR5+ ICOS+ cells 
(182). PD-1 plays a pivotal role in the GC (GC) and long-lived plasma cell formation 
and B cell proliferation (113,134). The discovery of Bcl6 as a TFH specific TF 
(77,84,147) changed the standards of identifying TFH, by now linking the presence of 
this subset to its function in supporting B cells and antibody production. Therefore, 
when doing research on TFH, one cannot simply look at the surface phenotype but 
must also consider the functional output of the population.  
The aim of this PhD work was to investigate the heterogeneity of TFH populations 
in two different immunisation/infection models (SRBC immunisation and S. enterica 
infection), which give rise to phenotypically distinct TFH populations, and to test 
whether there are functional consequences of this heterogeneity. In Chapter 3 I 
performed an extensive profiling of the TFH populations with the markers known 
from literature to be connected to TFH, showing that there is indeed a considerable 
level of heterogeneity within the TFH populations. I also took a more global approach 
to characterising TFH by subjecting different subsets to microarray analysis. 
Differential gene expression of general cellular pathways and immune pathways 
(including TFH related genes) confirmed that isolated populations are indeed discreet 
cell subsets. In the following chapter (Chapter 4) I investigated the interactions of 
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different TFH with cognate B cells, which ultimately led to important conclusions 
about the TFH development pathway. In the final chapter (Chapter 5) I studied the 
potential for interaction between these TFH subsets by performing co-immunisation 
experiments and, following an unexpected result of TFH expansion, I try to broadly 
address the question regarding specificity of those TFH cells.  
 






TFH population was first identified by flow cytometry as CXCR5+ ICOS+ subset 
within CD4+ T cells (183,184). PD-1 protein has soon become recognized as another 
relevant surface marker (22,129). Currently CXCR5 and PD-1 are the most 
commonly used cell surface markers used for defining the TFH subset. Additionally, 
the Bcl6 TF is used as an intracellular marker for bona fide TFH (77,84,85). 
Therefore, in my work I have identified different TFH subsets by using these three 
commonly accepted markers: PD-1, CXCR5 and Bcl6. 
 In all of the experiments presented the spleen was used as the source of TFH 
isolation. The gating strategy for TFH identification (Fig. 3.1A, upper panel) involved 
selecting the lymphocytes based on their side and forward scatter appearance (SSC-
A vs FSC-A) and then excluding doublets (SSC-A vs SSC-W) and CD8+ T cells 
(SSC-A vs CD8). B cells were identified alongside CD4+ T cells (CD19 vs CD4). As 
an important technical control, surface expression of CXCR5 on B cells was graphed 
(Fig. 3.1A, lower panel, first and second graph to the left). Since B cells are 
uniformly CXCR5 positive (4,5), this was an important quality control for CXCR5 
staining (which proved to be technically challenging at times). Finally, PD-1 and 
CXCR5 double positive cells were selected within the CD4+ T cells (Fig. 3.1A, 
lower panel, second graph to the right). Relevant isotype controls were used to 
determine PD-1 and CXCR5 positive cut-off gates on CD4+ T cells (Fig. 3.1A, lower 
panel, first graph to the right). Live/dead stain, often used to gate out dead or 
apoptotic cells, was not commonly used since staining of the fresh ex-vivo 
splenocytes resulted in around 90% or 98% viability (for S. enterica and SRBC 
model, respectively) and, most importantly, early experiments showed that gating out 
dying cells did not have any impact on downstream TFH analysis.  
The TFH analysis of early stages of the immune response to the immunisation with 
SRBC or S. enterica infection provided clear results indicating that TFH observed in 
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the early stages of S. enterica infection displayed much lower levels of PD-1 on the 
cell surface than corresponding CXCR5 positive population generated during the 
SRBC response. This phenomenon raised curiosity in our lab and, therefore a time 
course analysis of the TFH populations was carried out to investigate the kinetics of 
the CXCR5, PD-1 and Bcl-6 expression in the two models. 
 In the SRBC immunisation, TFH populations (expressing high and low levels of 
PD-1, therefore termed ‘PD-1HI’ and ‘PD-1LO’ TFH) became visible around day 5 and 
peak in frequency around day 7 (Fig. 3.1 B and D). However, in the S. enterica 
model, TFH cells appear earlier (around day 3), express predominantly low levels of 
PD-1 (hence ‘PD-1LO TFH’) and their frequency peaks around day 9 p.i. (Fig. 3.1C 
and D). In both models PD-1HI and PD-1LO TFH populations decline from day 9 
onwards (Fig. 3.1 B-E) and by day 15 are contracted almost to the levels observed in 
non-immunised animals (graphed as day 0).  
In striking contrast to the SRBC model, in S. enterica infection the PD-1HI TFH 
population is present at a very low frequency (0.36% ± 0.05, of CD4+ T cells at day 
6, Fig. 3.1 C and D). Furthermore, even the few TFH, which fall into the PD-1HI gate 
in the S. enterica model express less PD-1 protein on the surface than the PD-1HI TFH 
arising after SRBC immunisation (MFI of PD-1: 5404±1273 for the PD-1HI TFH in  
S. enterica infection vs. 7437±235 for the PD-1HI TFH in SRBC model, p<0.05). This 
shows that the distinction between PD-1HI and PD-1LO TFH in terms of PD-1 
expression is consistent during the first week of the response (Fig. 3.1E). 
Interestingly, PD-1HI TFH from both models express more CXCR5 protein than PD-
1LO TFH (Fig. 3.1F), which suggests potential differences in the positioning of these 
cell subsets (MFI of CXCR5: PD-1HI TFH vs PD-1LO TFH: 2526±195 vs 1818±36 for 
the S. enterica infection and 2162±43 vs 1597±42  in SRBC model, p<0.001 for both 
models). 
One might argue that classifying TFH into PD-1HI and PD-1LO subsets depends on 
arbitrary positioning of the PD-1HI and PD-1LO gates. However, the gates are 
consistent for all samples and the results from multiple experiments are highly 
reproducible, which illustrates the validity of distinguishing the TFH subsets based on 
their PD-1 expression. Additionally, high and low expression of PD-1 is observed 
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already from day 3 of the response to both SRBC and S. enterica, and the TFH 
phenotype remains stable over time (Fig 3.1E).  
Summing up, within the first two weeks of the response to SRBC, the TFH 
population peaks around day 7 and there is a clear distinction between PD-1HI and 
PD-1LO TFH cell subsets. This is in contrast to the S. enterica model, where the vast 
majority of TFH cells express low to intermediate levels of PD-1 and the PD-1HI TFH 
population is scarce in terms of frequency. Therefore, clear phenotypical 
heterogeneity within CXCR5 positive cells has been recognised in two different 
models of the immune response. Whether this phenomenon carries also functional 




The TFH population is linked to GC support (discussed in the Introduction, p. 27) 
and therefore the presence of these structures in SRBC and S. enterica 
immunisations was assessed to establish the functional capacity of different TFH 
subsets.  
GC B cells can be identified and quantified by means of flow cytometry as a 
subset of CD19+ lymphocytes expressing high levels of TF Bcl6 (185). The gating 
strategy for identifying GC B cells (Fig. 3.2A) involved the positive selection of 
lymphocytes, single cells and CD19 B cells while excluding CD4+ T cells at the 
same time (as some of CD4+ cells, namely TFH, will be Bcl-6 positive). GC B cells 
were finally identified as cells expressing both CD19 and Bcl6 (Fig. 3.2A, second 
graph from the right). The relevant isotype control was used to confirm the 
specificity of the staining (Fig. 3.2A, far right).  
In keeping with other published findings (171) and previous observations from 
our lab, GC B cells were absent during the first 2 weeks of the response to S. 
enterica (Fig 3.2C, D), since, as discussed before (Introduction, p. 40), GC formation 
in this model is delayed until around week 7 p.i. In striking contrast to this, GC B 
cells were abundantly found in animals immunised with SRBC as early as day 5 p.i. 
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with the peak of the expansion around day 9 and a decline in frequency by day 15 
(Fig. 3.2B, D). The summary of GC B cell frequencies and numbers (Fig. 3.2D and 
E, respectively) illustrated clearly that while the SRBC model gives a robust GC 
response within the first two weeks p.i., these structures are completely absent in the 
S. enterica infection (GC B cells as % of B cells at day 6 p.i.: 0.58±0.06 in S. 
enterica model vs 3.49±0.58 in SRBC model, p<0.01). These results were confirmed 
by flow cytometry analysis using alternative surface markers (with GC B cells 
identified as CD19+ cells positive for peanut agglutinin (PNA) and negative for IgD, 
Appendix Fig. 7.5).  
In conclusion, the clear presence of GC in SRBC model and their absence in  
S. enterica infection raised questions about the function of PD-1LO TFH cells found in 
the latter model. Considering that the PD-1HI TFH subset is present in the model 




The reasons for the absence of the PD-1HI TFH subset in S. enterica are unknown. 
One of the most noticeable differences between SRBC and S. enterica 
immunisations is splenomegaly found in the latter model. This is in contrast to SRBC 
response, where spleen architecture is intact and B cell follicles and T cell zones are 
easily distinguished. I therefore decided to address the question whether altered 
splenic structures found in the early stages of S. enterica infection hamper the 
formation of PD-1HI TFH by, for example, disrupting the niche required for this 
subset to develop or survive.  
The standard infectious dose of S. enterica in our lab is 106 CFU/mouse and this 
dose causes, as mentioned, severe splenomegaly. However, increase in the spleen 
size can be limited by using a lower infectious dose (104 CFU/mouse) or heat killed 
(HK) bacteria. Previous work of an honours student in our lab, Lewis Cawkwell, 
showed that at a lower infectious dose (1x104 CFU) there is a significant immune 
response in terms of CD4+ and CD8+ T cell activation and cytokine secretion by  
T cells (unpublished data). At the same time, with respect to the FDC network and  
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B cell follicles, the splenic structure appears comparable to the undisrupted spleen of 
naïve animals. To test the hypothesis that distorted splenic structures impede the 
formation of PD-1HI TFH in S. enterica infection, I infected animals with the standard 
dose of live S. enterica  (1x106 CFU/mouse), a low dose of live bacteria (1x104 
CFU/mouse) and also HK bacteria. TFH and GC formation were assessed 6 days p.i. 
by flow cytometry. In agreement with previous studies from our lab, animals 
immunised with 1x106 CFU had on average 5 times larger spleens than naïve 
animals (Fig 3.3A). Importantly, splenomegaly was not observed in infection with 
the lower dose of live bacteria and HK bacteria (Fig 3.3A). The difference in the 
immunisation dose was reflected in bacterial burden measured on day 6 p.i. (Fig. 
3.3B). Animals immunised with the 1x106 CFU dose of live bacteria displayed 
higher CFU count per spleen and per gram of spleen than animals with the lower 
dose immunisation (Fig. 3.3B). 
As shown previously (Fig.3.1C and D), immunisation with the standard dose of 
1x106 CFU of S. enterica did not generate many PD-1HI TFH but PD-1LO TFH were 
found abundantly (Fig. 3.3C-E). Fascinatingly, this was also the case for the lower 
dose and HK bacteria immunisation (Fig. 3.3C-E). In all three immunisation models 
the frequency and numbers of PD-1HI TFH were comparable to unimmunised animals 
(Fig. 3.3D and E, left). PD-1LO TFH cells were found at the highest frequency and 
numbers in the high-dose immunisation model (Fig. 3.3D and E, right. PD-1LO TFH 
as % of CD4+ T cell: 7.05±0.17 for high dose S. enterica vs. 2.35±0.22% for low 
dose and 2.83±0.33 for HK bacteria). A detectable increase in PD-1LO TFH frequency 
(although of lower magnitude) above the levels observed in naïve animals was also 
found in the lower dose infection and HK bacteria immunisation. However, these 
parameters were not always statistically significant, partly due to the fact that naïve 
animals used for this experiment showed higher background levels of PD-1LO TFH 
than usually observed. 
The induction of GC B cells was further assessed as a functional readout of TFH 
presence. As expected, in the light of the missing PD-1HI TFH population, GC B cells 
(CD19+ Bcl6+, Fig. 3.3F) were also absent in all immunised groups in terms of 
frequency and numbers (Fig. 3.3G). 
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Summing up, altered splenic structures do not prevent formation of PD-1HI TFH 
and GC populations in S. enterica infection as these lymphocyte populations are not 
found in the infection/immunisation models when the splenic architecture is intact. 
The expansion of PD-1HI TFH seems to be proportional to the infectious dose, since 
infection with higher dose of S. enterica leads to greater PD-1LO TFH expansion than 
in the low dose or HK bacteria immunisation. Concluding further, the PD-1LO TFH 
population found in the early stages of immune response to S. enterica is not able to 




So far the presence of TFH populations expressing high or low levels of the PD-1 
protein on the cell surface has been established in S. enterica and SRBC models. It 
was further important to establish whether other proteins associated with the TFH 
function were differentially expressed between the PD-1HI TFH and PD-1LO TFH 
populations. To investigate the levels of the relevant cell surface and intracellular 
markers TFH profiling by flow cytometry and qPCR based on the published TFH 
studies was carried out.  
Firstly, the levels of TFs important for the TFH lineage were measured by qPCR 
on sorted TFH populations isolated on day 6 p.i. with SRBC or S. enterica (sorting 
strategy is described in Material and Methods chapter on p. 52.) In the SRBC model, 
message levels of the Bcl6 TF, recognised as a master regulator of the TFH lineage 
(Introduction p. 21), has been found highly expressed in PD-1HI TFH (Fig. 3.4A, left) 
and to a lesser extent in the PD-1LO TFH subset. In S. enterica infection PD-1LO TFH 
expressed significantly more Bcl6 mRNA than CXCR5- T cells (Fig. 3.4A, left). The 
frequency of PD-1HI TFH cells found in the S. enterica model was too low to allow 
for cell isolation and RNA extraction.  
Taking advantage of the fact that the flow cytometry enables analysis of protein 
levels in cells found also at very low frequencies, a time course analysis of Bcl6 
protein expression was carried out in the first two weeks of the response to SRBC 
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and S. enterica (Fig. 3.4B). In both models PD-1HI TFH showed much higher Bcl6 
expression than PD-1LO TFH and, interestingly, these differences in expression levels 
were clear already at the early stage of the response (day 3 p.i.). Intriguingly, at day 3 
p.i. PD-1HI TFH from S. enterica infection express just as much Bcl6 protein as  
PD-1HI TFH from SRBC. However, on day 5-6 p.i. there is no difference in protein 
levels between PD-1HI TFH and PD-1LO TFH in the S. enterica model (Fig. 3.4B, 
right). In contrast to that finding, PD-1HI TFH from the SRBC model further increased 
their expression of Bcl6 from day 3 p.i. and at day 6 p.i. have around twice as much 
protein as PD-1LO TFH from the same model (Fig. 3.4B, right). The peak of the Bcl6 
expression for all analysed populations was observed around day 7 p.i. Importantly, 
both TFH populations (PD-1HI TFH and PD-1LO TFH) expressed more Bcl6 protein than 
CXCR5- T cells and naive T cells (CD62L+ CD44-, graphed as day 0), and this is true 
for both investigated models. CXCR5- cells from both models show consistently low 
levels of Bcl6 throughout the response, comparable to the levels of naïve T cells (day 
0).  
Blimp1 (B lymphocyte-induced maturation protein 1), the antagonist TF of Bcl6, 
was described to have a reciprocal expression pattern in the TFH population and the 
effector cell populations, with TFR being the only T cell subset expressing significant 
levels of both proteins at the same time (134). Since reliable flow cytometry staining 
for Blimp1 protein was not available at the time the experiment was carried out, 
qPCR analysis of sorted populations isolated at day 6 p.i. was used to asses the level 
of the transcript Prdm1, encoding for the protein Blimp1. In keeping with other 
studies, the population with the highest expression of Bcl6 mRNA and protein (PD-
1HI TFH from SRBC) had the lowest expression of Prdm1 mRNA (Fig. 3.4A, centre) 
and vice versa. CXCR5- cells from both models, being poor in Bcl6 expression, show 
abundant message for the Blimp1 protein (Fig. 3.4A, centre).  
The Ascl2 (Achaete-scute complex homolog 2, Drosophila) TF has recently been 
identified in TFH as an important protein in driving CXCR5 expression (Introduction 
p. 23, (99)) and therefore it was expected to be found most abundantly in CXCR5 
positive populations. Levels of Ascl2 mRNA were assessed by qPCR on day 6 p.i. 
due to lack of reagents for flow cytometry.  Indeed, the PD-1HI TFH from SRBC 
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model showed by far the highest expression of Ascl2 mRNA. Interestingly, PD-1LO 
TFH populations (which are CXCR5 positive) from both the SRBC and S. enterica 
model expressed comparable levels of Ascl2 mRNA to CXCR5- T cells isolated from 
both models (Fig. 3.4A, right).  
One possible functional difference between the PD-1HI TFH and PD-1LO TFH 
subsets from both models could be that one of the populations consists of TFR cells 
(discussed on p. 31), which express significant amounts of both Bcl6 and Foxp3 TFs. 
The expression of the latter protein was assessed by flow cytometry. Since there is a 
clear dichotomy in Foxp3 expression (Foxp3+ and Foxp3- cells can be clearly 
identified on the histogram), the frequency of Foxp3 positive cells was calculated for 
each TFH subset to address the question about the quantity of TFR in each TFH 
population.  In the SRBC model, the highest frequency of Fopx3+ cells was found 
among CXCR5- cells from day 5 onwards (Fig. 3.5 C, % of Foxp3+ cells within 
CD4+ T cells at day 6: 26.23±0.85). These are most likely ‘classical’ regulatory T 
cells, since they express Blimp1 transcript (Prdm1, Fig. 3.4A, centre) and neither 
Bcl6 transcript nor protein (Fig. 3.4A, left and 3.4B). PD-1HI TFH and PD-1LO TFH 
populations from SRBC show a comparable, lower frequency of Foxp3+ cells (Fig. 
3.5C.; % of Foxp3+ cells within CD4+ T cells at day 6: 5.81±0.74 for PD-1HI TFH and 
5.34±0.58 for PD-1LO TFH ). This frequency is not significantly higher than the 
incidence observed for the naïve T cells (CD62L+ CD44-, graphed as day 0, % of 
Foxp3+ cells within CD4+ T cells 5.26±0.45). 
Importantly, the analysis of the Foxp3 expression in the populations raised in the 
S. enterica model revealed that the highest frequency of Foxp+ cells (42.8±7.1%) is 
found among PD-1HI TFH, suggesting their role as TFR subset  
(Fig. 3.4C). PD-1LO TFH from S. enterica showed much lower frequency of Foxp3 
epositive cells (comparable to TFH populations from SRBC model and naïve T cells, 
Fig. 3.4C; 6.4 ± 0.52% of CD4+ T cells). CXCR5- T cells showed slightly higher 
proportion of Foxp3+ T cells than PD-1LO TFH and naïve T cells (14.87 ± 1.00%), 
although this differences was not statistically significant. Since the Foxp3 function 
depends not only on the frequency of Foxp3+ cells but also on the levels of the Foxp3 
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protein expressed in the cells (quantity versus quality), the geometrical MFI of the 
Foxp3 protein was analysed for all Foxp3+ populations.  
Summing up the TF expression analysis, PD-1HI TFH from SRBC resemble the 
classic, GC associated TFH population as described in the literature in terms of their 
high expression of Bcl6 and Ascl2 and low expression of Blimp1 mRNA levels 
(77,84,99). In the SRBC model TFR cells are restricted neither to the PD-1HI TFH nor 
the PD-1LO TFH population and are found most abundantly among CXCR5- T cells. 
In contrast to that, PD-1HI TFH from the S. enterica model seem to represent the TFR 
population, since they express high levels of Bcl6 and 40% of cells express also the 
Foxp3 TF. PD-1LO TFH from both models seem to be intermediate populations in 
terms of their Bcl6 protein and Prdm1 mRNA expression. This analysis further 
enforces the idea of heterogeneity within the TFH population beyond the surface 
expression of the PD-1 protein.   
3.2.5 The	analysis	of	IL-7Rα	expressed	by	TFH	subsets	points	to	PD-1HI	TFH	as	GC	
associated	population.	
Certain cytokine receptors are important for TFH development and their surface 
expression distinguishes TFH from other effector cell subsets. I have, therefore, 
investigated the expression of relevant cytokine receptors markers by flow cytometry 
and qPCR.   
IL-7Rα (CD127) is a member of a common γ-chain family of cytokine receptors. 
It is highly expressed on the naïve T cells and becomes subsequently down regulated 
upon T cell activation (186,187). IL-7 signalling was also shown to drive 
homeostatic T cell expansion in lymphopenic conditions (188). Most importantly, 
low IL-7Rα expression was associated with GC-associated populations of TFH 
(78,144). To determine further whether any of the PD-1HI TFH or PD-1LO TFH subsets 
resemble the reported GC supporting population I have investigated the expression 
of IL-7Rα by analysis of Il7r mRNA by qPCR and the cell surface protein by flow 
cytometry. Two methods were chosen to assess the IL-7Rα expression since all of 
the investigated populations (TFH cells and CXCR5- T cells from both model) are 
activated T cells and the levels of IL-7Rα are consequently expected to be very low. 
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PD-1HI TFH, PD-1LO TFH and CXCR5- T cells were isolated by fluorescence 
activated cell sorting at day 6 p.i. with SRBC or S. enterica. The qPCR analysis of 
mRNA levels for Il7r gene showed that PD-1HI TFH from SRBC model express the 
lowest amounts of Il7r mRNA (significantly less than CXCR5- T cells from the same 
model, Fig. 3.5A, left), while PD-1LO TFH populations from both S. enterica infection 
and SRBC immunization show comparable levels of mRNA to the CXCR5- T cell 
populations from the same models (Fig3.5A, left).  
The flow cytometry analysis confirmed that PD-1HI TFH at day 6 p.i. with SRBC 
or S. enterica infection have the lowest amount of IL-7Rα on the cell surface (Fig. 
3.5A, right), which is in agreement with detected mRNA levels for Il7r. CXCR5- T 
cells from both models expressed the highest amounts of the IL-7Rα protein and PD-
1LO TFH were found to be intermediate in IL-7Rα (Fig.3.5A, right).  
Another cytokine receptor implicated in TFH development and function is IL-2Rα 
(CD25, Introduction p. 26). It has been found to be expressed preferentially by non-
TFH populations and only in low amounts on the TFH cell surface (75). STAT5, the 
downstream signalling pathway of IL-2Rα, was shown to inhibit the commitment to 
the TFH pool (109,110). Therefore it was important to determine whether there is a 
differential expression of IL-2Rα between PD-1HI TFH and PD-1LO TFH, as this could 
provide an insight into developmental pathways taken by each subset.  
In agreement with other studies (109,110), IL-2Rα expression was the highest for 
CXCR5- T populations in both S. enterica and SRBC model at day 6 p.i. (Fig. 3.5B, 
right). Furthermore, all of the TFH populations had lower IL-2Rα expression than the 
CXCR5- T cells from their models (Fig. 3.5B, right). However, no significant 
differences between PD-1HI TFH and PD-1LO TFH were found in either the SRBC or S. 
enterica model at day 6 p.i. (Fig. 3.5B, right). The time course analysis of the cell 
surface IL-2Rα levels (Fig. 3.5B, left) revealed similar expression kinetics in both 
models. Slight initial up regulation of IL-2Rα (with respect to naïve T cells, graphed 
as day 0) was observed on day 3 p.i. in all populations. Interestingly, a clear 
distinction between IL-2Rα high and low populations in both models was visible by 
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day 5-6 p.i. From day 7 onwards the levels of IL-2Rα expression seem to be 
stabilised (Fig.3.5B, left).  
The results obtained from the analysis of IL-7Rα and IL-2Rα cytokine receptors 
suggested that: 1) PD-1HI TFH are indeed a GC-associated population (low IL-7Rα 
expression, as reported in the literature); 2) PD-1HI TFH and PD-1LO TFH might follow 
similar developmental pathways, which are different from the one of CXCR5- T cells 
(no differences in IL-2Rα expression between PD-1HI TFH and PD-1LO TFH, with 
both populations expressing less IL-2Rα than CXCR5- T cells). Thus, further 
important phenotypical differences between PD-1HI TFH and PD-1LO TFH, and first 
clues about the development pathways of the subsets were established.  
3.2.6 Expression	of	Ccr7,	PSGL-1	and	CD62L	suggests	differences	in	positioning	
and	homing	potential	between	PD-1HI	and	PD-1LO	TFH	subsets.	
Spleen and lymph nodes are highly organised structures with a clear segregation 
of T cells and B cells into discrete zones (Introduction p. 2). Since the movement of 
T cells and subsequent T-B cell interaction are important for differentiating into TFH 
or T effector cells, several proteins that play a role in lymphocyte positioning in SLO 
were investigated.  
CCR7 is recognised as a T cell retention signal (189). It binds CCL19 and 
CCL21, produced by fibroblastic reticular cells (190). The pattern of expression is 
reciprocal with CXCR5, with B cell areas high in CXCR5 and low in CCR7, and 
naïve T cells showing the opposite expression pattern (Introduction p. 2). Expression 
of Ccr7 mRNA was carried out by qPCR on FACS sorted TFH populations since 
protein staining for the protein proved to be technically difficult despite several 
attempts.  
In agreement with published studies (183,184,191) in the SRBC model PD-1HI 
TFH express significantly less Ccr7 mRNA than PD-1LO TFH and CXCR5- T cells 
(Fig. 3.6A). Interestingly, PD-1LO TFH were found to be equally rich in the message 
for Ccr7 as CXCR5- T cells, suggesting that PD-1LO TFH co-express CCR7 and 
CXCR5 at the same time.  
Chapter	3	–	Characterisation of TFH populations 
 74	
In the S. enterica model PD-1LO TFH and CXCR5- T cells express similar, low 
amounts of Ccr7 mRNA (no statistically significant difference, Fig. 3.6A). 
Therefore, similarly to the situation observed in the SRBC model, the PD-1LO TFH 
seem to co-express CXCR5 and CCR7. Of note, naïve T cells show the highest Ccr7 
mRNA levels (scale of relative mRNA levels is below 1 as it was normalised to 
naïve T cells levels using delta delta method.).  
Another T cell retention signal binding CCL21 and CCL19 is CD162 (P selectin 
glycoprotein ligand 1 [PSGL-1], (192)). Down regulation of PSGL-1 on TFH cells 
was reported to be essential for TFH migration to the follicles as well as GC (58,79). 
Analysing the expression of PSGL-1 was, therefore, important to obtain information 
about the positioning of the investigated TFH subsets. In agreement with the 
literature, the highest expression of PSGL-1 was found on the naïve T cells (Fig. 
3.6.B, left, graphed as day 0). By day 3 down regulation of PSGL-1 was observed on 
PD-1HI TFH, PD-1LO TFH and CXCR5- T cells from both the SRBC and S. enterica 
model (Fig. 3.6.B, left). Interestingly, CXCR5- T cells formed in S. enterica infection 
are the only population which regained and stabilised high PSGL-1 expression from 
day 5 onwards, comparable to the levels found on the naïve T cells. Around day 6 
(Fig. 3.6 B, left) levels of PSGL-1 seem to stabilise for all populations. Importantly, 
PD-1HI TFH show significantly less surface levels of PSGL-1 than PD-1LO TFH and 
CXCR5- T cells at day 6 p.i. and this is true for both models (Fig. 3.6.B,right). Low 
PSGL-1 expression on PD-1HI TFH is in agreement with other studies characterising 
GC TFH populations (58,79,87). 
As well as considering the positioning within the SLO, entry to or exit from these 
structures is important in T cell migration. CD62L is a key protein involved in 
homing to lymph nodes as it mediates the lymphocytes’ entry via HEV (193,194). 
The highest expression is confined to naïve T cells and T cell activation results in 
CD62L down regulation by active shedding of CD62L from the cell surface (195). 
Analysis of the CD62L protein expression by flow cytometry showed that in the 
SRBC model, the PD-1HI TFH population expressed very low amounts of CD62L at 
day 6 p.i. (Fig. 3.6.C, right) and this is in striking contrast to PD-1LO TFH and 
CXCR5- T cells, which have high cell surface levels of CD62L (Fig. 3.6.C, right). 
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PD-1LO TFH from the SRBC immunisation can be described as CD62L intermediate 
population, showing at day 6 p.i. significantly less CD62L than CXCR5- T cells and 
more than PD-1HI TFH (Fig. 3.6.C, right). In the S. enterica model the expression of 
CD62L seems to be generally much weaker than in the SRBC model (Fig. 3.6.C). 
This might reflect a higher T cell activation status in the immunization with an 
actively replicating pathogen. Importantly, also in the S. enterica model at day 6 p.i. 
PD-1HI TFH had significantly less CD62L on their surface than CXCR5-T cells (Fig. 
3.6.C, right). PD-1LO TFH cells, similarly to the SRBC model, show intermediate 
levels of CD62L expression (Fig. 3.6.C, right).  
The time course analysis of the CD62L expression in the SRBC system (Fig. 
3.6.C, left) revealed that PD-1HI TFH become a CD62L low population already on day 
3 and then further steadily down regulate CD62L over time. PD-1LO TFH and 
CXCR5- T cells from the same model showed consistently higher CD62L levels than 
PD-1HI TFH. In the S. enterica model PD-1HI TFH, PD-1LO TFH and CXCR5- T cells 
consistently express low levels of CD62L. 
Overall, the expression pattern of CD62L indicates that whereas CXCR5- T cells 
and PD-1LO TFH cells generated after SRBC immunisation can easily enter the lymph 
node from the circulation (due to high levels of CD62L on the cell surface), PD-1HI 
TFH cells are far less likely to access the lymph nodes due to strong down regulation 
of CD62L. This is also true in the S. enterica model, albeit the differences between 
the CXCR5- T cells, PD-1LO TFH cells and PD-1HI TFH cells are of lower magnitude.  
Summing up the results of analysis of the proteins involved in T cell migration, 
PD-1HI TFH, PD-1LO TFH subsets and CXCR5- T cell from both models of 
immunization displayed different expression patterns of Ccr7 mRNA and CD62L 
and PSGL-1 protein. This analysis indicated that PD-1HI TFH cells from the SRBC 
model have unique positioning properties within the B cell follicle and are the GC-
associated population, as described previously in literature (due to low expression of 
Ccr7 mRNA and PSGL-1 protein). Furthermore, PD-1LO TFH and PD-1HI TFH 
populations showed different homing potential to the lymph nodes (measured by 
CD62L expression). Overall, the results further confirm the discrete natures of PD-
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Investigating TFH populations in terms of their phenotype by analysing expression 
of TFs, cytokine receptors and molecules involved in positioning provided an 
important insight into the TFH heterogeneity. One of the main questions that still 
remained to be answered is whether any of the TFH subsets has reached the stage of 
terminal differentiation, characterized by a decreased potential to proliferate. This 
property of the cell can be assessed with flow cytometry by staining for the Ki67 
protein. Ki67 is a nuclear protein essential for rRNA synthesis (196). It is expressed 
in the cells that undergo active proliferation in the cell cycle (late G1, S, G2 and M 
phase of the cell cycle) and is absent in the stationary (G0) phase of the cycle 
(197,198). I, therefore, investigated Ki67 expression in TFH populations to determine 
whether there are differences in the proliferative activity in each of the cell subsets, 
which would indicate their developmental stage in terms of terminal differentiation.  
In the SRBC model (Fig. 3.7A) an early proliferative burst can be observed at day 
3 p.i. for all of the investigated populations (PD-1HI TFH, PD-1LO TFH and CXCR5- T 
cells), with PD-1HI TFH being the brightest in the Ki67 staining (Fig. 3.7C). On day 5 
p.i. all of the groups slow down in the proliferation cycle and by day 6 there are no 
significant differences between the investigated TFH and CXCR5- T cell groups (Fig. 
3.7C, right). From day 7 p.i. in all populations analysed in the SRBC model the 
potential for proliferation decreases and remains stable until day 15 p.i. (Fig. 3.7A). 
 In S. enterica infection (Fig. 3.7.B) PD-1LO TFH show a significant increase in 
proliferation compared to PD-1HI TFH and CXCR5- T cells at day 3 p.i. (Fig. 3.7D, 
left). All three populations (PD-1HI TFH, PD-1LO TFH and CXCR5- T cells) display 
their peak of proliferation around day 5-6 p.i. Similarly to the SRBC model, there are 
no significant differences between the groups at day 6 p.i. (Fig. 3.7D, right). From 
day 9 p.i. onwards proliferation was stabilised in all analysed subsets, with PD-1HI 
TFH expressing slightly more Ki67 than PD-1LO TFH and CXCR5- T cells (Fig. 3.7B). 
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Summing up, in both models there is an initial peak of T cell proliferation, 
followed by a contraction phase and a stable Ki67 expression from around day 7 
onwards. Interestingly, at day 3 p.i. with SRBC PD-1HI TFH were the only population 
displaying a significant proliferative burst in contrast to PD-1LO TFH and CXCR5- T 
cells, whereas in the S. enterica model PD-1LO TFH proliferated the most. 
Additionally, the proliferation peak is observed at day 3 p.i with SRBC, and is 
slightly delayed in the S. enterica model, where it occurs at day 5. This data shows 
that although there is an early peak of expansion in certain TFH populations (PD-1HI 
TFH for SRBC and PD-1LO TFH for S. enterica model) at later time points there are no 
significant differences in proliferation (as measured by Ki67 staining) and, therefore, 




So far the investigation of the TFH populations involved the analysis of individual 
proteins based on current knowledge. This approach, although very useful, is biased 
(by focusing mainly on the known candidate proteins only) and limited by the 
availability of reagents, funds and time. One of the approaches that offer an unbiased 
and unlimited insight into the transcriptional activity of the cell are microarrays. This 
technology provides information about all genes that are actively transcribed in the 
cell. Combining it with bioinformatics and statistical analysis enables to build a 
general overview of the relationship between the cell populations as well as to 
identify uniquely expressed transcripts for further investigation.  
In order to perform the microarray analysis of TFH subsets extensive fluorescence 
activated cell sorting was carried out on spleen cell suspensions 6 days p.i. with 
SRBC or S. enterica. RNA was further extracted from the sorted cell populations and 
subjected to microarray analysis (described in Materials and Methods chapter on 
p.54). Various types of data analysis and representation were performed to illustrate 
the relationship between the TFH subsets. The overview of the cell sorting, RNA 
processing and microarray analysis is illustrated in Fig. 3.8.  
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Principal component analysis (PCA) was used to investigate the relationship 
between the samples based on differential gene expression. It works by employing a 
mathematical algorithm to remove the redundancy within the data (199). Plotted on a 
2d or 3d axis, the artificial dimension (called principal component), which represents 
maximal variation of the data, is graphed on each axis (199). In other words, PCA 
reduces dimensionality of the dataset by re-aligning the dimensions of the dataset to 
maximise the variability that can be plotted on a minimal set of axes. This is a very 
powerful, unbiased approach, which allows very quickly an assessment and 
visualization of the general relationship between the samples and the experimental 
groups. Samples with the most similar gene expression pattern are positioned closely 
together. PCA therefore serves as an important quality control, since replicates form 
the same group should always cluster close to each other.   
PCA was performed on the TFH microarray data by selecting all 3726 
differentially expressed genes (regardless of fold change and with adj. P value  
< 0.001). Importantly, all the samples isolated from the same experimental group 
(biological replicates) form tight clusters (Fig. 3.9), which confirms the high 
technical quality of the array. The analysis of the positioning of discrete 
experimental groups shows clearly that naïve T cells sorted from non-immunised 
mice are the most isolated cluster with the greatest distance to all other groups, 
which are activated T cells (Fig. 3.9). Fascinatingly, PD-1LO TFH from the S. enterica 
model are positioned most closely to PD-1HI TFH from SRBC model, which suggest 
general similarities in gene expression. It would be interesting to see the positioning 
of PD-1HI TFH from S. enterica on this diagram. Unfortunately, this was not possible 
due to the very low frequency of these cells. Intriguingly, PD-1HI TFH and PD-1LO 
TFH from SRBC model, even though positioned closely to each other, form discrete 
clusters, indicating that these cell subsets are indeed separate populations. 
It is important to bear in mind that the PCA discussed above was performed on all 
the differentially expressed transcripts, which would include genes involved in 
metabolism, proliferation, apoptosis, biogenesis etc. It is therefore essential to assess 
whether the observed patterns of relationships could also be applied to 
immunologically relevant pathways.  




The next step in the microarray analysis was to confirm the character of the 
isolated populations based on current knowledge. That is, to confirm that T cells with 
surface expression of CXCR5 and PD-1 express the transcripts assigned to 
previously isolated and analysed TFH populations described in literature.  
The expression of 30 genes previously analysed in TFH populations is presented in 
the form of a heatmap (Fig. 3.10). Yellow to red colour indicates up regulation of the 
gene and blue colour depicts down-regulation of the transcript (with respect to 
various house keeping genes). The dendrogram presented at the top of the heatmap 
shows the relationship between isolated groups. This graphical form of hierarchical 
clustering works by finding and placing next to each other the most similar pairs of 
samples, then adding the second similar one and so on until all the features are bound 
together (200). Once again, biological replicates cluster together, which confirms the 
high quality and relevance of the microarray (Fig. 3.10). Starting from the right-hand 
side, CXCR5- T cells from the SRBC model are most closely related to PD-1LO TFH 
from SRBC. Then, surprisingly, PD-1LO TFH and CXCR5- cells from S. enterica 
infection come out as the ones with most similar gene expression patterns. Strikingly, 
PD-1HI TFH are positioned the furthest to the left and, therefore, are the group with 
the most unique gene expression pattern. Unexpectedly, even naïve T cells cluster 
first with other activated groups rather than with PD-1HI TFH. This further confirms 
that PD-1HI TFH are the most discrete subset.  
The surface phenotype of the isolated TFH populations (expression of CXCR5 and 
PD-1 proteins) is clearly reflected in the amount of the transcript present in the cells 
(Fig. 3.10). CXCR5 positive populations from the SRBC and the S. enterica model 
show higher expression of CXCR5 mRNA than CXCR5- T cells. The same pattern of 
expression is observed in PD-1: PD-1HI TFH from SRBC have the highest PD-1 
transcript levels (Pdcd1). PD-1LO TFH from both the SRBC and the S. enterica model 
show the same PD-1 message expression as CXCR5- and are comparable to each 
other. Importantly, levels of mRNA of both PD-1 and CXCR5 are higher than in 
naïve T cells. Notably, high levels of expression of the master TFH TF, Bcl-6, in PD-
Chapter	3	–	Characterisation of TFH populations 
 80	
1HI TFH and PD-1LO TFH from both models confirms the TFH ‘identity’ of these 
subsets (since they express more mRNA than CXCR5- T cells from the same 
models). With regard to IL-21, a ‘signature’ cytokine of TFH, PD-1HI TFH from SRBC 
model produce the highest amount of the transcript, although all of the activated T 
cell groups (PD-1LO TFH and CXCR5- T cell populations) seem to express more Il21 
mRNA than naïve T cells. Moreover, a brief look at expression of the transcripts 
associated with Th1 and Th2 response (Ifng and Tbx for Th1 response and Il4 and 
Gata3 for Th2 response) confirms the expected character of the response for S. 
enterica and SRBC models (Th1 and Th2, respectively). Overall, this gives 
confidence in the nature of the isolated material and confirms that the surface 
phenotype selected for the separation of the cells is reflected on the transcriptional 
level.  
Finally, PD-1HI TFH are the only population which shows the hallmark TFH profile 
(as described in literature) by low expression of Ccr7, Il7r, Il2ra, Cd160, Slamf1 and 
high levels of transcripts Bcl6, Il21, Ascl2, Btla, Cd81 and Sh2d1a (Fig. 3.10). This 
raises the intriguing question of the function and identity of isolated PD-1LO TFH cell 
populations. 
Summing up, both graphs (Fig. 3.9 and 3.10) provide an interesting insight into 
the heterogeneity within isolated TFH populations. Importantly, the two pieces of 
analysis presented (PCA of all differentially expressed genes and heatmap presenting 
expression of TFH-related transcripts) suggest that PD-1HI TFH and PD-1LO TFH from 
SRBC model are indeed separate cell subsets.  
Overall, PCA of immunologically relevant pathways emphasises discreet nature 
of the isolated cell subsets. Thus, combining an unbiased, global approach and 
literature-based selection of the relevant pathways provided more information on the 
relationship between the TFH populations from the SRBC and S. enterica models.  
3.2.10 Unique	gene	expression	in	TFH	populations	points	towards	PD-1HI	TFH	as	the	
most	specialized	cell	subset.	
One of the easiest ways of comparing differential gene expression between 
populations is by creating Venn diagrams. Venn diagrams are a simple graphical 
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output, illustrating shared and unique genes of the investigated cell subsets. The 
analysis of the genes that are differentially expressed by TFH and CXCR5- cell 
populations from SRBC and S. enterica was carried out by selecting transcripts 
which fold change in expression are larger than two and for which the P value is 
lower than 0.001. Full lists of the differentially expressed genes can be found in an 
excel file on the CD. 
In the S. enterica model (Fig. 3.11A) PD-1LO TFH have 1703 genes differentially 
expressed (up or down regulated) with respect to naïve T cells, whereas CXCR5- T 
cells have 2403 differentially expressed transcripts compared to naïve T cells. Both 
populations share changes in the expression of 1307 genes (Fig. 3.11A, full lists the 
differentially expressed genes can be found in an excel file on the CD). and this most 
likely reflects cell activation.  
In the SRBC model PD-1HI TFH, PD-1LO TFH and CXCR5- T cells have an altered 
expression of 1296, 653 and 685 genes with respect to naïve T cells, respectively. 
The highest number of uniquely expressed genes was observed for  
PD-1HI TFH (599 genes) and the lowest for PD-1LO TFH (18 genes). There were 92 
unique transcripts for CXCR5- T cells. A significant proportion of altered genes was 
shared between all populations (437 transcripts), comprising 33% of all differentially 
expressed genes in PD-1HI TFH, 67% for PD-1LO TFH and 64% for CXCR5- T cells, 
which reflects the activation status of all cell populations. In striking contrast to the 
very high number of unique genes for PD-1HI TFH (nearly 600 genes), PD-1LO TFH 
altered exclusively expression of very few transcripts (less than 20 genes). This 
could be explained by the fact that PD-1HI TFH are the most specialised cell subset 
while PD-1LO TFH cells are at an earlier stage of the differentiation, or that there are 
few PD-1HI TFH precursors embedded in the PD-1LO TFH population. The fact that 
PD-1LO TFH share more of the differentially expressed genes with PD-1HI TFH than 
with CXCR5- T cells (151 versus 109 genes, respectively) suggests a closer 
relationship to the former population (Fig. 3.11B). A full list of the differentially 
expressed genes can be found in an excel file on the CD. 
The comparison of differential gene expression with respect to naïve T cells gives 
an idea of the overall changes in T cells due to cell activation and this is very useful 
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as a first line of analysis. However, it does not allow for a direct comparison of the 
TFH populations. In order to do that another Venn diagram was created (Fig. 3.11C), 
where the number of unique genes in each of the TFH population was determined by 
comparison to the CXCR5- T cells from the same model. This analysis removed 
genes that were commonly altered genes due to the cell activation and allowed for 
the extraction of the genes characteristic for each TFH population. Surprisingly, there 
are very few genes (5) whose expression pattern is shared between all TFH 
populations (PD-1HI TFH and PD-1LO TFH from the SRBC model and PD-1LO TFH 
from the S. enterica model). However, this can be attributed to the exceedingly 
different nature of the models. Interestingly, PD-1LO TFH generated during S. enterica 
infection share more transcripts with PD-1HI TFH from SRBC than PD-1LO TFH from 
SRBC model (Fig. 3.11C), despite being phenotypically more similar to the latter 
population (based on the surface expression of CXCR5 and PD-1). The vast majority 
of genes differentially expressed between each of the TFH populations and CXCR5- T 
cells are unique for each TFH cell subset (213 genes for PD-1HI TFH from SRBC 
model and 157 for PD-1LO TFH from S. enterica model). PD-1LO TFH raised in SRBC 
model showed very low numbers of genes differentially expressed with respect to 
CXCR5- T cells (only 9 genes). This supports the idea that PD-1LO TFH are a 
relatively ‘young’ cell subset that undergoing a process of differentiation, where 
switching on CXCR5 expression is a possible first step towards further 
specialisation. Therefore, most of the transcripts remain as yet unchanged with 
respect to CXCR5- population.  Since sorted populations showed very high purity 
(Materials and Methods chapter, Fig. 2.1), the contamination of the sorted CXCR5+ 
cells with the CXCR5- subset is a highly unlikely reason for the similar gene 
expression between these populations. Full lists of the differentially expressed genes 
can be found in an excel file on the CD. 
3.2.11 PD-1HI	TFH	have	an	enhanced	potential	to	interact	with	B	cells	
The main function of the TFH population is associated with the formation and 
support of GC after physical interaction with B cells. Since the initial analysis of 
TFH-related transcripts revealed that PD-1HI TFH are the subset resembling ‘classical’ 
TFH, it is reasonable to speculate that PD-1HI TFH might also show higher expression 
of other molecules involved in T-B cell interactions. To investigate this aspect 
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microarray analysis was employed and the transcriptome of isolated TFH populations 
was probed for the genes encoding proteins known to be important in T-B cell 
contacts.  
For many proteins involved in direct T-B cell interaction increased message levels 
with respect to naïve CD4+ T cells were detected in all experimental SRBC groups 
(PD-1HI TFH, PD-1LO TFH and CXCR5- cells, Fig. 3.12), such as most of the SLAM 
family members or SAP proteins (Slamf1, 3-7 and 9, Sh2d1a) and co-stimulatory or 
co-inhibitory receptors of the CD28 superfamily of molecules (Icos, Cd28 and 
Ctla4). However, there was no significant change between TFH populations and 
CXCR5- T cells in the expression of those transcripts, which suggests that none of 
the above proteins has a selective and exclusive role for the PD-1HI TFH population. 
On the other hand, genes encoding BTLA and CD81 proteins showed the same 
expression pattern as PD-1 (they cluster together on the heat map), with expression 
levels highest for PD-1HI TFH and lowest for CXCR5- T cells in SRBC (Fig. 3.12, 
framed fragments of the heat map). Similarly, CD30L transcript (Tnfsf8) showed also 
significantly higher expression for PD-1HI TFH than 2 other experimental SRBC 
groups (Fig. 3.12, framed fragments of the heat map). Fold changes and P values for 
the transcripts of interests are presented in Table 3.1. The functional importance of 
these molecules in the context of the TFH-B cell dialogue is described in the 
Discussion part of this chapter.  
In conclusion, the microarray analysis of the TFH populations, PCA of significant 
differences in the gene expression between PD-1HI TFH, PD-1LO TFH and CXCR5- T 
cells (including all altered genes as well as immunologically relevant pathways) 
further confirmed the discrete nature of the TFH subsets with PD-1HI TFH resembling 
the most commonly studied TFH population in the literature. Furthermore, the 
analysis of proteins involved in the T-B cell interaction identified three potential 
protein candidates whose mRNA is significantly increased in PD-1HI TFH with 
respect to PD-1LO TFH and CXCR5- T cells from the SRBC model.  




• SRBC response generates PD-1HI and PD-1LO TFH, while the former 
population is missing after S. enterica infection (Fig. 3.1B, C and D). 
• GC B cells are found abundantly after SRBC immunisation but not after 
 S. enterica infection (Fig. 3.2B, C and D). 
• Altered splenic structures do not hamper PD-1HI TFH and GC formation after 
S. enterica immunisation (Fig. 3.3D,E and G) 
• PD-1HI and PD-1LO TFH populations display different levels of the TFs Bcl6, 
Blimp1, Ascl2 and Foxp3 (Fig. 3.4A, B and C). 
• Analysis of IL-7Rα expressed by TFH subsets points to PD-1HI TFH as the GC-
associated population (Fig. 3.5 A). 
• Expression of Ccr7, PSGL-1 and CD62L suggests differences in positioning 
and homing potential between PD-1HI and PD-1LO TFH subsets (Fig. 3.6). 
• PD-1HI and PD-1LO TFH populations show early bursts of proliferation with 
equal potential towards the terminal differentiation stage (Fig. 3.7). 
• The TFH phenotype of the isolated populations is reflected on the 
transcriptional level (Fig. 3.10 and 3.11A) 
• Principal component analysis of all differentially expressed genes (Fig. 3.9) 
confirms the discreet nature of isolated TFH populations.  
• The PD-1HI TFH subset expresses the highest number of unique genes (Fig. 
3.11C) and this points towards PD-1HI TFH as the most specialized cell subset. 
• The PD-1HI TFH population has an enhanced potential for interacting with  
B cells by expressing BTLA, CD30L and CD81 (Fig. 3.12). 
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Fig	 3.1.	 Induction	 of	 TFH	 populations	 after	 immunisation	 with	 SRBC	 or	 S.	 enterica	
infection	over	time.	
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1HI	 TFH	 (left)	 and	PD-1LO	TFH	 (right)	 frequencies	and	 (E)	cell	numbers.	 (F)	Representative	
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SRBC	or	 S.	 enterica	 in	 isolated	T	 cell	populations.	Analysis	of	protein	 levels	 for	Bcl6	 (B)	
and	Foxp3	(C)	over	time	(left)	or	on	day	6	p.i	(right)	with	with	SRBC	or	S.	enterica	by	flow	
cytometry.	




Statistical	 significance	 was	 determined	 by	 One-way	 ANOVA	 with	 post-ANOVA	 Tukey’s	
test	for	multiple	comparisons.		
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	Fig	3.5.	Analysis	of	selected	cytokine	receptors	expressed	by	TFH	populations.		
(A)	 Analysis	 of	 Il7r	 mRNA	 levels	 by	 qPCR	 (left	 side	 graph)	 or	 IL-7R	 protein	 by	 flow	
cytometry	(right	side	graph)	at	day	6	p.i	with	SRBC	or	S.	enterica.	
(B)	 Flow	cytometry	analysis	of	 IL-2Rα	 (CD25)	protein	 levels	expressed	 in	 isolated	T	 cell	
populations	 over	 time	 (left	 side	 graph)	 or	 at	 day	 6	 p.i	 (right	 side	 graph)	with	 SRBC	 or		
S.	enterica. 
Fig.	 3.5	A,	 left:	 data	 representative	 of	 2	 independent	 experiments	with	 similar	 results,	
each	group	consists	of	3	replicates.	Fig.	3.5	A	right	and	3.5	B:	data	representative	of	one	
experiment	with	n=3.		
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T	 cell	 populations.	Analysis	of	protein	 levels	 for	 CD162	 (PSGL-1,	B)	 and	CD62L	 (C)	 over	
time	(left)	or	on	day	6	p.i	with	with	SRBC	or	S.	enterica	in	isolated	T	cell	populations.	
Statistical	 significance	 was	 determined	 by	 One-way	 ANOVA	 with	 post-ANOVA	 Tukey’s	
test	for	multiple	comparisons.	Data	representative	of	2	independent	experiments	with	3	
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Data	 representative	 of	 a	 single	 experiment	 with	 3	 animals	 per	 time	 point.	 Each	 dot	
symbolises	 1	mouse.	 Statistical	 significance	was	 determined	 by	 One-way	 ANOVA	with	
post-ANOVA	Tukey’s	test	for	multiple	comparisons	(Fig.	3.7	C	and	D).	 









































































































































































































































































































































































































































































































































































































































































































































































Correlation plot of post−QC normalised data
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Fig	3.8.	Microarray	analysis	of	TFH	populations	
(A) Overview	of	 isolated	 T	 cell	 populations	 at	 day	 6	 p.i.	with	 SRBC	 (left)	 or	S.	 enterica		
(centre)	 and	 	 naïve	 mice	 (right).	 Cells	 were	 stored	 in	 TRIzol	 at	 -80°C	 until	 further	
processing.		
(B) RNA	isolation	was	carried	out	with	RNeasy	kit	(Qiagen;	left).	RNA	was	then	quantified	
by	 Nanodrop	 (centre	 left)	 and	 quality	 was	 confirmed	 by	 Bioanalyser	 (centre	 right).	
Isolated	RNA	was	hybridised	to	Affymetrix	mouse	microarrays	(MoGene).	
(C) Raw	data	obtained	from	microarray	were	subjected	to	quality	control	(boxplots,	left).	
Data	 were	 further	 normalised	 (heatmap,	 right).	 Heatmaps	 were	 used	 as	 a	 graphic	
representation	of	the	results	(bottom).	
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Fig	 3.11.	 Venn	 diagrams	 representing	 numbers	 of	 differentially	 expressed	 genes	
between	isolated	T	cell	populations.	
(A)	 Genes	 differentially	 expressed	 in	 PD-1LO	 TFH	 and	 CXCR5-	 T	 cells	 isolated	 after		
S.	enterica	infection	with	respect	to	naïve	T	cells.		
(B)	 Genes	 differentially	 expressed	 in	 PD-1HI	 TFH,	 PD-1LO	 TFH	 and	 CXCR5-	 T	 cells	 isolated	
after	SRBC	immunisation	with	respect	to	naïve	T	cells.	
(C)	Genes	differentially	expressed	 in	PD-1HI	TFH	and	PD-1LO	TFH	 from	SRBC	 immunisation	
and	 PD-1LO	 TFH	 from	 S.	 enterica	 infection	 with	 respect	 to	 CXCR5-	 T	 cells	 from	 the	
corresponding	model.		























2.3 1.7 1.5 1.3 1.6 1.2 
*** ** * ns * ns 
Cd81 
2.2 1.0 2.0 2.2 1.1 0.5 
** ns * * ns ns 
Tnsfs8 
(CD30l) 
5.1 2.2 2.4 2.3 2.1 0.9 











































































































































































































































































































































PD-1HI TFH  
&$*;&&













Fig	 3.12.	 Microarray	 analysis	 of	 transcripts	 encoding	 proteins	 involved	 in	 T-B	 cell	
interactions.	
(A)	 Heat	map	 showing	mRNA	 expression	 of	 transcripts	 encoding	 proteins	with	 known	












After SRBC immunization, the sub-specialisation of TFH populations based on the 
surface levels of PD-1 have resulted in the identification of two discreet subsets of 
TFH that exhibit further differences in expression of many markers, including Bcl6, 
Ascl2, Blipm1, Foxp3, IL-7R, CD62L, CCR7 and PSGL-1. PD-1HI TFH, found 
abundantly in the SRBC model, but at a very low frequency after S. enterica 
infection, displayed a set of features associated with a GC supporting population 
(114): elevated levels of CXCR5 (Fig. 3.1F), Bcl-6 and Ascl-2 (Fig. 3.4A and B), 
low expression of IL-7R (Fig. 3.5A), low mRNA levels of CCR7 (Fig. 3.6A) and 
Blimp-1 (Fig. 3.4A) and high mRNA levels of IL-21, IL-4, CXCR4, BTLA and 
CD81 (Fig. 3.10). Therefore, even though PD-1 expression on CXCR5+ T cells 
displays a continuous rather than discreet character, the phenotypic analysis between 
PD-1HI TFH and PD-1LO TFH resulted in a discrimination of two populations with 
many significant differences in the expression of cell surface and intracellular 
markers. 
The general separation between TFH populations was very elegantly further 
illustrated by the analysis of global gene expression changes (Fig. 3.9) as well as 
immunologically relevant transcripts (Fig. 3.11). In all the cases of PCA, including 
genes known to be important for TFH identity (Fig. 3.10 and 3.11A), PD-1HI TFH, PD-
1LO TFH and CXCR5- T cells formed very discreet subsets with strikingly different 
gene expression pattern with respect to naïve T cells (Fig. 3.11). PD-1HI TFH elicited 
in SRBC immunisation showed the highest number of unique transcripts when 
compared to naïve T cells (Fig. 3.12B) and CXCR5- T cells from SRBC model (Fig. 
3.12C). Interestingly, PD-1LO TFH from the SRBC model seem to share more 
similarities in gene expression with the PD-1HI TFH population than with CXCR5-  
T cells (Fig. 3.12B), which suggests a potential differentiation of PD-1LO TFH to  
PD-1HI TFH. 
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3.3.2 	Positioning	and	migratory	potential	of	TFH	populations.	
 T cell positioning within SLO is absolutely crucial in eliciting and sustaining an 
optimal immune response. Naïve T cells, held in the T cell zone, express high levels 
of CCR7 and PSGL-1, which are considered to be a ‘T cell zone retention signal’. 
Up regulation of CXCR5 on T cells and movement towards the T-B cell border, 
followed by the penetration of B cell follicles is generally considered a first step 
towards acquiring the TFH phenotype and function. The up-regulation of CXCR5 
occurs at the same time as the down-regulation of CCR7 and this reciprocal change 
in chemokine expression is thought to be essential for the entry to the B cell zone. 
However, results from our lab (unpublished data) show that CXCR5-deficient T cells 
are equally capable of homing to the B cell follicle as CXCR5-sufficient T cells and 
this is in keeping with other studies (22). However, interestingly, CXCR5 is essential 
for accessing the GC rather than the B cell follicle (unpublished data). Therefore, 
with regard to T cell positioning down-regulation of CCR7 seems to playing a 
crucial role in providing entry to the B cell follicle (22) and eventually into the GC as 
it is finally lost.  The balanced expressed of both CXCR5 and CCR7 seems to be 
critical for maintaining the PD-1LO TFH population in the follicular mantle. 
Remarkably, only the PD-1HI TFH subset from SRBC immunisation actively down 
regulates Ccr7 mRNA (Fig. 3.6A) or the PSGL-1 protein (Fig. 3.6B). The fact that 
PD-1LO TFH from the S. enterica and SRBC models, expressing intermediate levels 
of CXCR5 (Fig. 3.1F), do not down regulate CCR7 message or the PSGL-1 protein 
to the same extent as PD-1HI TFH (Fig. 3.6B) further supports the idea of a 
differential positioning and consequently of different functions of these cell subsets. 
This is in agreement with other published studies, which described that GC-
associated TFH express low amounts of PSGL-1 and CCR7. However, it is important 
to stress that location of TFH cells in S. enterica immunisation has not been directly 
assessed with microscopy and so one cannot conlude whether these T cells reside in 
the B cell follicles, in their close apposition or in the T cell zones.  
A recent study by Weber et al. provided insight into the coordinated regulation of 
CXCR5, CCR7 and PSGL-1 expression by the TF Krüppel-like factor 2, Klf2 (58). 
Klf2, which is repressed by ICOS, directly binds to DNA encoding CXCR5, CCR7 
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and PSGL-1 (58). Interestingly, this phenomenon results in the repression of CXCR5 
but has an opposite, activatory effect on the expression of CCR7 and PSGL-1(58). 
Furthermore, the PD-1HI TFH population was found to express the lowest amounts 
of the CD62L protein (Fig. 3.6C) and transcript (Sell, Fig. 3.10). Intermediate levels 
of CD62L were found on PD-1LO TFH and the highest for CXCR5- T cells, with the 
same expression pattern in S. enterica and SRBC models. These results further 
indicate that PD-1HI TFH have the weakest migratory potential and are the subset least 
capable to move via HEV of SLO. CD62L expression, therefore, logically reflects 
the differences in the positioning of the TFH subsets. PD-1HI TFH, buried within the 
GC of B cell follicles, are the furthest away from exit and entry points of the 
lymphocytes (HEV), whereas PD-1LO TFH and CXCR5- T cells, positioned within the 
T cell zone or closer to the B-T cell border, still retain the possibility to move in and 
out of the SLO. 
3.3.3 PD-1HI	TFH	from	the	SRBC	model	perform	different	function	than	PD-1HI	TFH	
from	the	S.	enterica	model	
The PD-1LO TFH population is the dominant TFH subset elicited during the  
S. enterica response but some TFH cells with PD-1HI phonotype can still be found. 
Although the PD-1HI TFH population is present in the S. enterica model at a very low 
frequency (0.36% ± 0.05, of CD4+ T cells at day 6, Fig.3.1C and D) this result is 
highly reproducible and consistent. Interestingly, the analysis of the TFs expressed 
by the PD-1HI TFH subset in S. enterica infection revealed that a significant 
proportion of this population (42.8% ± 7.1, Fig. 3.4C) expresses also the Foxp3 TF, 
which makes them bona fide TFR (134). A possible function of the TFR population at 
this stage of the response could be to limit the ongoing extra-follicular antibody 
production, which also requires T cell help (171). Also, the fact that the proliferation 
peak of the PD-1HI TFH population in S. enterica is observed later than the one of PD-
1HI TFH from the SRBC model (day 5 as opposed to day 3, Fig. 3.7) further indicates 
that the former population might be linked to the early extra-follicular response. 
Meanwhile, the proliferation peak at day 3 for PD-1HI TFH in SRBC immunisation is 
in agreement with the time frame of the expansion of the GC-supporting population, 
since GC B cells are clearly visible at day 5 (Fig. 3.2B and D) and productive T-B 
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cell interaction, therefore, needs to happen earlier. Additionally, the proliferative 
delay of PD-1HI TFH in the S. enterica model (day 5) as opposed to SRBC (day 3) 
may also reflect the complexity of the response to multiplying and simple antigen. 
 Fascinatingly, when comparing the expression of Bcl6 in the PD-1HI TFH subset 
from S. enterica infection and PD-1HI TFH from the SRBC model, it becomes clear 
that both populations express equivalent levels of the Bcl6 protein at day 3 (which 
are significantly higher than observed in PD-1LO TFH and CXCR5- T cells from both 
models). However, around day 6 PD-1HI TFH from S. enterica have dropped Bcl6 to 
levels lower than the ones observed in PD-1LO TFH from the same model, whereas 
PD-1HI TFH from SRBC immunisation have a further reinforced Bcl6 expression (Fig. 
3.4B). This could be explained by the fact that there is a window (between days 3 
and 5) in which a certain signal needs to be received by TFH cells in order to further 
increase Bcl6 levels. Alternatively, the highest levels of Bcl6 might only be 
expressed when GC structures are formed due to the dialogue between TFH and early 
GC B cells, and therefore the S. enterica model will not express such high amounts 




The analysis of the molecules known to be involved in the interactions between  
T and B cells revealed transcripts for few proteins (BTLA, CD30L and CD81) that 
are exclusively up-regulated in PD-1HI TFH (Fig. 3.11). As PD-1HI TFH are possibly  
a GC-associated population, one could expect more transcripts of proteins involved 
in T and B cell contact to be selectively altered in this subset. Low number of 
differentially expressed transcripts could be explained by the fact that, firstly, some 
of the genes involved in the interaction are not regulated on the transcriptional level, 
and, therefore, would not be identified by the microarray study. Secondly, the 
microarray technology works on mRNA extracted from many individual cells and it 
represents an ‘average’ gene expression profile of the isolated subset. Although it is  
a very reliable means to obtain general information about large-scale changes 
between the populations, it is not possible to extract changes in the expression of a 
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very small cell subset. Therefore, if there is a more specialized TFH population within 
PD-1HI TFH subsets (e.g. the cells with the highest levels PD-1 and CXCR5) it would 
not be possible to identify those cells with microarray, as this utterly selective gene 
expression would be ‘blurred’ or ‘dominated’ by the profile of other, more numerous 
cells. Thirdly, the effects of the interaction of TFH with B cells within GC might be 
mediated by the close and selective positioning of the cells, rather than by altering 
the surface expression of the proteins involved in the interaction. Consequently, all 
three subsets (PD-1HI TFH, PD-1LO TFH and CXCR5- T cells) may express equivalent 
levels of a certain protein but the functional consequences of this would be different 
in each case due to the distinct space occupied by each population within the SLO. 
Nevertheless, three transcripts involved in the contact between T and B cells were 
identified by microarray analysis as exclusively up regulated (Btla, Tnfsf8 and Cd81) 
in PD-1HI TFH (Fig. 3.13)  
B and T lymphocyte attenuator (BTLA) is a co-inhibitory receptor, member of the 
same family as CTLA4 and CD28 (115). CXCR5+ T cells were found to express 
higher levels of BTLA than CXCR5- T cells (116) and our results are in keeping with 
this finding. Moreover, it has been shown that BTLA4 has a role in limiting the 
production of both antigen-specific antibodies as well as autoantibodies by limiting 
the IL-21 derived by TFH (116). However, effects of T-cell intrinsic BTLA 
expression have not been investigated and since BTLA is also expressed on GC  
B cells it would be important to elucidate its function in each of the cell types (116). 
Higher expression of BTLA in PD-1HI TFH within the GC might be essential to 
prevent excessive antibody production at a later stage of the immune response and 
therefore represents a negative feedback loop in the T-B cell dialogue. 
CD81, another protein of interest, is a co-stimulatory receptor, physically 
associated with the CD4 and CD8 co-receptor in T cells (201). It is also expressed on 
B cells, where it forms part of the complex with CD21, CD19 and Leu13 (201). 
Importantly, CD81 has been shown to have a role in the physical T-B cell interaction 
by up regulating LFA expression on T cells (202) and activating integrin α4β1 in  
B cells, as well as increasing IL-4 synthesis in T cells responding to antigen 
presented by B cells but not by monocytes (203). Therefore, a higher expression of 
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CD81 by PD-1HI TFH supports the idea of enhanced physical interaction between  
PD-1HI TFH and B cells. In further agreement with the role of CD81 as published in 
the literature, IL4 mRNA was one of the most highly up regulated genes in the  
PD-1HI TFH population (represented on the heat map in Fig. 3.10). 
Tnfsf8 is a transcript encoding for the CD30L (CD153) protein, a member of a 
TNF superfamily. It is a ligand for CD30 (204). CD30L is expressed on many cell 
types upon activation, including T and B lymphocytes, granulocytes, macrophages 
and eosinophils (204). The role of CD30L in generation of humoral response does 
not seem to be fully elucidated. The engagement of CD30L on T cells with CD30 on 
B cells has an inhibitory effect on the antibody production (205). However, there are 
also reports that describe opposite consequences of the CD30-CD30L interaction 
with effects on B cells, including enhanced proliferation, cytokine secretion and 
antibody production (204). CD30L was also reported to play a role in maintaining 
the balance between Th1 and Th2 type of an immune response (206). 
The results of the TFH microarray show the highest expression of CD30L mRNA 
(Tnfsf8, Fig. 3.13) in PD-1HI TFH from SRBC model with a moderate expression in 
other activated cell types (PD-1LO TFH and CXCR5- T cells from both models) and 
this is in agreement with previously published studies (182). This could illustrate 
another negative feedback mechanism, alongside BTLA, involved in controlling the 
quantity and quality of the antibodies produced. Alternatively, since the role of 
CD30L is still controversial, it might also be one of the selective interactions 
between PD-1HI TFH and B cells involved in sustaining GC reaction.  
Interestingly, the specific up regulation of co-inhibitory molecules (BTLA, 
CD30L?) and co-stimulatory proteins (CD81, CD30L?) in PD-1HI TFH underlines the 
importance of a controlled T-B cell interaction as part of a balanced immune 
response.  
Overall, the microarray results suggest that although many transcripts encoding 
proteins important in the T-B cell interaction are commonly altered in PD-1HI TFH, 
PD-1LO TFH and CXCR5- T cells from SRBC model, there are some changes that are 
exclusive to PD-1HI TFH (BTLA, CD81 and CD30L). The role of these proteins could 
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be further investigated, in a first step, by confirming the expression pattern on the 
protein level by flow cytometry. Again, the fact that a certain TFH population 
expresses a set of molecules also found in GC B cells reinforces the idea that a 
reciprocal dialogue between these cells is an essential process for providing fully 
functional TFH and GC B cells. 
3.3.5 Kinetics	of	the	SRBC	and	S.	enterica	models		
The important aspect of the microarrays is that this technology gives an overview 
of the transcriptional profile of the cell or population at a particular time point only. 
TFH populations from SRBC and S. enterica models display different kinetics of 
activation as measured by incorporation of the proliferative marker Ki67 (Fig. 3.7A), 
with PD-1HI TFH peaking in proliferation at day 3 while PD-1LO TFH proliferate the 
most at day 5. Microarray analysis was carried out at day 6 p.i. with either SRBC or 
S. enterica, which means that the TFH populations were at different proliferative 
stages. This could result in differential expression of many transcripts, for instance 
proteins associated with metabolism, ribosome synthesis or translation. However, 
although it is important to keep this issue in mind, the microarray approach is still 
valid when assessing potential for the B cell help and the expression of the proteins 
associated with bone fide GC TFH. 
 
In subsequent chapters I investigated further some of the questions raised in this 
chapter, such as the potential of the PD-1LO TFH under appropriate conditions to 
become PD-1HI TFH (Chapter 4). I was also interested to know how the two 
populations of TFH would develop in a situation where a response to S. enterica and 
SRBC is happening concurrently (Chapter 5).  
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4 The role of cognate T-B cell interactions in T follicular 
helper cell (TFH) formation in SRBC immunisation 
4.1 Introduction 
The contributions of the TFH cell population to successful generation of GC 
responses are widely recognized and have already been discussed in detail elsewhere 
in this thesis (Introduction p. 27- ‘Function of TFH cells’). Interestingly, however, 
there is a growing interest in investigating the reciprocal nature of T-B cell 
interactions and in disentangling the signals by which B cells influence the TFH 
population. 
The essential role of B cells in the TFH development in various experimental 
models is demonstrated by the fact that the TFH population is not formed in B cell 
deficient mice in response to SRBC immunisation (134), viral infection (75,77) or 
parasite infection (73). Furthermore, depleting B cells at day 2, 6 or 10 post  
S. enterica infection with anti-CD20 beads leads to the loss of both early stage TFH 
and the already established TFH population within 24 hours of the treatment 
(unpublished data from our lab). Therefore, the anti-CD20 depletion study indicates 
that B cells play a crucial role in TFH survival. Furthermore, it may suggest that TFH 
cells require continuous contact with cognate B cells as a survival signal rather than a 
single interaction at a certain time point. 
 As professional APCs the nature of the B cell interaction with T cells can be 
either cognate or non-cognate. While the cognate interactions necessarily require 
physical contact between T and B cells to allow the pairing of MHC-peptide 
complex with TCR, the non-cognate interactions can involve either delivery of 
soluble mediators (e.g. cytokines) or the engagement of surface bound receptors, 
such as ICOS-L, CD80/86, CD28 and CD84. Experiments conducted with MD 4 
mice, where all B cells carry BCR specific for hen egg lysozyme (HEL) antigen, 
showed only transient TFH development after SRBC immunisation or viral infection 
(57,75,77). However, the TFH frequency in the early stages of the response is still 
significantly higher than in B cell deficient mice, which suggests that some  
TFH-B cell interactions can be of non-cognate character and later on antigen 
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presentation by B cells might be crucial for sustaining the TFH population. It is 
important to keep in mind, though, that induction of TFH depends on the DCs, as 
discussed in the Introduction on p. 19. 
 Furthermore, the need for physical, non-cognate interactions between T and 
B cells was elegantly demonstrated in a recent study that establishes that engagement 
of ICOS-ICOSL receptors from T cells and non-cognate B cells, respectively, is 
crucial for recruiting TFH to the B cell follicle (56). ICOS-ICOSL engagement 
between T cells and cognate B cells, respectively, was also found to be important for 
TFH development in environments with low amounts of antigen (207). 
 The opinion that B cells deliver a unique, cell-specific signal to TFH, 
optimizing their development and functional character, seems to be prevalent in the 
scientific field. However, one study reported that the need for an encounter between 
TFH and B cells is only due to the fact that at the later stages of the immune response 
B cells take over antigen presentation from DCs (208). Therefore, the requirement 
for cognate T-B cell contact can be overcome by an extra dose of antigen. This 
suggests that there is no qualitative difference between, for example, DCs and  
B cells, and that their differing roles in the induction and maintenance of the TFH 
population is purely due to the fact that as immune response progresses B cells 
become the main APC, while DCs play a more important role in the priming stages. 
This notion has been challenged in subsequent publications, which show that priming 
by DC and B cells has different outcomes for the generation of TFH populations in 
vitro (81) and in vivo in the viral infection model (83,209). Furthermore, an elegant 
study by Qi et al. demonstrated that disrupting physical interactions between TFH and 
B cells (transgenic SAP-deficient5 OT.II CD4+ T cells and peptide immunisation) 
impairs TFH survival and GC formation (25). Importantly, in this model interactions 
between T cells and DCs are not affected, which further suggests a special character 
of physical T-B cell interactions (25).  
Overall, it is clear that TFH cells need the presence of B cells to fully develop and 
to survive. T-B cell interactions require physical contact between TFH and B cells and 
																																																								
5	SAP (SLAM-associated protein) is a cellular adaptor providing signaling for the 
SLAM family members, such as CD84, 2b4, Ly9 and Ly108 (142). 
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the character of the interaction can be both cognate and non-cognate. However, there 
are some inconsistencies in the reports investigating the need for and timing of 
antigen presentation by B cells in influencing TFH population development. It is also 
possible that multiple types of TFH-B cell interactions are required at different stages 
or for different types of immune response. 
 
4.2 Aims of the chapter 
In the previous chapter I have shown that there is heterogeneity within the TFH 
population and that PD-1HI TFH and PD-1LO TFH subsets differ in their expression of 
the surface and intracellular markers. The aim of this chapter is to determine whether 
both of the TFH subsets (PD-1HI TFH and PD-1LO TFH) are dependent on antigen 
presentation by B cells. This aspect has been addressed by using mixed BM chimeras 
with the B cell compartment exclusively deficient in MHC II expression (Materials 
and Methods chapter, p. 49) in a SRBC immunisation model, since, in contrast to  
S. enterica infection, SRBC immunisation gives rise to both PD-1HI TFH and PD-1LO 
TFH cell subsets.  I characterize PD-1HI TFH, PD-1LO TFH and GC B cell populations in 
BMHCII-/- chimeras by flow cytometry, using both surface and intracellular markers 
and show that there is a striking difference in their dependency on cognate B cells. 
The second question addressed in this chapter concerns TFH plasticity and 
differentiation pathway. I investigated two possible models of TFH development in 
the context of the interactions with cognate B cells (Fig.4.1). In the first, the linear 
model (Fig. 4.1A), the commitment to the TFH pool is made early during the course 
of the immune response (at the stage of the naïve T cell) and the pool of TFH-
precursor cells is consequently established alongside other effector T cell lineages. In 
this linear model the TFH differentiation pathway is separate from the effector CD4+ 
T cell pathway and there is no conversion between the two cell types (activated  
T cells do not become TFH cells). In the second one, the continuous differentiation 
model (Fig. 4.1B), there is a similar stepwise progression from a naïve T cell to pre- 
TFH and then TFH cell with possible recruitment of the activated effector cells to the 
TFH pool.  A final aspect of the TFH differentiation process is the ultimate fate of TFH 
cells and the question whether they can revert back to become non-TFH effector  
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T cells (and, for instance, lose CXCR5 expression). By using an adoptive transfer 
approach and mixed BM chimeras I demonstrate that activated PD-1+ T cells (both 
CXCR5+ and CXCR5-) can enter TFH pool. Furthermore, I show that there is a 
significant plasticity observed within the PD-1LO TFH cell subset. In contrast to that, 
the PD-1HI TFH population seem to be much more restricted in their ability to convert 
to other cell subsets. My overall aim in this chapter is to investigate how B cells (by 
presenting an antigen) influence the plasticity and differentiation of TFH population. 
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In order to investigate the requirements for cognate interactions with B cells, 
BMHCII-/- chimeras were immunised with SRBC and TFH formation was assessed 6 
days later by flow cytometry (Fig. 4.2A). In these BM chimeras all of the B cells are 
deficient in MHC II expression whereas other APCs show 20% reduction in the 
MHC II expression. As controls, WT chimeras were used, which have undergone 
BM reconstitution but were supplemented with WT, and not MHC II deficient, BM 
and hence all the cellular compartments have normal MHC II expression. The 
phenotype of B cells in each type of the chimeric mice was confirmed by analysing 
MHC II expression levels on B cells (Fig. 4.2B)6. As a positive control for the 
induction of the PD-1HI TFH population WT mice were also immunised with SRBC. 
Representative flow cytometry plots and TFH gating is showed in Fig. 4.2C. 
The results show that after SRBC immunisation BMHCII-/- chimeras generate  
PD-1LO TFH cells in comparable frequency and numbers to WT chimeras (Fig. 4.2D 
and E, respectively, right panel). In a striking contrast to that, the PD-1HI TFH 
population is virtually absent in BMHCII-/- chimeras when compared to either WT 
chimeras or WT mice (Fig. 4.2D and E, respectively, left panel) immunised with 
SRBC. 
This experiment demonstrates that there are differential requirements for cognate 
interactions with B cells between PD-1HI TFH and PD-1LO TFH, and while antigen 
presentation is necessary for the formation of the PD-1HI TFH population it seems to 
be dispensable for the generation of PD-1LO TFH cells.  
4.3.2 	PD-1LO	TFH	present	in	BMHCII-/-	chimeras	express	intermediate	levels	of	Bcl6	
Results from chapter 3 (Fig. 3.4A and B) show that PD-1LO TFH generated in WT 
mice express lower levels of Bcl6 than PD-1HI TFH, hence PD-1 and Bcl6 expression 
																																																								
6	The	slight	 shift	 in	MHC	 II	expression	between	 two	MHC	 II	positive	groups	 (B	cells	 from	WT		
mice	and	WT	chimeras)	was	also	observed	in	the	isotype	control	and	thus	it	does	not	reflect	true	
differences	in	the	protein	expression.	 
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correlate in immunised WT mice. It is therefore important to determine the levels of 
Bcl6 expression in the PD-1LO TFH population in BMHCII-/-  chimeras to confirm that 
the observed surface phenotype (lack of high PD-1 expression) is reflected in the 
level of intracellular master TF. 
Flow cytometry analysis showed that PD-1LO TFH raised in BMHCII-/- chimeras 
express comparable levels of Bcl6 to PD-1LO TFH from WT chimeras or WT mice 6 
days post SRBC immunisation (Fig. 4.3 A and B). All PD-1LO TFH populations 
express lower levels of Bcl6 than the PD-1HI TFH populations from either WT 
chimeras or WT mice. Nevertheless, Bcl6 expression in PD-1LO TFH is higher than in 
CXCR5- CD4+ T cells from all immunised groups (Fig. 4.3 A and B). 
4.3.3 BMHCII-/-		chimeras	lack	GC	response	
As TFH cells are essential supporters of GC response it is important to investigate 
the presence of these structures in WT and BMHCII-/- chimeras 6 days post SRBC 
immunisation (as in Fig. 4.2A). As a positive control for GC induction WT mice 
immunised with SRBC were included. GC B cells were identified by flow cytometry 
by expression of Bcl6 in CD19+ B cells (representative plots are shown in Fig. 4.4A).  
While WT chimeras show a clear induction of the GC B cell population (around 
8% ± 0.84 of B cell population) after SRBC immunisation, in BMHCII-/- chimeras GC 
B cells were virtually undetectable and comparable to levels observed in naïve WT 
mice or naïve BMHCII-/- chimeras (around 0.35% ± 0.29, of B cells Fig. 4.4B and C). 
There was no statistical difference in GC B cell frequencies and numbers between 
immunised WT mice and WT chimeras. The absence of GCs in immunised BMHCII-/- 
chimeras was further confirmed by histology (Trüb et. al., manuscript in 
submission).  
This result demonstrates that in BMHCII-/- chimeras after SRBC immunisation GCs 
are not formed despite the presence of the PD-1LO TFH subset. Additionally, this 
confirms that the PD-1HI TFH subset is the main population supporting GC B cells. 
Therefore, deficient MHC II expression by B cells can impede the GC formation by 
halting the generation of PD-1HI TFH cells. 




In BMHCII-/- chimeras all B cells lack MHC II expression but there is also a 20% 
deficiency in MHC II expression in other cell types (e.g. DCs, macrophages, 
basophils, mast cells and plasmacytoid DC). Therefore, one could argue that the 
decreased capacity of antigen presentation in other cells could also influence PD-1HI 
TFH formation. To control for this effect an additional group of chimeras with 20% 
deficiency in MHC II expression on all cell types (including B cells) was created. 
Data from our lab (Barr et al., manuscript under revision) show that in these control 
chimeras immunised with SRBC, PD-1HI TFH are formed in comparable frequency 
and numbers to immunised WT chimeras, which excludes the possibility that 
impaired antigen presentation in other cell types recapitulates the phenotype 
observed in the experimental BMHCII-/- chimeras. 
B cell transfer experiments were carried out to further confirm the role of the B 
cells as main APCs in PD-1HI TFH formation in BMHCII-/- chimeras after SRBC 
immunisation. BMHCII-/- chimeras have received either WT or MHC II-/- B cells (10 
million B cells per mouse) of syngeneic background alongside SRBC immunisation 
(Fig. 4.5A). TFH formation and Bcl6 expression were assessed 6 days later by flow 
cytometry. The phenotype and purity of transferred B cells (more than 92%) was 
confirmed prior to the transfer (Fig. 4.5B). The following groups were used as 
control groups: 1) naïve BMHCII-/- chimeras and 2) immunised BMHCII-/- chimeras with 
no B cells transferred  
As expected, naïve BMHCII-/- chimeras showed very low levels of TFH present (as 
previously in Fig. 4.2C) and upon immunisation with SRBC only the PD-1LO TFH 
population was observed to develop (Fig. 4.5C, upper panel). Interestingly, this was 
also the case in BMHCII-/- chimeras, which received MHC II-/- B cells. Importantly, the 
transfer of WT B cells into BMHCII-/- chimeras induced the development of both PD-
1LO TFH and PD-1HI TFH cells (Fig. 4.5C). The summary of TFH frequencies and cell 
numbers is shown in Fig. 4.5D and E, respectively. 
In experimental BMHCII-/- chimeras that received MHC II sufficient CD19+ B cells 
these cells made up only 5-15% of the B cell populations at day 6 p.i. (this 
Chapter	4	–	TFH - B cell interactions 
 115	
population was not detectable in the BMHCII-/- chimeras, which received MHC II-/- B 
cells, Fig. 4.5C, lower panel). This suggests that only a small fraction of B cells 
expressing MHC II  (around 10%) is sufficient to fully restore PD-1HI TFH frequency.  
It was also important to confirm that PD-1HI TFH in BMHCII-/- chimeras 
supplemented with WT B cells had recovered high expression of Bcl6. The results 
graphed in Fig. 4.5F and G show that the PD-1HI TFH population from WT B cell 
transfer group expressed high levels of Bcl6. Furthermore, the PD-1LO TFH 
populations from both BMHCII-/- chimeras and WT mice expressed significantly less 
Bcl6.  
Summarising, the B cell transfer experiment confirms that B cells are crucial for 
the development of a TFH subset characterized by high expression of PD-1 and Bcl6 
by presenting antigen via MHC II. On the other hand, cognate B cell interactions 
seem to be dispensable to induce a TFH subset that expresses PD-1 and Bcl6 on a low 
level as this latter population was not affected in any of the B cell transferred groups 
in terms of frequency, cell numbers and Bcl6 expression.  
4.3.5 Transfer	of	MHC	II-sufficient	B	cells	rescues	GC	formation	in	BMHCII-/-	
chimeras	immunised	with	SRBC	
The restoration of the PD-1HI TFH population in BMHCII-/- chimeras with the 
transfer of WT B cells leads on to the question whether GC formation is also rescued 
in this setting. Indeed, providing WT B cells expressing MHC II, but not MHC II-/- B 
cells, fully restored the GC B cell population (Fig. 4.6A and B) as assessed by flow 
cytometry 6 days post SRBC immunisation. Interestingly, in BMHCII-/- chimeras 
which received WT B cells only around 10% of total B cell population expresses 
MHC class II but this is enough to fully restore GC B cells. 
4.3.6 PD-1LO	TFH	cells	in	BMHCII-/-	chimeras	are	stalled	in	the	differentiation	to	 
PD-1HI	TFH.	
As previous experiments have shown, the presence of PD-1LO TFH per se is not 
enough to drive the GC reaction in SRBC immunisation in BMHCII-/- chimeras (Fig. 
4.4A) but the transfer of WT B cells rescues the formation of both PD-1HI TFH and 
GC populations (Fig. 4.5D, E and 4.6B). Newly-formed PD-1HI TFH cells in BMHCII-/- 
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chimeras receiving WT B cells could be derived directly from the naïve CD4+  
T cells. Alternatively, the PD1LO TFH that are present in the BMHCII-/- chimeras could 
be stalled in this differentiation state and so might continue their progression to the  
PD-1HI TFH pool after experiencing cognate interactions with MHC II+ B cells. 
Whether these pre-PD-1HI TFH cells, embedded in the PD-1LO TFH pool, survive for 
some time in the absence of cognate B cells (or, in contrast, undergo apoptosis if 
required signals are not received at a certain point) is also an intriguing question, as it 
raises the subject of TFH plasticity and of the reciprocal conversion between PD-1HI 
TFH and PD-1LO TFH populations. 
To address the issue of TFH ontogeny described above, adoptive transfer 
experiments were performed in which the PD-1LO TFH population (carrying the 
CD45.2 allelic marker) isolated from BMHCII-/- chimeras 6 days post SRBC 
immunisation was subsequently transferred into lightly irradiated (300Gy) congenic 
WT  hosts (expressing CD45.1 allele). These mice were then challenged with SRBC 
approximately 36h post transfer and analysed 3 days later (Fig. 4.7A). I sought to 
answer the question whether PD-1LO TFH from BMHCII-/- chimeras could give rise to 
PD-1HI TFH after encountering B cells expressing MHC II and receiving fresh antigen 
supply.  
As a control, PD-1+CXCR5- T cells were also isolated from BMHCII-/- chimeras 
(activated extra follicular T cells, termed CXCR5- cells). Alongside BMHCII-/- 
chimeras, SRBC immunised WT chimeras were used for the isolation of PD-1LO TFH, 
PD-1HI TFH and CXCR5- cells. The sorting strategy was identical to that used in the 
TFH cell isolation for the microarray (Fig. 2 on p. 57) and the purity of the sorted 
populations was similar (80-90%). However, the possibility of contamination 
between different populations cannot be fully excluded.   
Analysis of the TFH phenotype 5 days post adoptive transfer  (as showed in Fig. 
4.7) shows that, firstly, most of the PD-1LO TFH lose CXCR5 expression and acquire 
CXCR5- PD-1+ T cell phenotype (46.38±1.69% of all transferred cells for WT 
chimera and 42.54±6.21% for BMHCII-/- chimeras, Fig. 4.7B and C). Secondly,  
a proportion of PD-1LO TFH cells retains their original CXCR5 and low PD-1 
expression levels (Fig. 4.7B and C, 9.86±1.27% of all transferred cells for WT 
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chimera and 6.26±1.5% for BMHCII-/- chimeras). Thirdly, and most importantly, the 
PD-1LO TFH population from BMHCII-/- chimeras can give rise to PD-1HI TFH (Fig. 
4.7B and C), and the frequency of conversion is similar to the PD-1LO TFH isolated 
from WT chimeras (Fig. 4.7D, % of all transferred cells with PD-1HI TFH phenotype 
derived from transferred PD-1LO TFH populations: 10.88±0.76% for WT chimera and 
6.98±0.88% for BMHCII-/- chimeras). Notably, there is an equal division of transferred 
PD-1LO TFH into PD-1LO TFH or PD-1HI TFH cells: out of around 20% of CXCR5+ 
cells half of them acquired high PD-1 expression and half has retained low PD-1 
expression (Fig. 4.7D).  
Interestingly, the CXCR5- population seems to be the most conservative in the 
retention of their phenotype (Fig. 4.7E). Most of the cells show CXCR5- phenotype 
after the transfer (58.53±0.99% of all transferred cells for WT chimeras and 
50.46±2.26% for BMHCII-/- chimeras). Only a small proportion acquires CXCR5 
expression and becomes PD-1LO TFH or PD-1HI TFH.  
Overall the above results demonstrate that PD-1LO TFH from BMHCII-/- chimeras 
and PD-1LO TFH from WT chimeras are equivalent in their abilities to convert to  
PD-1HI TFH and to CXCR5- cells in the SRBC immunisation model. 
In the next step, I have addressed the question whether PD-1HI TFH generated from 
PD-1LO TFH isolated from WT or BMHCII-/- chimeras show high Bcl6 expression 
levels, as observed in the de-novo induced PD-1HI TFH population in WT mice. 
Indeed, the analysis of Bcl6 MFI at day 5 post adoptive transfer clearly showed that 
PD-1LO TFH populations converted to PD-1HI TFH up regulate their Bcl6 expression 
(Fig. 4.7F and G). Furthermore, there are no differences, again, between PD-1LO TFH 
isolated from BMHCII-/- chimeras and WT chimeras (Fig. 4.7F and G).  
Collectively, the TFH adoptive transfer experiments showed that PD-1LO TFH from 
BMHCII-/- chimeras are equivalent to PD-1LO TFH from WT chimeras in their capacity 
to acquire PD-1HI TFH phenotype and up regulate Bcl6 levels, further suggesting that 
PD-1LO TFH are not in a terminally differentiated state and still exhibit considerable 
plasticity.  
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4.3.7 PD-1HI	TFH	convert	at	low	frequency	to	PD-1LO	TFH.		
The results from section 3.6 have illustrated that PD-1LO TFH can convert to  
PD-1HI TFH upon adoptive transfer. Whether the opposite phenomenon is possible 
(PD-1HI TFH acquiring PD-1LO TFH phenotype) is also an intriguing question.  
To address this issue PD-1HI TFH from WT chimera immunised with SRBC were 
analysed at day 5 post-adoptive transfer (as in Fig. 4.7A). Similarly to the PD-1LO 
TFH population, most of the transferred cells (51.0 ± 2.8% of transferred CD45.2 
population) have lost CXCR5 expression and acquired the CXCR5- T cell phenotype 
(Fig. 4.8A and B). However, out of the remaining CXCR5 positive cells the vast 
majority retained high PD-1 expression: PD-1HI TFH phenotype was 4 to 5 times 
more abundant than PD-1LO TFH phenotype after the transfer (% of all transferred 
PD-1HI TFH-derived cells with PD-1HI TFH phenotype vs. PD-1LO TFH phenotype: 
20.13 ± 2.65% vs. 4.62 ± 0.87%). Therefore, it is worth noting that while CXCR5 
positive PD-1LO TFH cells split equally after transfer and antigen re-challenge into 
PD-1LO TFH and PD-1HI TFH, PD-1HI TFH preferentially keep their original phenotype. 
Overall, PD-1HI TFH show less plasticity than the PD-1LO TFH subset. (However, it is 
important to keep in mind that around 50% of both populations lose CXCR5 
expression after adoptive transfer).  
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4.3.8 Results	summary	
• The development of PD-1HI TFH cells in response to SRBC immunisation 
requires antigen presentation by B cells, while PD-1LO TFH cells are formed 
independently of cognate B cell interactions (Fig. 4.2C, D and E ). 
• Despite prevalence of PD-1LO TFH cells expressing intermediate levels of 
Bcl6 GCs are not found after SRBC immunisation in the BMHCII-/- chimera  
(Fig. 4.4). 
• The PD-1HI TFH population and GC formation are restored in BMHCII-/- 
chimeras by transfer of WT B cells, but not MHC II-/- B cells, in SRBC 
immunisation (Fig.4.5C, D and E; Fig.4.6). 
• The adoptive transfer of PD-1LO TFH, isolated from BMHCII-/- chimera, to WT 
host and re-challenge with antigen demonstrates plasticity of this cell subset 
and its potential to differentiate into PD-1HI TFH population, which expresses 
high levels of Bcl6 (Fig.4.7B, C and D). 
• PD-1HI TFH cells preferentially retain their phenotype after adoptive transfer 
and antigen re-challenge and convert at low levels to PD-1LO TFH cells, 
showing overall less plasticity than PD-1LO TFH subset (Fig. 4.8). 
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Fig	4.2.	Formation	of	PD-1HI	TFH	depends	on	cognate	interactions	with	B	cells.	




Data	 pulled	 from	 5	 independent	 experiments	 (n=3-5,	 BMHCII-/-	 chimeras	 +	 SRBC),	 4	
independent	 experiments	 (n=3-5,	WT+	 SRBC),	 6	 independent	 experiments	 (n=1,	WT	 +	
SRBC),	 2	 independent	 experiments	 (n=1,	 BMHCII-/-	 chimeras)	 and	 4	 independent	
experiments	(n=1,	WT),	each	dot	represents	one	mouse.	
Statistical	 significance	 was	 determined	 by	 One-way	 ANOVA	 with	 post-ANOVA	 Tukey’s	
test	for	multiple	comparisons. 
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CXCR5 neg 6.53 TF stain_AB_chimera_SRBC_002.fcs
PD-1 LO TFH 4.41 TF stain_AB_chimera_SRBC_002.fcs




Bcl6 expression in TFH populations



















(A)	 Representative	 	 flow	 cytometry	 plots	 of	 Bcl6	 expression	 in	 PD-1HI	 TFH	 (pink	 line),	 
PD-1LO	TFH	(blue	line) and	CXCR5-	CD4+	T	cell	populations	(black	line)	in	each	experimental	
group	 6	 days	 after	 immunisation	 with	 SRBC.	 Shaded	 area	 shows	 isotype	 control.	 (B)	
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Fig	4.5.	Continued	overleaf.	
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day	 0.	 Representative	 flow	 cytometry	 of	 PD-1HI	 TFH,	 PD-1LO	 TFH	 and	 CD4+	 T	 cell	
populations	 from	 each	 of	 the	 experimental	 group	 (C,	 upper	 panel)	 and	 MHC	 II	
expression	on	CD19+	B	cells	(C,	 lower	panel).	(D)	Summary	of	PD-1HI	TFH	and	PD-1LO	TFH	
frequencies	 and	 (E)	 cell	 numbers.	 Representative	 flow	 cytometry	 plots	 of	 	 Bcl6	
expression	 in	 of	 	 PD-1HI	 TFH,	 PD-1LO	 TFH	 and	 naïve	 CD4+	 T	 cells	 (F,	 upper	 panel)	 and	
summary	of	geometrical	mean	fluorescence	intensity	(G).		
Data	 pulled	 from	 two	 independent	 experiments	 with	 2	 animals	 per	 group	 (BMHCII-/-	
chimera,	BMHCII-/-	chimera	+	SRBC)	or		4	animals	per	group	(BMHCII-/-	chimera	+	WT	or	KO	B	
cells);	each	dot	represents	one	mouse.	
Statistical	 significance	 was	 determined	 by	 One-way	 ANOVA	 with	 post-ANOVA	 Tukey’s	
test	for	multiple	comparisons.	
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Fig	 4.6.	 Transfer	 of	 WT,	 but	 not	 MHC	 II	 -/-	 B	 cells,	 rescues	 GC	 formation	 in	 BMHCII-/-	
chimeras	at	day	6	post	SRBC	immunisation.	
(A)	 Representative	 flow	 cytometry	 plots	 of	 GC	 B	 cells	 from	 each	 of	 the	 experimental	
group.	 Gate	 frequencies	 indicate	 percentage	 of	 B	 cells.	 (B)	 Summary	 of	 GC	 B	 cell	
frequencies	 (left)	 and	numbers	 (right).	Data	pulled	 from	 two	 independent	experiments	
with	2	to	4	animals	per	group;	each	dot	represents	one	mouse.		
Experimental	repeats	as	in	Fig.	4.5.	
Statistical	 significance	 was	 determined	 by	 One-way	 ANOVA	 with	 post-ANOVA	 Tukey’s	
test	for	multiple	comparisons.	
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Conversion of CXCR5- cells



























Conversion of PD-1LO TFH cells




























Conversion of PD-1LO TFH cells
































Conversion of PD-1LO TFH cells













































































































PD-1HI	 TFH	 and	 up	 regulate	 Bcl6	 expression	 upon	 the	 transfer	 to	 WT	 host	 and	 re-
challenge	with	SRBC.	





from	WT	 chimeras	 (F)	 or	 	 BMHCII-/-	 chimeras	 (G)	 on	 day	 0	 (left)	 or	 day	 5	 post	 transfer	
(right).	
Data	 pulled	 from	 2	 independent	 experiments	 (n=4-5,	 WT	 chimera)	 or	 3	 independent	
experiments	(n=3-5,	BMHCII-/-	chimeras).	Each	dot	represents	a	mouse.	




































































TF_isotype_AB_chimera_SRBC.fcs CXCR5 neg 4.68
TF_stain_AB_chimera_SRBC.fcs CXCR5 neg 5.24
TF_stain_AB_chimera_SRBC.fcs PD-1 LO TFH 4.34





















frequency	 to	 PD-1LO	 TFH	 upon	 the	 transfer	 to	WT	 host	 and	 re-challenge	 with	 SRBC.		
(Experimental	outline	as	in	Fig.	4.6.A)	
(A)	Flow	cytometry	plots	of	TFH	populations	isolated	from	WT	chimera	on	day	0	(left)	or	
























































Conversion of PD-1HI TFH cells






























Using the SRBC immunisation model and BMHCII-/- chimeras provided an 
important insight into the requirement for the B cell antigen presentation in the TFH 
development. While the generation of the PD-1LO TFH population 6 days post SRBC 
immunisation was not affected in terms of both cell frequency and numbers when 
compared to the control WT chimera or WT mice, PD-1HI TFH were virtually absent 
when B cells were lacking MHC class II expression. The fact that the PD-1HI TFH 
population depends so closely in its development on cognate contact with B cells 
further suggests potentially different locations and functions of these cells linked to 
B cell support and GC development. Another likely explanation for the observed 
phenomenon is that the PD-1HI TFH population requires continuous TCR stimulation 
as one of the survival signals (suggested by Shane Crotty (114)). In the context of the 
immune response this seems to be a plausible explanation since those GC-residing 
TFH could have a constant access to the antigen from the surface of FDCs, which 
hold deposits of the antigen required for the B cell selection post SHM (210). 
Additionally, it has also been shown that the ablation of FDC leads to the 
disappearance of both GC B cells and TFH (31). The issues of TCR specificity and 
diversity within TFH populations are discussed in more details in Chapter 5. 
PD-1LO TFH raised in BMHCII-/- chimeras in response to SRBC display lower levels 
of TF Bcl6 than PD-1HI TFH in the immunised control WT chimeras. Therefore it can 
be proposed that one of the mechanisms through which cognate B cells support PD-
1HI TFH formation might be by providing high Bcl6 expression. However, it is 
important to point out that a small proportion of TFH raised in BMHCII-/- chimeras after 
SRBC immunisation falls into the PD-1HI TFH gate and expresses high levels of Bcl6 
that are equivalent to PD-1HI TFH from immunised WT mice or WT chimeras. This 
suggests that cognate interaction between TFH and B cells is enhancing or stabilising 
high Bcl6 expression but may not be an absolute requirement for its induction. These 
results are in agreement with other studies which show that in the absence of cognate 
B cells CXCR5+ PD-1+ TFH cells are still formed and express higher levels of Bcl6 
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than naïve T cells (57,208,209). Furthermore, it was demonstrated that the 
maintenance of high CXCR5 and high PD-1 expression depends on antigen 
presentation by B cells (57). Finally, the TFH subset expressing high levels of Bcl6 
was not found when antigen presentation was limited to conventional CD11c+ APC 
(209), which further highlights the need for cognate B cells in the formation of PD-
1HI TFH cells. 
Transfer experiments required separating the PD-1HI TFH and PD-1LO TFH 
populations. Although the purity of the sample was always assessed post sorting, 
possible contamination issues of PD-1LO TFH cells with PD-1HI TFH cell during 
sorting cannot be formally excluded. This could have the consequences for the 
downstream analysis of the phenotype acquired post activation, since low numbers of 
PD-1HI TFH cells transferred alongside PD-1LO TFH could theoretically expand in the 
adaptive host and restore PD-1HI TFH population. 
4.4.2 	BMHCII-/-	chimeras	lack	GC	response	after	SRBC	immunisation	
The development of GCs in BMHCII-/- chimeras in response to SRBC was 
completely abolished in terms of GC B cell frequency and number. At the same time, 
PD-1LO TFH cells were abundantly found in the spleens of immunised BMHCII-/- 
chimeras, indicating that the presence of this subset per se is not enough to drive GC 
structures in response to SRBC. This is in keeping with other findings, which show 
that despite the presence of cells with TFH-like phenotype (CXCR5+ PD-1+ Bcl6+) 
GC formation is still impaired (208,209). 
One could speculate that the lack of GC response in BMHCII-/- chimeras in the 
SRBC model is rather a direct effect of the lack of MHC II expression on B cells 
than a secondary consequence of the missing PD-1HI TFH subset. Interestingly, the 
study by Barnett et al. revealed an absence of the GC structure alongside the missing 
PD-1HI TFH population despite using the animal model in which MHC II expression 
is actually restricted to B cells (209). Another interesting aspect of T-B cell 
interaction worth considering is the possibility that GC B cells (and possibly cognate 
B cells) secrete a cytokine or other soluble factor, which influences TFH generation in 
the first place. Deenick et. al. challenged this idea by showing that the TFH 
population is not formed when T cells cannot physically engage with B cells despite 
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abundant GC structures present (208). They do so by transferring OT.II cells of WT 
and SAP KO background (the latter population being unable to form stable 
conjugates with B cells) to WT congenic recipients and immunizing with cognate 
antigen. TFH cells were found to be exclusively derived from WT and not SAP KO 
OT.II cells (208), despite restored GCs. This experiment argues against the presence 
of a secreted germinal-centre-derived soluble factor as an exclusive means by which 
B cells support the TFH development and further highlights the need for physical 
contact between T and B cells in TFH generation.  
The fact that B cells function as a crucial APC in the generation of the PD-1HI TFH 
is further illustrated in my results by the B cell transfer studies, where providing 
BMHCII-/- chimeras with only 5-10% of WT B cells alongside SRBC immunisation 
restored both PD-1HI TFH and GC formation. Unfortunately, from my analysis it 
cannot be distinguished whether GCs generated in this model were derived from a 
WT or MHC II deficient B cells (although that would be possible by means of flow 
cytometry). However, it is highly likely that they are of WT origin. To investigate 
the significance of co-stimulatory molecules displayed on the surface of cognate  
B cells, similar B cell transfer experiments, using BMHCII-/- chimeras and SRBC, 
could be carried out with ICOS-L or CD40L deficient B cells. Additionally, the 
transfer of in vitro activated non-cognate B cells (for example of MD4 background) 
could further help to investigate the importance of the activation status and antigen 
presentation by B cells in the PD-1HI TFH and GC formation. Also, providing WT  
B cells at different time points (for example at day 3 or 5 post SRBC immunisation) 
would help to understand the kinetics of cognate T-B cell interactions required for 
PD-1HI TFH population survival. 
In summary, the presence of PD-1LO TFH, and the lack of both GCs and PD-1HI 
TFH in the absence of cognate B cells elegantly illustrate the functional consequences 
of the phenotypic differences observed in the previous results chapter.  
4.4.3 PD-1LO	TFH	cells	from	BMHCII-/-	can	convert	to	PD-1HI	TFH	and	express	high	
levels	of	Bcl6.		
The adoptive transfer of the PD-1LO TFH population (isolated from either WT or 
BMHCII-/- chimeras immunised with SRBC and re-challenged within 48 h post 
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transfer) demonstrated that this population is able to give rise to a PD-1HI TFH 
population, which expresses high levels of Bcl6. This is a very important finding. 
Firstly, it illustrates that TFH cells need to interact with cognate B cells in order to 
acquire the PD-1HI TFH phenotype and stably express Bcl6. Secondly, it shows that 
activated T cells can become PD-1HI TFH cells after receiving the appropriate signal. 
One might speculate that some of the PD-1LO TFH cells stall in their progression (but 
do not undergo apoptosis) to the PD-1HI TFH stage until cognate interaction with B 
cells has occurred. Overall, the possibility of a conversion from PD-1LO TFH (and, to 
a lesser extent, also CXCR5- cells) to PD-1HI TFH shows that recruitment to the latter 
pool is a continuous process, occurring beyond the priming stage of a naïve CD4+ T 
cell during an immune response. Importantly, the significant level of heterogeneity 
within the PD-1LO TFH population is illustrated by the fact that the split between the 
cells acquiring PD-1LO TFH or PD-1HI TFH phenotype is close to 50% (among 
CXCR5+ cells).  
Interestingly, adoptively transferred CXCR5- cells (isolated either from SRBC-
immunised WT or BMHCII-/- chimeras) can also acquire a TFH phenotype although 
their frequency of conversion is lower than the one observed for the PD-1LO TFH 
subset. Intriguingly, CXCR5- cells seem preferentially to become PD-1HI TFH rather 
than PD-1LO TFH. Therefore, adoptive transfer experiments suggest that neither PD-
1LO TFH nor CXCR5- cells are terminally differentiated cell subsets, and as activated 
cells, both can continuously supply the PD-1HI TFH pool. This is important for the 
progression of a secondary immune response, since the possibility of drawing PD-1HI 
TFH, which support GCs, from more than one cell population creates the option to 
respond to newly arising antigens (for example in case of mutating viruses) or 
pathogens closely related, but not identical, to the ones encountered in the past.  
4.4.4 The	PD-1HI	TFH	population	generated	in	WT	chimera	after	SRBC	
immunisation	preferentially	retains	its	phenotype	after	adoptive	transfer.		
The adoptive transfer of the PD-1HI TFH population (isolated from WT chimeras 
immunised with SRBC and re-challenged within 48 h post transfer) provided an 
important insight into the differentiation state of this cell subset. Although the 
majority of the transferred PD-1HI TFH population has lost CXCR5 expression 
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(similarly to PD-1LO TFH cells), the cells that remained CXCR5 positive showed also 
high PD-1 and Bcl6 expression. Therefore, very few of the original PD-1HI TFH cells 
have converted to PD-1LO TFH cells. Importantly, whereas PD-1LO TFH split equally 
after the transfer between PD-1LO TFH and PD-1HI TFH (when taking into account 
CXCR5 positive cells), there were on average 5-6 times more PD-1HI TFH than  
PD-1LO TFH after the antigen boost than when the PD-1HI TFH population was 
transferred. This finding suggests that the PD-1HI TFH population is in a more 
terminally differentiated state than PD-1LO TFH since it shows very little plasticity. 
Moreover, when the frequency of conversion to PD-1HI TFH cells is compared 
between originally isolated PD-1HI TFH, PD-1LO TFH and CXCR5- cells (from either 
WT or BMHCII-/- chimeras), it is clear that most of the PD-1HI TFH cells generated after 
adoptive transfers come from the PD-1HI TFH subset. This may be advantageous for 
the organism during a secondary infection, since the ability to draw a GC-associated 
population from the pool of the cells, which has already been selected on the basis of 
their ability to interact with cognate B cells might shorten the time of the response. 
Intriguing questions arising from the analysis of PD-1HI TFH transfers regards the 
signals, which are required by this population to retain its phenotype. After the 
transfer to congenic recipient cells have a possibility to interact with all APC 
(including B cells) post SRBC boost. It is therefore reasonable to speculate that 
continuous access to the antigen might be one of the requirements for retaining high 
CXCR5, PD-1 and Bcl6 expression, since PD-1HI TFH subset expresses higher levels 
of these proteins than PD-1LO TFH population. This hypothesis could be further tested 
by adoptive transfer of the PD-1HI TFH population to congenic hosts without SRBC 
boost and by assessing their phenotype in the steady state conditions after they have 
been deprived of antigen supplies. 
Alongside antigen recognition and TCR signaling, the PD-1HI TFH phenotype can 
be driven by other receptors (including co-stimulatory molecules) displayed on the 
surface of different APCs. The contributions of cognate interactions between PD-1HI 
TFH and APCs could be investigated by adoptively transferring the PD-1HI TFH 
population to MHC II KO mice. Furthermore, the involvement of B cells specifically 
could be explored by transferring PD-1HI TFH cells into BMHCII-/- chimeras. Finally, to 
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disentangle the role of DCs in this process, depletion of CD11c+ DCs could be 
performed prior to the PD-1HI TFH transfer into CD11c DTRX mice (211)7. 
Transferring the PD-1LO TFH population alongside would provide a more detailed 
insight into the different requirements for contact with cognate APCs of these two 
populations. 
4.4.5 Loss	of	CXCR5	expression	post	adoptive	transfer	
One of the important observations from adoptive transfers of TFH populations 
from the SRBC-immunised WT and BMHCII-/- chimeras to the WT hosts is that  
a majority of CXCR5 positive cells (PD-1LO TFH and PD-1HI TFH) down regulate 
CXCR5 expression by day 3 post transfer and re-challenge with SRBC.  
In all of the adoptive transfer experiments (including 24h transfer) the recipient 
animals have received a light dose of irradiation, which could influence splenic 
structure, the positioning of transferred cells and the subsequent chemokine receptor 
expression. This does not explain, though, why some cells retained CXCR5 
expression. Another possibility is that finding the ‘right’ location by transferred cell 
is a random process, and therefore some cells will find the right way and survive 
with keeping their original phenotype whereas other will loose or change their 
chemokine receptor expression.  
In the published study with Bcl6 reporter mice, vast majority (80-90%) of 
CXCR5+ and CXCR5- cells have retained their original phenotype after adoptive 
transfer and antigen challenge (87). This proportion has decreased to 50% (of 
CXCR5+ cells keeping their phenotype) when cells were left to rest in antigen-free 
environment for 20-30 days (87). The important difference in the experimental set up 
is that TFH cells were isolated in my experiments at the peak of the response to SRBC 
(day 6 p.i.) whereas Liu and colleagues transferred small population of cells from the 
draining lymph nodes 20-30 days p.i. with protein antigen. Therefore, these cells had 
a chance to stabilize their phenotype (and undergo contraction phase). Nevertheless, 
																																																								
7	These transgenic mice have diphteria toxin receptor expressed under the CD11c 
promoter and efficient depletion of CD11C+ DC can be achieved by administration 
of diphteria toxin (211). 
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phenotype of cells, which retained CXCR5 expression, provided important 
information about differentiation cues of TFH population. 
4.4.6 Transferred	TFH	populations	have	different	recovery	rates.	
In the TFH adoptive transfer experiments with WT or BMHCII-/- chimeras 
immunised with SRBC significant differences in the frequency and numbers of the 
CD45.2 positive cells could be observed between transferred populations recovered 
from CD45.1 congenic recipients mice at day 3 post transfer. CXCR5- cells showed 
consistently the highest frequency of recovery and PD-1HI population the lowest 
(Appendix Fig. 7.6). This could be explained, firstly, by differences in dissemination 
to other organs post transfer, secondly, by different proliferation rates (discussed in 
Chapter 3 in part 3.2.) or, thirdly, by distinct intrinsic apoptotic and survival 
properties of the transferred populations.  
The observed differences in the recovery of transferred populations were not due 
to differences in the dissemination of the isolated subsets within other SLO, as 
CD45.2 transferred cells were virtually non-detectable in the axillary, brachial, 
inguinal, mesenteric, and popliteal lymph nodes in any of the transferred groups 24h 
post i.v. injections (data not shown). Furthermore, entry to the lymph nodes via HEV 
requires CD62L expression (212). The population found with the lowest frequency 
after the transfer (PD-1HI TFH, Appendix Fig. 7.6) expresses very low levels of 
CD62L (Fig. 3.6C), which makes PD-1HI TFH even less prone to lymph node homing, 
and this explanation is therefore not very plausible.  
The second likely explanation for the observed recovery rates concerns the 
differences in proliferation between the populations. As shown in Fig. 3.7, Ki67 
staining points to the fact that there are no differences in proliferation between PD-
1HI TFH and other populations. 
Finally, the third possible explanation could be the differences in the survival of 
those populations due to their intrinsic pro-apoptotic potential. This question has not 
been directly addressed but one could do it by flow cytometry staining for proteins 
known to be involved in apoptosis, such as Bcl-2 and activated Caspase-3 and 
Caspase-7. Nevertheless, despite differences in the recovered numbers of the 
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transferred cells, the proportion of PD-1HI TFH, PD-1LO TFH and CXCR5- cells 
converting into other subsets was very consistent between the animals used in 
multiple experiments and the large group size enabled statistical testing of the 
hypothesis.  
4.4.7 Discussion	summary	
The experiments presented in this chapter investigate cognate T-B cells 
interaction using a model in which MHC II deficiency is almost exclusive to the B 
cell compartment. Interestingly, the study by Barnett et. al. uses the opposite strategy 
by employing transgenic mice, where MHC II expression is restricted to the B cell 
compartment (B-MHC II mice, (209)). Adoptive OT.II T cell transfer and peptide 
immunisation demonstrated that when MHC II expression is limited to B cell lineage 
CD4+ T cells are primed inefficiently and TFH cells and GCs are not formed (209). 
Interestingly, when LCMV-specific Smarta T cells are transferred to the B-MHC II 
mice and challenged with LCMV, 90% of transgenic T cells show TFH phenotype 
(compared to 50% in a WT control), which indicates that priming in vivo by B cells 
in the context of viral infection skews antigen specific T cells towards the TFH 
phenotype. Intriguingly, in this adoptive transfer model GC are not formed and 
almost no IgG+ antigen specific antibodies found (209). Overall, the paper 
demonstrates that when B cells are the only functional APC functional TFH cells are 
not induced, despite up regulating expression of CXCR5 and PD-1 on the cell 
surface after viral infection. Interestingly, exclusive MHC II expression by DCs also 
leads to the generation of CXCR5+ PD-1+ TFH cells expressing Bcl6, but, again, these 
cells are not functional in terms of IL-21 secretion and GC support (81). Restoring 
MHC II expression in DCs (alongside MHC II competent B cells) rescues both TFH 
and GC development (209), which illustrates that cooperation between different 
APCs is essential to provide optimal TFH and humoral responses after protein or 
peptide immunisation, or viral infection (209), (81).  
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5 TCR repertoire of TFH populations generated after 
immunisation with SRBC and S. enterica 
5.1 Introduction 
In Chapter 3 I have investigated PD-1HI TFH and PD-1LO TFH populations formed 
after immunisation with SRBC and S. enterica by characterising their phenotype by 
flow cytometry and investigating their transcriptional profile using microarray 
analysis. In the following chapter (Chapter 4) I studied the dependency of PD-1HI 
TFH and PD-1LO TFH from SRBC model on cognate interactions with B cells, leading 
ultimately to a discussion on the development and plasticity of TFH cells. In this 
chapter I go on to investigate the relationship and potential for interaction between 
PD-1HI TFH and PD-1LO TFH subsets. I was interested to know if the aborted TFH 
differentiation I observed during S. enterica infection (PD1LO TFH) could be 
corrected by a concurrent immune response to SRBC, which drives strong PD1HI TFH 
response. Not only was this the case but the co-immunisation study with SRBC and 
S. enterica resulted in an unexpectedly high number of PD1HI TFH.  
We wanted to see if the expanded PD1HI TFH cells after co-immunization were 
Salmonella–specific PD1LO TFH that were converted to PD1HI TFH under the influence 
of the SRBC response. Alternatively, the SRBC-specific PD1HI TFH could be 
expanded as a result of the concomitant response to S. enterica (and adjuvant effect). 
To address this question we needed to identify the specificity of the T cells in each of 
the responses. As appropriate MHC II tetramers were not readily available we 
sequenced TCR V genes, as we hypothesized that the two responses would exhibit 
different and readily distinguishable TCRα/β V gene repertoire expansions. The 
results of TCRβ V gene sequencing show that, indeed, S. enterica infection leads to 
the expansion of selected TCR clones while SRBC immunisation results in 
polyclonal T cell activation with little evident clonal selection. 
 Fascinatingly, TFH populations expanded in the co-immunised animals seem to 
exhibit an expansion of both SRBC- and Salmonella-activated T cells demonstrating 
that presence of SRBC can recruit Salmonella-specific PD-1LO TFH into the PD-1HI 
TFH population. Finally, the analysis of TCR diversity showed no differences 
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between PD-1HI TFH and PD-1LO TFH from SRBC model, demonstrating that there is 
no preferential TCR combination in any of the populations. This ultimately led to the 
discussion of TCR repertoire diversity within the TFH populations. 
5.1.1 TCR	structure	and	diversity	
The specificity and binding strength of the TCR to peptide:MHC complex has a 
crucial impact on the selection, survival and differentiation of each T cell (213-215). 
Whether T cells are recruited to the TFH pool on the basis of their TCR clonotypes is 
unclear and so far only a handful of studies (discussed later) have addressed this 
issue. This chapter opens the discussion on the TCR repertoire found in different TFH 
populations by using next generation sequencing technology to interrogate TCR 
diversity of PD-1HI and PD-1LO TFH cells from the SRBC and S. enterica models. 
The T cell receptor (TCR) is a heterodimer made of two chains, α and β (Fig. 
5.1A). Each chain consists of variable (V), diversity (D, only in β chain), joining (J) 
and constant (C) subunits ((216,217), Fig. 5.1). TCRαβ arrangement occurs in 
thymus where stochastic recombination of V, D and J segments takes place to ensure 
that a great number of diverse TCRs is generated in the T cell population (213). 
Adding or deleting nucleotides in a random fashion at the junctions of the segments 
(V-J for α chain; V-D and D-J for β chain) further enhances TCR diversity (214). 
Finally, random pairing of α and β chains also increases combinatorial TCR variety 
(213,214). Overall, the number of possible unique TCRs is estimated at 1x1018 for 
mouse and 1x1015 in human (218,219). However, this number is limited by the 
thymic selection (due to deletion of self-reacting clones and clones that have no 
affinity for MHC) and overall the estimated number of TCRs actually found in the 
periphery is a couple of magnitudes lower: 2x106 clonotypes in mouse and 2.5x107 in 
human (213), although some sources estimate human TCR clones as 3x106 
(218,220).  
The TCR sequence diversity is focused in complementary-determining regions 
(CDRs), which are parts of TCR contacting peptide:MHC molecule ((213,221), Fig. 
5.1 B and C). There are three CDRs (CDR1-3) within the α chain and three within 
the β chain. The CDR1 and CDR2 regions of TCR interact with the MHC molecule, 
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whereas the CDR3 region forms an antigen-binding site as it is positioned above the 
peptide in the p:MHC complex (Fig. 5.1C, (213)). CDR3 covers parts of the V, D 
and J segments (Fig. 5.1B) and the flexibility of CDR3 loops adds further 
promiscuity in the TCR binding by enabling the recognition of peptides with similar 
sequences (222).  
The importance of TCR diversity is illustrated by the mouse models in which, due 
to genetic manipulation, the diversity of TCR has been artificially limited. For 
example, in NZW mice with deleted TCR segments Vβ5 and Vβ8-13 TCR diversity 
shows a 60% reduction and there is a severe impairment in immune responses to 11 
out of 22 tested antigens (213). OT-1β transgenic mice with only 2% of normal TCR 
diversity (4x105 clones) fail to reject F1 BM (213). Furthermore, in humans, 99.9% 
reduction of TCR results in a 7 to a 100 fold reduction in responses to mitogens and 
antigens (213). The above examples clearly show that TCR diversity is absolutely 
essential for maintaining effective immune responses to foreign and self antigens. 
5.1.2 Repertoire	analysis	by	Next	Generation	Sequencing	
So far TCR diversity was investigated and estimated by a method called PCR 
spectratyping or immunoscope (213,218, 219). This approach was labour, time and 
cost intense and was significantly limited in resolution by only providing information 
about the CDR3 length and not the exact nucleotide sequence (220). A breakthrough 
for TCR interrogation occurred when next generation sequencing (NGS) became 
commercially available (220). NGS enables to investigate the TCR repertoire in an 
unprecedented fashion by providing the TCR sequence on the level of the single cell. 
Moreover, the enormous diversity of TCR sequences can only be captured by 
collecting the data of a very large number of unique TCRs (218). We have therefore 
decided to employ the NGS technology to probe the TCR repertoire of TFH 
populations and address the unappreciated issue of TCR diversity in TFH subsets 
(Fig. 5.2). 
Sorted TFH populations isolated 6 days p.i. with SRBC or S. enterica were 
subjected to mRNA isolation and cDNA synthesis on magnetic beads. This was 
followed by creating amplicons (amplified sequences of interest) of TCR-β V-
regions using PCR with indexed primers, which enabled the identification of the 
Chapter 5 – TCR repertoire of TFH populations 
 142	
TCR sequence derived from a single cell. The PCR products were then separated by 
gel electrophoresis and purified by extraction from the agarose bands. Concentration 
by ethanol precipitation was performed as a last step prior to sequencing. The 
overview of the whole process is presented in Fig. 5.2. 
Next generation sequencing can be performed with many platforms, which differ 
in sequencing biochemistry. For this study, the Illumina MiSeq sequencing 
technology was used (223). This technology is described as sequencing by synthesis 
since it detects the single nucleotides as they are inserted into growing DNA strands 
(224). Briefly, dNTPs carry a reversible terminator with a fluorescent tag attached. 
dNTPs are imaged as they are incorporated in the strand (only one base is inserted at 
the time) and the terminator is subsequently cleaved, allowing for the insertion of the 
next base (224). This approach is preferable for the analysis of TCR due to its high 
accuracy (it is less prone to insert or delete nucleotides, so called in–del mistakes, 
than e.g. Roche 454 sequencing, (218)). Important advantage of Illumina MiSeq over 
other sequencing platforms (e.g. Illumina 2500, also commonly used in RNA 
sequencing) is that it provides reliable read for sequences of around 400 bp long, 
which means that whole V gene sequence is covered with a single read (and there is 
no need for re-assembling shorter forward and reverse reads). In the platforms 
providing shorter reads final sequences are then reassembled bioinformaticaly, which 
is impossible for V genes due to the high number of very similar sequences. 
Additionally, in this study 3’ end of the V region was a first part to be sequenced, 
which is important as a quality of sequencing goes down as the read length 
progresses. Therefore, the TCR sequencing was designed to ensure that variable 
sequences will be a full length and a high quality sequence, without need for 
sequence re-assembly. 
TCR sequencing focuses on the CDR3 region, since, due to its tremendous 
diversity, it is characteristic for only one clone of T cell (218). Moreover, it can be 
sequenced with shorter reads and higher throughput (218). As a result, specialised 
programmes tailored for the investigation of CDR3 regions of the sequencing data 
became available (as described below). These programmes join sequencing 
technology with bioinformatic analysis.  
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Vast amount of data generated by NGS requires a careful analysis in order to 
provide reliable and reproducible results. Open source software programmes emerge 
as a standard strategy designed for the specific analysis of the primary data (218). 
One such software created especially for the analysis of the sequencing results of 
TCR α and β chains is MiTCR (225). This platform was used for the analysis of the 
TFH TCR repertoire described in this chapter since it is specialised in CDR3 sequence 
extraction (218). In addition to that, the MiTCR programme enables quality control 
of the raw sequence, identification of V, D and J segments, correction or deletion of 
low quality reads and clonotypes assembly (Fig. 5.3, (225)). It thus represents an 
excellent, standardised tool to investigate details of lymphocyte biology with the 
single cell receptor resolution.  
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TCR sequencing - primer strategy 
Read 1 primer (400 cycles)Indexing primer (6 cycles)
GOI
Gene-specific   P5 Illumina adapter
5'UTR
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TCR-β	 V	 region	 prior	 to	 sequencing.	 (D)	Analysis	 pipeline	 of	MiTCR,	 platform	 used	 for	
sequencing	data	analysis.	Horizontal	bars	 show	raw	sequencing	 reads	and	vertical	bars	
show	 sequence	 quality.	 CDR3	 sequences	 are	 extracted	 from	 all	 reads.	 V,	 D	 and	 J	









Results presented earlier showed that immunisation neither with heat-killed nor 
live S. enterica is able to generate PD-1HI TFH populations (Fig. 3.3C-E, p. 90). This 
could be attributed either to the nature of the S. enterica infection or the strong 
inflammatory conditions present during early stages of the response. Nevertheless, 
the question of whether the PD-1HI TFH subset could be generated and sustained in 
the environment created during early stages of the response to S. enterica was an 
intriguing issue. In order to address this question I performed a co-immunisation 
experiment, in which WT mice were immunised with both SRBC and HK S. enterica 
or SRBC and live, replicating S. enterica (at a standard dose of 1x106 CFU).  
TFH phenotype and the presence of GC were assessed on day 6 p.i.. Thus, we sought 
to answer the question whether the PD-1HI TFH population, which would most likely 
be raised after the immunisation with SRBC, could be present in co-immunised 
animals. This experiment would also provide an answer to the question whether one 
TFH subset dominates over another, since for instance prevalence of PD-1LO TFH in  
S. enterica could impede the formation of PD-1HI TFH subsets.  
Presence of SRBC alongside HK bacteria or live S. enterica did not have any 
influence on the spleen weight (Fig. 5.3A) or infectious dose (Fig. 5.3B). As 
expected, single immunisation with SRBC generated PD-1HI TFH and PD-1LO TFH 
populations and single immunisation with HK bacteria or live S. enterica produced 
only the PD-1LO TFH subset (Fig. 5.3C-E). Fascinatingly, in the co-immunised groups 
of SRBC and HK bacteria or SRBC and live bacteria the PD-1HI TFH population was 
not only present but also, surprisingly, expanded in frequency (1.18±037% for SRBC 
vs. 1.84±0.37 for SRBC and HK bacteria and 3.89±0.91% for SRBC and live 
bacteria, Fig. 5.3C and D, left) and total cell numbers (Fig. 5.3C and E, left). The 
expansion was more prominent when live bacteria were present alongside SRBC 
rather than HK bacteria. Intriguingly, the frequency and cell numbers of PD-1LO TFH 
cells were also expanded in co-immunised groups (again, with greater magnitude for 
live bacteria than for HK bacteria, Fig. 5.3. C-E). Importantly, the frequencies of PD-
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1LO TFH found in co-immunised groups are greater than the additive effect of both 
immunisations (combined frequencies after immunisation with S. enterica only and 
SRBC only).  
The analysis of the presence of GC showed, as expected, a lack of these structures 
in single immunisation with HK or live bacteria (Fig. 5.3F and G). Fascinatingly, GC 
B cells were clearly induced in terms of frequency and numbers when SRBC were 
present alongside HK or live bacteria (Fig. 5.3F and G). Moreover, the frequency of 
GC B cells in co-immunised groups was comparable to the one in the SRBC only 
group.  
The most fascinating questions emerging from the co-immunisation study concern 
the nature of the expanded PD-1HI TFH and PD-1LO TFH populations. If the 
frequencies of PD-1HI TFH and PD-1LO TFH subsets in co-immunised groups were 
similar to the ones observed in the individual models, one could simply conclude that 
infection with S. enterica most likely does not prevent PD-1HI TFH formation in 
response to SRBC. However, synergistic (and not additive) results of expansion 
observed for both PD-1HI TFH and PD-1LO TFH questions this conclusion and raises 
the possibility that in some way SRBC immunisation could either facilitate de novo 
formation of PD-1HI TFH specific for S. enterica or that S. enterica infection provided 
enhanced conditions for SRBC-specific PD-1HI TFH expansion. Expended TFH 
population could be also a mixture of cells specific for SRBC or S. enterica. To 
tackle the fascinating issue of the specificity of the expanded TFH populations, TCR 
sequencing was performed on sorted TFH populations. 
5.2.2 Outline	of	TCR	sequencing	–	technique	and	protocols	
T cell isolation for TCR sequencing was carried out by fluorescence activated cell 
sorting, using the same protocol as for T cell isolation for the microarray analysis 
(materials and Methods chapter, p. 52 and Fig. 2, p. 57). Activated T cells were 
isolated 6 days p.i. with SRBC, S. enterica or both immunogens. Unimmunised 
animals were used as a source of naïve T cells (Fig. 5.2A). Frozen cell pellets (0.5 x 
106 T cells in each sample) were subjected to high purity mRNA isolation with oligo 
dT beads (Fig. 5.2A). The magnetic beads are covalently coupled to multiple 
thymine (T) residues, which pair with the polyA tail present at the 3’end of most 
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mRNA molecules. Importantly, other RNA species (ribosomal RNA, micro RNA 
and small nucleaolar RNA) as well as DNA or proteins do not carry the polyA tail, 
therefore are not bound by the beads and are easily removed during the isolation 
process.  
cDNA synthesis was carried out with SMART Moloney Murine Leukemia Virus 
Reverse Transcriptase (MMLV RT, Fig.5.2B). The MMLV RT is the enzyme used 
especially for the preparation of cDNA libraries, as its high sensitivity enables the 
amplification of rare mRNA copies and the preservation of the relative abundance of 
the original transcripts at the same time. MMLV RT has the additional property of 
switching the RNA template (Fig. 5.2B). Ribosylated guanine (rG)8 was introduced 
as a complementary sequence to the string of cytosines (C) at the 5’ of the 
untranslated region (UTR). As a result, MMLV RT continued the cDNA synthesis by 
adding the same primer for all cDNA molecules at 5’ end (Fig. 5.2B). Importantly, 
providing the same primer at 5’ end for all cDNA molecules removed the possibility 
of a V region bias during the PCR reaction, as there was no V-region specific primer 
used in the reaction. 
TCR-β variable (V) regions were further amplified by PCR with the use of 
indexed forward primers (containing SMART synthesis oligo sequence) and a 
reverse primer complimentary to the TCR-β constant region (Fig. 5.2C). Forward 
and reverse primers were fused to a P7 or a P5 illumina tag, respectively (Fig. 5.2C). 
Such prepared clones (amplicones) of V regions were extracted from agarose gel 
bands, precipitated by ethanol and subjected to sequencing on the MiSeq Illumina 
sequencer (with single-end reads of 400bp length). Custom read 1 primers and 
indexing primers complimentary to the amplification primer sequences were used in 
sequencing.  
The primary data obtained from sequencing were analysed by the open source 
software MiTCR utility (225) by using Python scripts (Fig. 5.2D). 
																																																								
8	This modification is essential for the MMLV template switch. 




Sequencing technology provides an unparalleled opportunity to gather 
information about the T cell receptor repertoire at any time during the course of an 
immune response. One of the main issues addressed by TCR sequencing is the 
magnitude of the diversity observed among all TCR sequences. When few T cell 
clones are selected for proliferation due to carrying the advantageous CDR3 
sequence (e.g. with a high affinity to the foreign antigen) clonal expansion is 
observed and such expanded TCRs are found at a much higher frequency than others. 
Alternatively, polyclonal T cell expansion takes place and many TCR sequences are 
found at similar frequencies, without any dominant clonotypes9 observed. The aim of 
the undertaken TCR sequencing of TFH populations was, firstly, to answer the 
question about the level of TCR diversity observed after SRBC immunisation and  
S. enterica infection and, secondly, to determine clonal expansion patterns that are 
likely to be characterstic of a response to a particular antigen (in this instance SRBC 
or S. enterica). 
Diversity value (D50) is a mean to express the level of diversity within the TCR 
repertoire. Diversity value is the number of most prevalent TCR clones, which make 
50% of the total TCR repertoire. It is calculated by: 1) working out the total number 
of CDR3 sequences, 2) sorting CDR3 sequences from the most prevalent to the least 
frequent, 3) adding the most frequent CDR3 sequences to reach half of all sequences 
in TCR repertoire. Therefore, the higher the number is, the greater is the observed 
diversity. Contrary to that, low D50 means a great expansion of some single clones.  
The results of the TFH sequencing of TCR show that, as expected, the highest 
diversity of TCR is observed in naïve T cells (CD62LHI CD44LO), isolated from non-
immunised animals (Fig. 5.4). Intriguingly, populations isolated from the SRBC 
immunisation model (PD-1HI TFH, PD-1LO TFH and CXCR5- T cells) show a degree of 
diversity similar to naïve T cells, with the D50 value around 15-20 (Fig. 5.4). 
Interestingly, experimental groups of T cells isolated from animals infected with S. 
enterica (PD-1LO TFH and CXCR5- T cells) show a much lower D50 value (in the 
																																																								
9	Clonotype is a TCR with the same D - J region and CDR3 sequence.  
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range of around 5, Fig. 5.4), indicating that clonal expansion of the selected CDR3 
sequences has taken place. Fascinatingly, in groups co-immunised with SRBC and S. 
enterica, the diversity value is placed between the immunisations with SRBC or S. 
enterica alone for PD-1LO TFH, suggesting a mixed expansion of both SRBC and S. 
enterica-activated populations. On the other hand, PD-1HI TFH, isolated from the co-
immunised animals show a D50 value within the range observed for single 
immunisation with S. enterica, which suggests that the clonal expansion of the 
immunodominant CDR3 sequences has taken place. CXCR5- T cells of animals co-
immunised with SRBC and S. enterica exhibit the lowest D50 value of all 
populations (Fig.5.4), therefore, showing diversity closer to the one observed in  
S. enterica immunisation. 
Overall, the analysis of the diversity value shows that SRBC immunisation leads 
to polyclonal T cell activation without expansion of single clones and the level of 
TCR diversity is similar to the one observed in naïve animals. S. enterica infection, 
however, results in the expansion of the few selected TCRs which dominate the 
repertoire. Surprisingly, the analysis of the TCR diversity (by D50 value) revealed 
that PD-1HI TFH population from co-immunised animals displays a similar range of 
clonal expansion to the one observed in the S. enterica infection alone (Fig. 5.4). 
Additionally, the PD-1LO TFH subset formed after co-immunisation exhibit diversity 
value placed between the ones observed in the single immunisation models. This 
suggests that PD-1LO TFH population might be a mixture of cells specific for  




Principal component analysis (PCA, employed already previously for the 
microarray study) explains variability within the dataset by removing redundancy of 
the data and bringing out strong patterns in a dataset. PCA of TCR sequencing 
results (Fig. 5.5) revealed that the TCR repertoires of PD-1HI TFH, PD-1LO TFH and 
CXCR5- T cells isolated from SRBC immunised mice are very similar to the one 
observed in naïve mice, since biological replicates of these populations are 
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interspaced and positioned very closely together. It also shows that neither of the TFH 
populations stands out in terms of having a unique TCR repertoire, which indicates 
that there is no preferential CDR3 sequence that would drive the expansion of a 
certain TCR clone. Interestingly, CXCR5- T cells and PD-1LO TFH from  
S. enterica are placed in a very distant part of the graph (Fig. 5.5), pointing to 
differences in the TCR repertoires of these groups with respect to naïve T cells and 
activated T cells isolated from SRBC immunised mice (Fig. 5.5). Intriguingly, 
populations isolated from co-immunised groups (PD-1HI TFH, PD-1LO TFH and 
CXCR5- T cells) position themselves in-between the groups isolated from the single 
immunisation models (Fig. 5.5 and 5.6), suggesting mixed specificity populations 
(with slight dominance of SRBC response) of TFH cells isolated from the co-
immunised animals.  
5.2.5 SRBC	immunisation	leads	to	polyclonal	TCR	activation,	whereas	S.	enterica	
infection	results	in	the	clonal	selection	of	immunodominant	TCR	sequences		
Clustering plots are very useful in assessing the degree of similarities between the 
sequences and visualizing the data. The algorithm used to generate clustering plots 
works by blasting all the sequences against each other and putting the link between 
the most similar sequences. A force-directed algorithm then places the sequences 
which are highly linked closer together10. The node size is proportional to the 
number of reads of the sequence and therefore reflects how prevalent each 
combination is in the isolated TCR repertoire. Each colour represents a family of J 
segments (since the J segment contributes more amino acids to CDR3 sequence than 
the V segment).  
The clustering analysis of TFH populations isolated after the SRBC immunisation 
shows, again,  that the TCR repertoire is very similar to the naïve T cells (Fig. 5.7 A 
and 5.8), further confirming the results described for the D50 value and PCA. The 
clustering analysis of PD-1HI TFH, PD-1LO TFH and CXCR5- T cells (from SRBC 
model, Fig. 5.8) clearly indicates the polyclonal character of the response with a very 
large diversity of TCR sequences and no expansion of single clonotypes (all the 
																																																								
10	Sequences, which are less than 90% similar, are considered not related, as this 
would create too many links between the samples and the force-directed algorithm 
would not be useful.  
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nodes are the same size, reflecting a similar frequency of multiple TCR sequences 
within the total TCR repertoire). 
In strong contrast to the results described above, the clustering analysis of the 
TCR sequences of PD-1LO TFH and CXCR5- T cells isolated after S. enterica 
infection indicates a clear expansion of the selected TCR clones (Fig. 5.9) since 
nodes vary in size with some sequences clearly being found most frequently within 
the TCR repertoire. As a consequence, the TCR repertoire found in S. enterica 
infection shows less TCR diversity than in naïve mice or after SRBC immunisation.   
Intriguingly, the clustering analysis of the T cell populations isolated from the 
animals co-immunised with SRBC and S. enterica (Fig. 5.10) shows that nodes vary 
in size, and that therefore clonal expansion, rather than polyclonal activation, has 
taken place within PD-1HI TFH. This result strongly indicates that at least some of the 
PD-1HI TFH, PD-1LO TFH and CXCR5- T cells expanded in the co-immunisation 
setting are, quite unexpectedly, specific to the S. enterica infection.  
5.2.6 Concluding	remarks	
Overall, the results of TCR sequencing identify a polyclonal T cell activation in 
SRBC immunization without clonal selection of certain CDR3 sequences. In strong 
contrast, S. enterica infection presents a more immunodominant system with clonal 
selection and expansion of certain VDJ chains (Fig. 5.4 and 5.9). The repertoire 
analysis of the expanded TFH populations from animals co-immunised with SRBC 
and S. enterica suggests a recruitment of TFH cells specific for both antigens (Fig. 5.4 
and 5.6-7), with a clear presence of immunodominant clones specific for S. enterica 
observed in the populations of PD-1HI TFH and PD-1LO TFH  (Fig. 5.10). 
5.2.7 Results	summary	
• Co-immunisation with SRBC and S. enterica leads to the expansion of  
PD-1HI TFH and PD-1LO TFH populations (Fig. 5.3). 
• TFH populations isolated after SRBC immunisation show higher TCR 
diversity than the TFH populations isolated after S. enterica infection  
(Fig. 5.4). 
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• SRBC immunisation leads to polyclonal TCR activation, whereas  
S. enterica infection results in the clonal selection of immunodominant TCR 
sequences (Fig. 5.8 and 5.9). 
• PCA suggests a mixed specificity of the TFH populations isolated from  
co-immunised animals (Fig. 5.6 and 5.7). 
• TCR clones specific to S. enterica are found in the PD-1HI TFH and PD-1LO 
TFH populations raised in co-immunised animals (Fig. 5.10).   
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(A)	 Spleen	 weight	 of	 immunised	 animals	 as	 indicated	 on	 day	 6	 p.i.	 (B)	 Ba terial	 lo d	
quantification	expressed	as	number	of	colony	forming	units	(CFU)	per	spleen	(left	side)	or	
per	gram	of	spleen	(right	side).	(C)	Representative		flow	cytometry	plots	of		PD-1HI	TFH	and	
PD-1LO	TFH	C 4+	T	 cell	populations	 in	each	 immunisation	model.	 (D)	Summary	of	PD-1HI	
TFH	(left)	and	PD-1LO	TFH	(right)	frequencies	and	(E)	cell	numbers.	(F)	Representative	flow	





Statistical	 significance	 was	 determined	 by	 One-way	 ANOVA	 with	 post-ANOVA	 Tukey’s	
test	for	multiple	comparisons	(Fig.	3.8	A,	C-F)	or	by	two-tailed	Student’s	t-test	with	95%	
confidence	(Fig.3.9	B). 
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Fig	5.4.	Analysis	of	TCR	diversity	within	isolated	T	cell	populations.	
Diversity	 value	 (D50)	 represents	 a	 minimum	 number	 of	 unique	 TCR	 clones	 that	 can	
account	 for	 50%	 of	 all	 reads.	 Higher	 d50	 value	 indicates	 greater	 diversity	 of	 TCR	
sequences.	
Experimental	groups	consist	of	mice	immunised	with	SRBC,	S.	enterica	or	both	SRBC	and	
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The co-immunisation experiments using SRBC and S. enterica revealed an 
unexpected expansion of the PD-1HI and PD-1LO TFH populations. The specificity of 
the expanded TFH populations is an intriguing issue.  
One of the ways to elucidate TFH specificity is by investigating T cell binding to 
MHC II tetramers. Unfortunately, this approach was not possible due to lack of such 
reagents. Another option would be to perform antigen-specific in-vitro re-stimulation 
assays on the sorted TFH populations. Since the protocols for the SRBC re-
stimulation were not well established in the lab and optimization of the assay on the 
sorted populations would be too time and cost consuming, this approach was not 
followed. Another alternative is to perform adoptive transfers of the TFH populations 
from co-immunised animals and provide an antigen boost in the host animals, 
followed by the measurement of the T cell activation, proliferation, and commitment 
to the memory pool and antibody responses. This approach, however elegant, is 
unfortunately not feasible, as sorts from single immunisations would have to be 
carried out in parallel as essential controls, and due to the low TFH frequency in the 
single immunisation models this would be difficult and costly to achieve. We, 
therefore, decided to employ TCR sequencing of the CDR3 region to tackle the 
fascinating issue of TFH specificity, which was already being used in the lab (Dr. 
Graeme Cowan). Considering the vast differences in the investigated immune 
responses (T-cell dependent Th-2 response to SRBC and strong inflammatory Th1 
response to S. enterica), we were hoping to identify TCR clones characteristic for 
SRBC or S. enterica and subsequently investigate if any of them would be dominant 
in the expanded TFH population raised in the animals co-immunised with SRBC and 
S. enterica. Alternatively, TCR diversity could be also addressed by flow cytometry, 
which could provide an information on the presence of selected V chains. 
 




The analysis of the diversity value and clustering plots as well as principal 
component analysis showed that the TCR repertoire of PD-1HI and PD-1LO TFH after 
SRBC immunisation is very similar to the one found in the naïve mice, where no 
clonal selection of any preferential CDR3 sequences takes place. Therefore, SRBC 
appear to stimulate a polyclonal T cell expansion. Intriguingly, there seem to be no 
differences in the TRC repertoire of the PD-1HI TFH and PD-1LO TFH populations in 
the SRBC model, even though, as discussed in the previous chapter, the PD-1HI TFH 
population requires cognate contacts with B cells for the its survival while the PD-
1LO TFH subset does not. Together the results of this thesis indicate that there is no 
single CDR3 sequence that would be preferentially selected for expansion in the 
SRBC immunisation, even in the TFH population relying on antigen provision by B 
cells (namely PD-1HI TFH). 
The TCR of the TFH population in the S. enterica infection model shows a very 
strong clonal selection/expansion of certain CDR3 sequences dominating in the 
response and therefore limiting the general diversity of the TCR repertoire. Clonal 
expansion indicates the presence of the immunodominant epitope preferentially 
recognised by T cells. Indeed, a few studies showed that the late, protective response 
to S. enterica is generated preferentially against the flagellin (226-228) and type III 
secretion system (229), while antibodies produced early after the infection are 
directed mostly against outer membrane proteins (171,230). Moreover, it was 
recently showed that S. enterica infection influences the structure and function of the 
thymus by altering the distribution of double negative (DN), double positive (DP) 
and single positive (SP) thymocytes (231). Interestingly, TCR usage in DP cells as 
well as CD8+ and CD4+ SP T cells (measured by the frequency of certain TCRVβ 
genes by flow cytometry) is also affected during S. enterica infection (231). 
Therefore, strong clonal expansion observed in S. enterica infection model can be 
explained by enhanced proliferation of the selected clones present in the spleen or 
the periphery as well as a consequence of increased TCR restriction during the 
thymic selection. 
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The differences in the activation kinetics between the SRBC and S. enterica 
models should be taken into account while considering clonal expansion of TFH 
populations. At day 6 p.i. TFH from S. enterica are almost at the peak of the 
proliferation, whereas TFH from SRBC (both PD-1HI and PD-1LO TFH) have expanded 
the most at day 3 and are already declining in frequency. This has a potential impact 
on the sequencing results, since TFH cells from S. enterica are most likely still 
undergoing clonal expansion and the sequencing profile will most likely look 
different once this process is completed. Nevertheless, the comparison of PD-1HI and 
PD-1LO TFH from SRBC model have provided an important cues on TCR repertoires 
in these populations.    
Since SRBC and S. enterica immunisation have vastly different impacts on the 
TCR repertoire (polyclonal response vs. clonal selection, respectively), the 
employment of TCR sequencing for the characterisation of the TFH populations in 
co-immunised animals was well justified. Intriguingly, the PD-1HI TFH and PD-1LO 
TFH populations isolated from co-immunised animals showed presence of the cells 
specific for SRBC and S. enterica at the same time. This result might not seem to be 
surprising for the PD-1LO TFH population, since this subset is present in both single 
immunisations models and the expansion observed upon co-immunisation seems to 
have an additive effect. However, the possibility of generating PD-1HI TFH cells 
specific for S. enterica in the co-immunised group is highly surprising, since this 
population is virtually absent when only S. enterica is used for immunisation (as 
discussed in Chapter 3). The next question therefore would be: what is the nature of 
the signal provided by SRBC, which drives the expansion of Salmonella-specific 
PD-1HI TFH? It could be a soluble factor (e.g. cytokine) released as part of the SRBC 
response, which would then drive progression of Salmonella-specific PD-1LO TFH 
into PD-1HI TFH alongside the formation of PD-1HI TFH specific for SRBC. 
Alternatively, an unknown feedback mechanism coming from SRBC-specific GC 
could push abundantly present Salmonella-specific PD-1LO TFH into PD-1HI TFH and 
only then GC specific for S. enterica would be established. However, this would 
have to be a non-antigen specific feedback signal, since antigens of SRBC and  
S. enterica are of vastly different natures. Nevertheless, taking into account how 
robust the GC response against SRBC is, both options are plausible. 
Chapter 5 – TCR repertoire of TFH populations 
 167	
5.3.3 Specificity	of	GC	in	SRBC	and	S.	enterica	co-immunisation.	
GC of unknown specificity were abundantly present in the animals co-immunised 
with SRBC and S. enterica (Fig. 5.3F and G), and this is in keeping with the 
presence of PD-1HI TFH as a GC-associated population.  
In S. enterica infection GC are not formed until 5 weeks post infection (171), 
when bacterial levels are vastly reduced. Therefore, GC formation can be brought 
forward by the treatment with antibiotics (171). Since the bacterial burden and spleen 
weight is similar in the group with single immunisation with S. enterica and the co-
immunised group, one could, therefore, expect that SRBC will be the main antigen 
against which GC are elicited.  However, the strong indication of the presence of 
Salmonella-specific PD-1HI TFH allows for the speculation that Salmonella-specific 
GC might be also present. Ideally, visualization of antigen specific B cells (for both 
S. enterica and SRBC) would provide a definitive answer to the question of the 
nature of GC present in co-immunised animals, but this approach is still technically 
challenging and I did not have time to perfect this. One of the available options 
would be B cell receptor (BCR) sequencing, provided that each of the single 
immunisation models will result in a different BCR repertoire. The indirect way to 
determine the specificity of GC B cells is by looking at the GC’s output - the 
antibody. Early stages of S. enterica infection elicit strong IgG2c responses directed 
mainly against outer membrane proteins but this is of extra follicular origin 
(171,172). The appearance of the GC is characterized by affinity maturation of the 
IgG2c antibody, and different antigens (flagellin and LPS) are targeted at this stage 
of the response (171). It would be interesting to determine whether the presence of 
SRBC influences the antibody levels specific for S. enterica during both early and 
late stages of the co-immunisation study and, vice versa, whether SRBC-specific 
antibody levels are altered in any ways during co-infection with SRBC and S. 
enterica. 
5.3.4 Tissue	disruption	in	co-immunised	animals	
In Chapter 3 it was shown that tissue disruption observed during S. enterica 
infection is not a direct reason for the absence of GC in this model, since during the 
immunisation with low dose bacteria or HK bacteria, where splenic structures are 
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normal, GC are still not formed (Fig. 3.3F and G). The results presented in this 
chapter describe the opposite situation: GC (of unknown specificity) are formed 
under conditions where splenic disruption has most likely taken place, since the 
animals co-immunised with SRBC and S. enterica show the same level of 
splenomegaly as in S. enterica only immunisation. However, the histology of the 
spleen found after co-immunisation has to be confirmed by microscopy. Overall, the 
results from Chapter 3 (Results section 3.3) and this chapter (Results section 5.1) 
show that, quite surprisingly, the formation of the PD-1HI TFH population and GC is 
not limited by gross alternations in the spleen’s anatomy.  
5.3.5 Influence	of	co-immunisation	on	T	cell	memory	responses	and	antibody	
formation		
One of the most interesting and important aspects of the co-immunisation study to 
be considered is the potential adjuvant effect of SRBC as a polyclonal T cell 
activator and the SRBC influence on the formation of Salmonella-specific T cell 
memory.  
Adoptive transfers of T cells derived from SRBC and S. enterica co-immunised 
animals to congenic hosts and re-challenge with S. enterica antigen would provide an 
interesting insight into TFH cell memory formation and the possible impact on 
Salmonella-specific antibody levels. Whether any of the expanded TFH populations 
(PD-1LO TFH or PD-1HI TFH) would preferentially be expanded upon secondary 
immunisation is also an open and fascinating question. It is worth mentioning that 
the CXCR5 - T cells (activated non-TFH cells) raised in the co-immunised animals are 
the group with the most restricted TCR diversity and strongest clonal expansion, and 
this might suggests clonal selection of the cells progressing into the memory pool. 
Therefore, it would be interesting to assess the phenotype and behaviour of this cell 
population after adoptive transfer and rechallenge with the antigen. Additionally, 
establishing whether any of the adoptively transferred TFH populations from the co-
immunised animals would enhance antibody responses after secondary immunisation 
with live S. enterica would provide an insight into the function of these cell subsets. 
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5.3.6 TCR	specificity	and	avidity	in	TFH	formation	
So far only a handful of studies have addressed the issue of TCR selection in the 
TFH formation. Ploquin et al. have followed Friend virus-specific polyclonal CD4+  
T cell population by investigating TCRβ transgenic T cell population with 25% of  
T cells showing high functional avidity for the virus and 75% showing lower 
functional avidity (83). The authors have concluded that the differentiation of virus-
specific TFH cells was not affected by the avidity for the antigen (83). In contrast to 
this finding, Fazilleau (82) et. al. suggested that T cells with more restricted and 
higher affinity of TCR are preferentially recruited to the TFH pool. This study used 
pigeon cytochrome c (PCC) immunisation, which in B10.BR mice elicits an antibody 
response with the selection of known variable regions (Vα11 and Vβ3). The further 
advantage of this system is the availability of antigen-specific peptide:MHC 
tetramers (raised against immunodominant peptide), which enables to track antigen-
specific T cell population (221).  
In the study published by Fazilleau et al. adoptive transfer of high and low affinity 
T cell clones indicated that TFH cells preferentially develop from high affinity clones 
(82). However, the differences in the TFH cell numbers raised from low and high 
affinity clones are quite modest. Furthermore, the ratio of high to low affinity TCR 
mRNA in TFH and non-TFH populations is of a similar range. Finally, the analysis of 
mRNA for IL-21, Bcl-6 and Blimp-1 proteins in high and low affinity T cell clones 
(after 3 day in vitro culture with DCs and the peptide) shows basically no difference 
in the message levels of these proteins. Nevertheless, TFH cells do bind more p:MHC 
complex than other effector cell subsets and TCR sequencing of single antigen-
specific TFH and non-TFH cells showed a higher TCR repertoire restriction for the 
former subset (82). 
The experimental setup of TCR sequencing from TFH populations raised after 
SRBC or S. enterica immunisation does not allow for speculation on the TCR 
affinity of certain CDR3 sequences but only on the prevalence of certain clones in 
the total TCR repertoire, as the TCR:pMHC complex interaction cannot be predicted 
based solely on the CDR3 sequence (220). Our results of a lack of preferential TCR 
restriction among TFH and non-TFH populations support the study of Ploquin et al. 
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(83) but stand in contrast to the finding of Fazilleau et al. (82). This can be explained 
by the experimental models used for the investigation: simple protein PCC 
immunisation might have a different impact on the TCR repertoire than the much 
more complex S. enterica infection. The SRBC immunisation, eliciting a clear T-cell 
dependent response, is far less characterized than the PCC model in terms of clonal  
T and B cell selection. The fact that it was not possible to follow a SRBC-specific  
T cell response might also influence the results. Overall, employing a more sensitive 
system for antigen-specific T cell tracking would greatly benefit TCR and CDR3 
characterization. Nevertheless, the fact that it was possible to detect a strong clonal 
expansion in the S. enterica infection and a lack of it in SRBC immunisation shows 
that even despite the antigen-tracking tool vast differences in the TCR repertoire 





6 Synoptic Discussion and Further Work 
6.1 TFH differentiation pathways 
The development of TFH cells has been intensively investigated since the 
discovery of the TFH subset (114). I would like to discuss several models of TFH 
differentiation considering recently emerging data to support each model. 
6.1.1 Linear	model	
The linear model of TFH differentiation (Fig. 6.1A) describes the differentiation of 
activated CD4+ T cells into TFH under the influence of cytokines IL-6 and IL-21. 
This would represent a situation analogous to the one of the Th1, Th2 and Th17 
subsets, which can be generated in vitro under the exposure of naïve CD4+ T cells to 
IL-12, IL-4 or IL-6 and TGF-β, respectively. An important aspect of this model is 
that the TFH differentiation is considered completely separated from other lineages. 
Some studies have shown that CD4+ T cells cultured with IL-6 and IL-21, indeed, 
produce IL-21 and that TFH-associated transcripts (CXCR5, and Bcl6) are also up-
regulated (55,84,100-103). On the other hand, some studies did not confirm the 
induction of the TFH profile in IL-21-producing cells grown in vitro (104,105). This 
finding is not really surprising, taking into account the fact that other T cell subsets, 
e.g. Th17 cells, also produce IL-21 (232). Moreover, the presence of IL-21 during 
the priming stage remains an important issue. Although DC can produce IL-6 (233), 
they have not been reported to produce IL-21 (actually, no APC has been shown to 
express IL-21 (114)). Furthermore, multiple evidence from in vivo studies show a 
limited impact of the IL-21 or IL-6 deficiency on TFH populations 
(72,79,102,107,114). The linear model of TFH differentiation also does not explain 
the requirement of cognate B cells in the TFH cell development (55,84,100-103,114). 
Therefore, the simple model of TFH differentiation upon exposure to certain 
cytokines during the activation stage is not enough to explain complexity of TFH 
biology. 
6.1.2 Pluripotent	model	
The pluripotent model also recognizes TFH as a lineage separate from the Th1, 
Th2 and Th17 subsets. In this model of TFH differentiation (Fig. 6.1B, (104,105,114)) 
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CD4+ T cells are primed by DCs, giving rise to the precursors of TFH and for instance 
Th1 cells. Then some of the pre-TFH move towards the T-B cell border (in response 
to undefined cues) and TFH cells are generated after the interaction with cognate B 
cells, which induces expression of Bcl6 and draws T cells deeper into the follicle to 
initiate the differentiation into GC TFH and GC B cells. However, the pluripotent 
model does not explain the fact that, as shown in multiple studies, Bcl-6 expression 
is readily detectable prior to the contact with cognate B cells (57,75,78,232). 
Furthermore, the signals guiding naïve T cells to become pre-TFH cells also remain 
unexplained. 
6.1.3 Secondary	program	model	
The secondary program model (Fig. 6.1C) differs greatly in principle from the 
previous two models. In the secondary program model TFH cells are not induced 
during the priming stage but are derived from already differentiated Th1, Th2 or 
Th17 cells (114,233). Therefore, differentiation into one of the non-TFH subsets is 
essential prior to the acquisition of the TFH phenotype, and therefore TFH are viewed 
as a ‘secondary program’ and not de facto a separate subset. After differentiation 
into, for example, Th1 effector cell, the Th1-specific program is inhibited and, 
possibly, by switching on Bcl6, the TFH phenotype is acquired. In agreement with 
this hypothesis, Th1 were found capable of acquiring the TFH phenotype under IL-2-
limiting conditions by alerting the balance of the Tbet/Bcl6 complex (114,234). 
Moreover, there is an overlapping gene expression pattern between TFH and other 
cell subsets, for instance, the expression of the master TFs of the Th1 and Th2 
subsets (73,77,90,129,132), and, in consequence, their characteristic cytokines. 
However, several facts argue against this hypothesis. For instance, the TFH 
development is unaltered in T-bet deficient mice (Tbx-/- mice) upon protein 
immunisation (69). Additionally, Bcl6+ TFH-like cells are present already at very 
early stages (day 2-3 p.i.) after priming and therefore there is simply not enough time 
for cells to undergo the full differentiation into, for example, Th1 cells and then to 
remodel the gene expression extensively to become TFH cells. Finally, the presence 
of master TFs of other lineages may simply be a means to express the cytokines that 
are controlled by this locus, which is also essential for TFH cells, and not a 




The integrated model of TFH differentiation is the most complex one and currently 
the most accepted in the scientific community (Fig.6.2). In principle, the integrated 
model recognizes TFH as a separate lineage among other T cell subsets. The pre-TFH 
state is induced during priming with APC via ICOS-ICOS ligand interactions and 
significant contributions from STAT3 signaling cytokines IL-6 and/or IL-21. After 
this commitment stage, Bcl6 is weakly expressed. The subsequent maintenance of 
the TFH phenotype depends on interactions with activated, cognate B cells via ICOS-
ICOSL interactions (114), although non-cognate by stander B cells have also been 
implicated in the  process (56). The third and final stage of TFH differentiation is the 
full polarization into GC TFH cells, which would depend on SAP-mediated 
interactions with cognate B cells in order to induce maximal expression levels of 
Bcl6 and CXCR5, PD-1, BTLA, ICOS and possibly of GL7. The GC TFH would be 
the only TFH subset capable of driving the GC response. The GC TFH could be 
maintained within the GC by IL-21 (acting in autocrine manner) as well as IL-6 
produced by FDCs, which additionally provide continuous access to the antigen held 
on the surface.  
 
The results presented in this PhD thesis strongly support the integrated model of 
TFH differentiation. First of all, I show that in the absence of antigen presentation by 
B cells, TFH cells expressing intermediate levels of CXCR5 and PD-1 are formed. 
These cells cannot support the GC formation. Secondly, MHC II expression by  
B cells is essential for the generation of the PD-1HI TFH population, which expresses 
high levels of Bcl6 and can drive the GC response. Most importantly, I provide 
evidence for a linear progression from the PD-1LO TFH stage to PD-1HI TFH 
differentiation. The PD-1LO TFH population deprived of cognate contact with B cells 
is stalled in its development into PD-1HI TFH. Importantly, PD-1LO TFH can continue 
this line of differentiation once antigen is experienced in the context of B cells. This 
illustrates a continuous supply to the PD-1HI TFH pool from PD-1LO TFH pool. The 
fact that in the absence of MHC II on B cells this final step in TFH differentiation 
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does not happen argues for a critical role of antigen-presentation by B cells in this 
process.  
6.2 Proliferation and terminal differentiation of TFH cells. 
The adoptive transfer of PD-1HI TFH into WT host (Chapter 4, Results section 4.7) 
revealed a limited plasticity of the PD-1HI TFH cell subset with a low conversion to 
PD-1LO TFH. This suggests that the PD-1HI TFH population represents a more 
terminally differentiated state of the TFH development. Whether multiple interactions 
with cognate B cells are important for sustaining the PD-1HI TFH population (thus, 
beyond induction stage) is still an unresolved matter. This issue could be addressed 
by an adoptive transfer of PD-1HI TFH to MHC II KO mice (or BMHCII-/- chimeras) and 
by investigating whether the PD-1HI phenotype would be lost in the absence of 
functional APC or, more specifically, cognate B cells. 
Fascinatingly, the differentiation of CD4+ T cells and B cells is governed to some 
extent by the same TFs. The choice between terminally differentiated plasma cells 
and proliferating GC B cells is mediated by Blimp-1 or Bcl-6, respectively. 
Similarly, the phenotype of effector T cells and TFH cells is also imposed by the 
presence of Blimp-1 or Bcl6, respectively. Whether this pattern of expression in 
CD4+ T cells is tied to the proliferative capacity as observed in B cells remains to be 
established.  
I have performed intracellular staining with the Ki67 nuclear marker characteristic 
for dividing, and not resting cells, and found no differences between PD-1HI TFH and 
PD-1LO TFH present in the SRBC immunisation model (Chapter 3, p. 76). This 
experiment did not provide conclusive evidence about the terminal differentiation of 
any subset. A study with IL-21+ reporter mice showed that IL-21+ TFH cells are not a 
terminally differentiated cell subset, as they are undergoing substantial cell division 
(measured by incorporation of thymidine analogue BrdU [bromodeoxyuridine] and 
propidium iodide staining) (69). Experiments with carboxyfluorescein succinimidyl 
ester (CFSE) are not particularly feasible in our model due to the low numbers of 
isolated polyclonal TFH cells and the high rate of cell death during the labelling 
process (roughly 50% of starting population). The monoclonal population could be 
used, however, as the studies with monoclonal and polyclonal system might yield 
Chapter	6	–	Synoptic	discussion	
 175	
different results (discussed in section 1.17 ‘TFH memory’, p.37) and therefore it is 
better to use a more physiological set up when possible.  
6.3 Specificity of TFH found in co-immunised animals 
The finding that co-immunisation with SRBC and S. enterica leads to the 
expansion of the TFH population is very surprising. This experiment is difficult to 
interpret without establishing the specificity of the expanded TFH cells and GC B 
cells. For numerous reasons (discussed in the Introduction to Chapter 5, p. 169) we 
decided to employ TCR sequencing, firstly, to characterize the clonal repertoire of 
the TFH populations in both models and, secondly, to use the observed differences to 
investigate the TFH populations in the co-immunised animals. Interestingly, SRBC 
activate T cells polyclonally without expansion of any selected clonotype. The 
opposite situation is observed after S. enterica infection, where certain T cell clones 
expand vastly over the others. Fascinatingly, the co-immunised groups indicate the 
presence of both TFH populations, since they carry characteristics of the TFH found in 
single immunisation with SRBC and with S. enterica. If PD-1HI TFH specific for  
S. enterica and SRBC in co-immunised animals are truly present, then the most 
important question is: what is the nature of the signal provided by SRBC that is 
required to generate PD-1HI TFH specific for S. enterica (and, consequently, drive a 
Salmonella-specific GC response)?  
One of the transcripts selectively expressed by PD-1HI TFH in the SRBC model is 
IL-4 (Fig. 3.10). IL-4 was found to play an essential role in GC formation (235,236) 
and therefore would be a plausible candidate protein responsible for facilitating TFH 
expansion. However, the absence of IL-4 was actually shown to enhance the Th-1 
type response (237). Therefore, the role of IL-4 in co-immunised animals would have 
to be addressed experimentally (by either using IL-4R KO mice or anti-IL-4 blocking 
antibodies).  
A completely separate conclusion comes from the analysis of each population 
within the single immunisation model. So, PD-1HI TFH and PD-1LO TFH (as well as 
CXCR5- T cells) raised after SRBC immunisation do not show evidence of clonal 
expansion. This is a significant finding since, first of all, there are not many studies 
that address the issue of the TCR repertoire within the TFH population. Some 
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published reports suggest that T cells with the highest TCR affinity are recruited to 
the TFH pool (82, 238), while others indicate that there is no preferential TCR usage 
in the TFH and Th1 effector cell population (83). Therefore, similar TCR usage 
between both of the TFH cell subset and the effector T cell population might indicate 
(although this is not a strict evidence) that there is no preferential specificity within 
any of the subsets. Thus, the TCR affinity might not influence the commitment to the 
TFH or T effector cell subset. 
Importantly, TCR sequencing does not directly determine the specificity. This 
issue can be directly addressed by in vitro restimulation assays or in vivo transfer 
studies, as described above (Introduction to Chapter 5, p. 169). Instead, TCR 
sequencing identifies clonal expansion patterns that are likely to be characteristic of a 
response to a particular antigen. Important cues and conclusions are derived from 
this study, while also more fascinating questions arise to be tackled in the future.  
6.4 TFH memory – Tcm or Tem population? 
CD4+ T cell memory is characterized by the presence of two populations:  
T central memory cells (Tcm) and T effector memory cells (Tem) (239). These 
populations are distinguished by the expression of CD62L, CD44 and CCR7 (239). 
Tcm cells express high amounts of CD62L and CCR7. They are thought to be 
circulating within SLO and proliferate rapidly upon re-exposure to the antigen. Tem 
express low levels of CD62L and CCR7, and they home preferentially to inflamed 
tissues (239). Both Tcm and Tem express high levels of CD44 on the surface, which 
is a marker of cell activation. Expression of CD62L is therefore important when 
considering the memory potential of the TFH population.  
My experiments have shown that PD-1HI TFH found within one week p.i. with 
SRBC have low CD62L expression, whereas PD-1LO TFH and CXCR5- T cells retain 
high CD62L expression, which points to the latter two populations as potential 
sources of TCM cells. Whether the same CD62L expression pattern is also found on 
persisting TFH is an interesting question. In the adoptive transfer experiments PD-1HI 
TFH did not up regulate the CD62L upon reactivation with SRBC (when measured at 
24 h post transfer or 72 h post transfer and boost). This suggests that PD-1HI TFH 
cells do not directly contribute to the Tcm memory population, although more 
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adequate memory studies (with resting antigen-experienced cells in antigen-free 
environment for extended period of time before re-activation) are required to address 
the question fully.  
Other published studies (discussed in the Introduction section ‘TFH memory’, p. 
37, (69,152) have clearly established that TFH cells are able to persist in the absence 
of the antigen and upon activation give rise to  cells with enhanced TFH phenotype as 
well as ‘classic’ effector T cells. The existence of memory TFH cells is an interesting 
phenomenon, since the GC reaction in the secondary response is of much lower 
magnitude than the one found in the primary response (27). Therefore, additional 
questions about the function of those TFH memory cells arise. 
6.5 TFH subsets in humoral responses 
An important aspect of TFH biology, which has not been addressed directly in this 
thesis, regards the role of PD-1HI TFH and PD-1LO TFH cells in the antibody 
production. Ideally, adoptive transfers of these TFH populations to congenic hosts 
would be followed by the assessment of antigen-specific antibody levels. 
Unfortunately, this approach is not feasible with SRBC as an antigen for several 
reasons. First of all, the transferred TFH population size is small (3-4x105 cells) and 
therefore its effect on the GC output could be too modest to investigate. Secondly, 
SRBC generate a very robust humoral response and therefore the WT TFH response 
concurrently taking place in the host could ‘mask’ the effects of the transferred 
population. Alternatively, an in vitro antibody production assay would provide some 
answers, but, as already discussed a few times before, this might not reflect the 
physiological situation observed in vivo.  
6.6 Concluding remarks and unanswered questions 
There are several important points in TFH biology that still require answers. 
Firstly, the initial signals driving commitment to either the TFH or effector T cell pool 
are not clear, and so far the strongest evidence point towards low IL-2 signalling 
(75,109,110). Secondly, signals governing the progression from TFH cell to fully 
polarized GC TFH cell are also elusive. Furthermore, the TCR repertoire of TFH cells 
and GC TFH cells in relation to T effector cells is also not well characterized. Finally, 
the ultimate differentiation state and the capacity to form memory by TFH cells as 
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well as the possible conversion to other cell types is still under investigation. 
Therefore, although the TFH function seems to be quite well understood, many 
questions focus on the origin and fate of the TFH cells. These aspects of TFH biology 
are highly significant for an optimal design of immune interventions. Expanding the 
fundamental knowledge about the TFH population will further enhance the possibility 
to manipulate humoral responses, either by enhancing them when needed (e.g. during 
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(A)	 Linear	model.	 Naïve	 T	 cells,	 following	 activation	 by	 dendritic	 cell	 (DC),	 differentiate	
into	 TFH	 cells	 under	 the	 influence	 of	 IL-6	 and	 IL-21.	 (B)	 Pluripotent	model.	 Interactions	
between	naïve	T	cells	and	DC	establish	a	pool	of	activated	T	cell	with	separate	precursors	
of	 each	 T	 cell	 subset.	 TFH	 cells	 are	 generated	 after	 interaction	with	 cognate	 B	 cells.	 (C)	
Secondary	program	model.	Activated	T	cells	differentiate	into	Th1,	Th2,	Th17	or	Treg	cells	
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represented	 in	 triplicate).	 Boxes	 have	 similar	 size	 and	 variability	 (represented	 by	
interquartile	 range)	 and	 median	 (vertical	 line	 symbolizing	 central	 value).	 Boxplots	 are	






Individual	 array	 quality	 is	 assessed	 by	MA	 plots.	 Y	 axis	 shows	 changes	 in	 the	 intensity	
(log2)	for	the	array	of	interest	and	X	axis	shows	average	intensities	across	all	arrays.	Most	
of	 the	genes	 (represented	by	 single	dots)	are	not	differentially	expresses	and	 therefore	
are	 positioned	 along	 horizontal	 axis.	 The	MA	 plot	 can	 identify	 issues	 with	 background	
intensity,	 saturation	measurement	or	dye	bias.	 In	 this	 study	no	 outliers	were	 identified	
based	 on	 MA	 plots.	 Each	 MA	 plot	 corresponds	 to	 one	 microarray.	 The	 code	 for	 the	
samples	1	to	18	is	presented	in	Table	2.2	on	p.	70.	
	
1	 2	 3	 4	
5	 6	 7	 8	
9	 10	 11	 12	





Density	plots	 show	how	 frequent	 certain	 intensity	was	measured	 for	 the	 samples.	Each	
line	 represents	 one	 microarray.	 Y	 axis	 shows	 density	 and	 X	 axis	 shows	 log2	 intensity.	






RNA	 degradation	 plots	 illustrate	 RNA	 decay	 process.	 They	 are	 generated	with	 normalised	
data.	 Each	 line	 represents	 one	microarray.	 Lines	 should	 be	 parallel;	 significantly	 different	
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(A)	 Gating	 strategy	 for	 GC	 B	 cells	 (C57Bl/6	 mouse	 on	 day	 6	 p.i	 with	 SRBC).	 (B)	
Representative	flow	cytometry	plots	GC	B	cell	populations	after	SRBC	immunisation	(B)	or	
S.	 enterica	 infection	 (C)	 over	 time.	First	 two	gating	 steps	 (lymphocytes	and	 single	 cells,	
not	shown)	as	 in	Fig.	3.1A.	 (D)	Summary	of	GC	B	cell	 	 frequencies	 (left)	or	cell	numbers	
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